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Introduction
 Thyroid hormone (TH) plays an important role in normal growth, development, 
and metabolic homeostasis. This is emphasized by severe growth retardation and 
neurodevelopmental impairment in patients with prolonged untreated congenital 
hypothyroidism or cretinism (1-4). Adults with hypothyroidism develop symptoms such 
as cold intolerance, constipation, fatigue, weight gain, bradycardia and depression (5). In 
contrast, heat intolerance, weight loss, and tachycardia are observed in hyperthyroid patients, 
illustrating the strong influence of TH in human metabolism (6,7).
 TH is synthesized in the thyroid gland and released to the circulation under a tight 
regulation by the hypothalamic-pituitary-thyroid (HPT) axis. Two major forms of TH are 
produced, namely 3,3’,5,5’-tetraiodothyronine or thyroxine (T4), and 3,3’,5-triiodothyronine 
(T3). Both T3 and T4 are transported across the plasma membrane by multiple thyroid 
hormone transporters such as monocarboxylate transporter 8 (MCT8). Transcriptional gene 
regulation (genomic actions) is the principal action of TH, which is mediated by binding of TH 
to its nuclear thyroid hormone receptors (TRs). Since T3 binds to TRs with a high affinity, it is 
regarded as the biologically active TH. T4, despite being the most abundant in the circulation, 
is considered as a prohormone because of its lower biological potency. T4 is converted to T3 
in peripheral tissues by outer ring deiodination (ORD) by the type 1 and type 2 deiodinase 
enzymes (DIO1 and DIO2).
Thyroid hormone synthesis and regulation
Thyroid hormone production
 TH is produced by the thyroid gland. The process starts by active transport of 
iodide (I-) into thyroid follicular cells via the Na+/I- symporter (NIS; SLC5A5) at the basolateral 
membrane. Intracellular I- is then delivered into the follicular lumen using a transporter at the 
apical membrane, possibly Pendrin (PDS; SLC26A4). Next, I- is oxidized by the membrane-
bound thyroperoxidase (TPO) enzyme, which requires the presence of H2O2 generated by 
the dual oxidase enzyme DUOX2 and its specific maturation factor DUOXA2. Oxidized iodide 
is incorporated (organified) into tyrosyl residue of thyroglobulin (TG), a large glycoprotein 
that serves as a matrix for TH synthesis, to create two iodinated forms, namely, mono- and 
diiodotyrosine (MIT and DIT). TPO also catalyzes the coupling of MIT and DIT, and of two 
DIT molecules to form T3 and T4, respectively. The iodinated TG is subsequently internalized 
back into the follicular cells by micropinocytosis and endocytosis. After TG is hydrolysed 
in lysosomes, T3 and T4 are released into the circulation by transporters, including the TH 
transporter MCT8. MIT and DIT are deiodinated in the cytosol of thyroid follicular cells by the 
iodotyrosine dehalogenase (DEHAL1) enzyme to recycle iodine for further TH synthesis (Figure 
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1) (8-10). Genetic defects in each step of TH synthesis result in thyroid dyshormonogenesis, 
which causes approximately 15% of all cases of primary congenital hypothyroidism (11,12).
 
Figure 1. Steps in thyroid hormone synthesis. 
Figure 2. The hypothalamic-pituitary-thyroid axis.
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Hypothalamic-Pituitary-Thyroid (HPT) axis 
 Thyroid hormone synthesis is stimulated by thyroid stimulating hormone (TSH; 
thyrotropin), a glycoprotein which is released from the anterior pituitary gland. TSH binds to 
the TSH receptor (TSHR), a G-protein coupled receptor at thyroid follicular cells, to promote 
multiple steps of TH synthesis, including iodide trapping in the thyroid gland, iodotyrosine and 
thyroglobulin synthesis, and thyroid hormone release. The concentration of TSH is controlled 
by thyrotropin-releasing hormone (TRH), produced in the TRH neurons in the paraventricular 
nucleus of the hypothalamus (13). High concentrations of TH can suppress the production of 
both TRH and TSH (Figure 2). Animal studies have shown that local conversion of T4 into T3 
by the DIO2 in tanycytes, specialized glial cells lining the third ventricle, plays a crucial role 
in TRH suppression by TH (14,15). Local DIO2 in folliculostellate cells, agranular cells in the 
human anterior pituitary, converts T4 to T3 and transports T3 to thyrotrophs in a paracrine 
manner for TSH suppression (16,17). Via this negative feedback mechanism, circulating TH 
concentrations are maintained within the normal range.
Thyroid hormone transport
 To facilitate its genomic action, TH has to enter the cells and bind to TRs. It was 
previously believed that TH entered the cells by passive diffusion because of its lipophilic 
property that would allow easy passage of TH through the phospholipid bilayers of the 
cell membrane. However, later evidence suggested that T3 and T4 are taken up into the 
cells by transporter proteins located at the plasma membrane of the cells. To date, several 
TH transporters have been identified, including the iodothyronine-specific transporters 
monocarboxylate transporters MCT8 (SLC16A2) (18,19) and MCT10 (SLC16A10 or TAT1) 
(20), the organic anion transporting polypeptide (OATP) family, especially OATP1C1 
(SLCO1C1) (21), the Na+-taurocholate co-transporting polypeptide (NTCP; SLC10A1) (22), 
and the L-type amino acid transporters LAT1 (SLC7A5) and LAT2 (SLC7A8) (23). 
 The importance of TH transport across the cell membrane is illustrated by the 
identification of patients carrying mutations in the TH transporters. The Allan-Herndon-Dudley 
syndrome (AHDS) was first described in 1944 in a large family with X-linked psychomotor 
retardation (24). Inactivating mutations in MCT8 were subsequently identified as a cause of 
this genetic syndrome (25,26). The clinical phenotype of AHDS includes cognitive impairment, 
intellectual disability, and central hypotonia. Thyroid function tests (TFTs) show low free and 
total T4, low reverse T3 (rT3), high free and total T3, increased T3/T4 and T3/rT3 ratio, and 
normal to mildly elevated TSH concentrations (18,27). Recently, Strømme et al. reported 
a homozygous missense mutation in OATP1C1 as a cause of developmental regression, 
progressive dementia, spastic diplegia, and cold intolerance in a 15-year-old girl with normal 
TFTs (28). Since OATP1C1 is important for TH transportation across the blood-brain barrier 
and into glia and neuronal cells in the brain, loss of the OATP1C1 function likely leads to brain-
specific hypothyroidism and neurodegeneration. 
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Thyroid hormone metabolism: deiodination
 As mentioned previously, T4 is the dominant form of TH that is secreted from the 
thyroid gland and is subsequently converted into the active form T3 at peripheral tissues. 
The deiodinase enzymes, a subfamily of three selenoproteins capable of removing an iodine 
atom from the inner (tyrosyl) or outer (phenolic) ring of TH, mediate this conversion (Figure 
3). The DIO1, expressed in the liver, kidney, and thyroid gland, can deiodinate both the inner 
and outer ring of T4 to produce T3 and rT3, respectively. The DIO2, which is ubiquitously 
expressed in brain, pituitary, retina, brown adipose tissue, innate immune cells, and skeletal 
muscle, is only able to deiodinate the outer ring (5’) of TH. The major role of DIO2 is therefore 
the conversion of T4 to T3 as well as the control of local tissue T3 concentration. The DIO3 is 
a TH-inactivating enzyme, as it can only deiodinate the iodine atom from the inner ring of T4 
and T3. DIO3 is mainly expressed in fetal tissue and plays a crucial role in embryogenesis. 
It is also expressed in retina, neurons, pituitary gland, and various type of tumors, such as 
hemangioma, glioma and gliosarcoma, basal cell carcinoma, pituitary adenoma, and papillary 
thyroid carcinoma (29-32). Both DIO2 and DIO3 work antagonistically to control intracellular 
T3 concentrations. DIO2 converts T4 to T3 and therefore increases TH signaling, whereas 
DIO3 inactivates T4 and T3 and decreases TH signaling (33). 
Figure 3. TH metabolism by deiodinase enzymes.
Thyroid hormone receptors and its genomic actions
 Genomic actions of thyroid hormone are initiated by binding of T3 to TRs. TRs either 
homodimerize with the other TR or, more preferably, heterodimerize with retinoid X receptor 
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target genes to regulate gene expression. In the absence of T3, the TRs recruit corepressor 
proteins that modify the chromatin structure, resulting in transcriptional repression of genes 
that are under positive control by TH. In the presence of T3, TRs then release the corepressors 
and recruit coactivators to induce gene transcriptional activation.
Multiple thyroid hormone isoforms
 TRs are members of the nuclear receptor superfamily. Similar to other nuclear 
receptors, TRs consist of multiple functional domains, including an amino-terminal A/B 
domain, a central DNA-binding domain (DBD), a hinge region, and a carboxy-terminal ligand 
binding domain (LBD). There are multiple TR isoforms, generated from two different genes; 
however, only three functional isoforms have been described that are capable of binding T3 
and controlling nuclear gene transcription, namely TRα1, TRβ1, and TRβ2 (Figure 4) (34-36). 
The structure of these three isoforms is highly homologous. TRα1 is encoded by THRA gene 
on chromosome 17. The alternative splice variant TRα2 is encoded by the same gene but 
has no T3-binding ability because of differences in length and amino acid composition in the 
C-terminal region. The THRB gene, located on chromosome 3, encodes two T3-binding TR 
isoforms, TRβ1, and TRβ2, which share high sequence homology in both DBD and LBD but 
differ in the length and amino acid sequences in the N-terminal A/B domain.
Figure 4. (A) Three TR isoforms that are capable of binding T3 and controlling gene transcription. 
TRα1 is encoded by THRA gene on chromosome 17. TRβ1 and TRβ2 are encoded by THRB gene on 
chromosome 3. (B) Comparison of the sequences shows a high sequence homology (bold) of the DBD 
(light grey) and LBD (dark grey) of the three TR isoforms. [A/B, A/B domain; DBD, DNA-binding domain; 
H, hinge region; LBD, ligand binding domain] (Adapted from Langlois MF et al. 1997, Hahm JB et al. 2013, 
and Wagner RL et al. 1995 (37-39))
 The expression of TR isoforms varies among tissues. TRα1 is predominantly 
expressed in the central nervous system, bone, cardiac tissue, gastrointestinal tract, and 
skeletal muscle while the non-T3 binding isoform TRα2 is more wildly expressed throughout 
the whole body. TRβ1 is principally expressed in the liver, kidney and thyroid gland, whereas 
1 52 120 410
1 106 174 461
1 121 189 476
A/B DBD H + LBD
TRα1
TRβ1
TRβ2
hTRα1 LKTSMSGYIPSYLDKDEQCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPTYSCKYD 94
hTRβ1 EEKKCKGYIPSYLDKDELCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPSYSCKYE 148
hTRβ2 SYSQKKGYIPSYLDKDELCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPSYSCKYE 163
hTRα1 SCCVIDKITRNQCQLCRFKKCIAVGMAMDLVLDDSKRVAKRKLIEQNRERRRKEEMIRSL 154
hTRβ1 GKCVIDKVTRNQCQECRFKKCIYVGMATDLVLDDSKRLAKRKLIEENREKRRREELQKSI 208
hTRβ2 GKCVIDKVTRNQCQECRFKKCIYVGMATDLVLDDSKRLAKRKLIEENREKRRREELQKSI 223
hTRα1 QQRPEPTPEEWDLIHIATEAHRSTNAQGSHWKQRRKFLPDDIGQSPIVSMPDGDKVDLEA 214
hTRβ1 GHKPEPTDEEWELIKTVTEAHVATNAQGSHWKQKRKFLPEDIGQAPIVNAPEGGKVDLEA 268
hTRβ2 GHKPEPTDEEWELIKTVTEAHVATNAQGSHWKQKRKFLPEDIGQAPIVNAPEGGKVDLEA 283
hTRα1 FSEFTKIITPAITRVVDFAKKLPMFSELPCEDQIILLKGCCMEIMSLRAAVRYDPESDTL 274
hTRβ1 FSHFTKIITPAITRVVDFAKKLPMFCELPCEDQIILLKGCCMEIMSLRAAVRYDPESETL 328
hTRβ2 FSHFTKIITPAITRVVDFAKKLPMFCELPCEDQIILLKGCCMEIMSLRAAVRYDPESETL 343
hTRα1 TLSGEMAVKREQLKNGGLGVVSDAIFELGKSLSAFNLDDTEVALLQAVLLMSTDRSGLLC 334
hTRβ1 TLNGEMAVTRGQLKNGGLGVVSDAIFDLGMSLSSFNLDDTEVALLQAVLLMSSDRPGLAC 388
hTRβ2 TLNGEMAVTRGQLKNGGLGVVSDAIFDLGMSLSSFNLDDTEVALLQAVLLMSSDRPGLAC 403
hTRα1 VDKIEKSQEAYLLAFEHYVNHRKHNIPHFWPKLLMKVTDLRMIGACHASRFLHMKVECPT 394
hTRβ1 VERIEKYQDSFLLAFEHYINYRKHHVTHFWPKLLMKVTDLRMIGACHASRFLHMKVECPT 448
hTRβ2 VERIEKYQDSFLLAFEHYINYRKHHVTHFWPKLLMKVTDLRMIGACHASRFLHMKVECPT 463
hTRα1 ELFPPLFLEVFEDQEV 410
hTRβ1 ELFPPLFLEVFED--- 461
hTRβ2 ELFPPLFLEVFED--- 476
A. B.
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TRβ2 is predominantly expressed in the retina, cochlea, as well as the hypothalamus and 
pituitary gland, where it plays a crucial role in the HPT axis regulation (34,35).
Isoform-dependent functions of TRs
 To date, it is unclear whether the different TR isoforms have specific functions 
or share a similar role in gene transcriptional regulation. Although the properties of all TR 
isoforms are quite similar in vitro, in vivo studies show clear differences in the consequences 
of mutations in the different receptors (35,40). TRα gene knock-out mice (TRα0/0) have growth 
retardation, intestinal malformation, delayed bone maturation, bradycardia, abnormal cardiac 
contractility, and hypothermia (41). In contrast, TRβ gene knock-out mice (TRβ-/-), in which 
both TRβ1 and β2 are absent, have normal growth, but HPT axis dysfunction, hearing loss, 
and abnormal retinal development (42-44). These findings suggest differences in intrinsic 
properties and/or cell-specific effects of the receptor isoforms. In addition, the phenotypes of 
these knock-out mice are matched by the phenotypes of patients with resistance to thyroid 
hormone (RTH) due to mutations of THRA gene which is different from the phenotype of 
patients carrying mutations of the THRB gene.
 It is generally assumed that differences in tissue distribution of the TRs predominantly 
dictate the isoform-specific functions. However, there is evidence suggesting that even in cell 
types where two TR isoforms are available, TRs regulate gene transcription in an isoform-
specific manner. For instance, in brown adipose tissue (BAT) where both TRα1 and TRβ1 
are expressed (45,46), TRα1 is responsible for norepinephrine-induced BAT thermogenesis 
whereas TRβ1 mediated expression of mitochondrial uncoupling protein 1 (UCP1), a 
mitochondrial membrane protein that plays a crucial role in BAT thermogenesis (47). Data 
from TR knock-out mice also showed that DIO1 expression have differences in tissue and 
isoform regulation. The expression is solely regulated by TRβ in the kidney but requires both 
TR isoforms in the liver (48). Furthermore, co-expression of both TRα1 and TRβ1 is also 
observed in Purkinje neurons, in which cell differentiation is T3-dependent. Only Thra knock-
out, but not Thrb knock-out, altered in vitro differentiation of Purkinje neurons, suggesting an 
TRα1-specific effect (49). However, both in vitro studies performed in other cell types and in 
vivo studies are needed to confirm these findings.
Ligand of TRs: T3 and beyond
 In 1952, it was recognized that T3 has a higher biological potency than T4 (50-
53). This fundamental discovery led to the clinical concept that T3 is the biologically active 
hormone. Crystal structures showed that the LBD of TRs consists of 12 α-helices (H1-H12) 
that fold into a hydrophobic-core pocket. T3 can be tightly accommodated in this pocket 
and induce conformational changes of the TR, especially at the location of H12, to enclose 
the ligand-binding pocket (54,55). This conformational rearrangement induces corepressor 
protein dissociation and allows coactivator protein association, which is essential for gene 
transcriptional activation.
17
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 Follow up studies suggest that T4 can also bind to TRs with a lower binding affinity 
(10-30 fold) than that of T3 (56-58). The T4-bound WT TRβ1 crystal structure revealed that 
the ligand-binding pocket of TRβ1 could accommodate both T3 and T4, although the H11-H12 
loop is more loosely packed in the presence of T4 than T3 (57). However, the molecular and 
structural mechanisms underlying the higher affinity of T3 than T4 have not been investigated 
in detail. In addition, the precise role of T4 as a prohormone and the possibility that T4 
might function directly as an active hormone in at least specific cellular contexts remains 
inconclusive.
 In addition to T3 and T4, there are naturally occurring TH metabolites that can also 
bind to TRs, such as 3,3’,5-triiodothyroacitic acid (Triac), the T3-derivative containing an 
acetic acid group. Evidence indicates that Triac binds to TRα1 with a similar affinity as T3 
and binds to TRβ1 and TRβ2 with a 3- to 6-fold higher affinity than T3 (59). Therefore, Triac is 
considered as a TRβ-selective agonist which can be used as a treatment option in a certain 
condition such as RTHβ and AHDS (60). However, since the concentration of Triac in human 
circulation is approximately 50-fold lower than that of T3, the physiological role of this TH 
derivative is yet unclear (60,61).
 Over the past decades, numerous TH analogs have been synthesized in order to 
create novel therapeutic agents for certain conditions, for instance, hyperlipidemia, obesity, 
and non-alcoholic fatty liver diseases (NAFLD) (62-66). These analogs can bind to TRs with 
differences in isoform specificity. However, most of them are designed as more specific for the 
TRβ isoforms to minimize the TRα-dependent cardiac side effects. A list with examples of TH 
analogs is summarized in Table1.
Table 1. TH analogs 
Compound Isoform specificity Potential benefit(s)
DITPA Non-selective ↓ cholesterol and triglyceride levels, ↑ cardiac 
output (without significant increase in heart rate)
GC-1 (Sorbetirome) TRβ ↓ cholesterol levels, ↓ hepatic steatosis, ↑ liver 
regeneration 
GC24 TRβ ↓ triglyceride levels
KB-141 TRβ ↓ triglyceride levels, ↓ body weight
KB-2115 (Eprotirome)* TRβ ↓ cholesterol and triglyceride levels, ↓ hepatic 
steatosis, ↑ hepatocyte proliferation
MB07811 TRβ ↓ cholesterol and triglyceride levels, ↓ hepatic 
steatosis
MGL3196 TRβ ↓ triglyceride levels, ↓ hepatic steatosis 
*Evidence shows adverse effects on cartilage and drug-induced liver toxicity (elevated AST, ALT, and gamma 
glutamyltranspeptidase).
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Multilevel regulation of TR transcriptional activation
Multiple configurations of thyroid hormone response elements
 To regulate gene transcription, both unliganded and liganded TRs (in combination 
with other TR or RXRs) bind to the TREs using the DBD. The TREs consist of two consensus 
hexanucleotide half-sites [(A/G)GGT(C/A/G)A] that can be arranged as a direct repeat (DR), 
inverted repeat (IR), and everted repeat (ER) (Figure 5) (35). The space between the two 
half-sites varies, depending on the orientation of the half-site. There is evidence showing that 
the orientation of TREs determines the dimerization pattern of TRs (67,68). In addition, in 
vitro studies of TRβ1 mutations show a differential effect on different TREs of some mutants 
(69,70), suggesting a TRE-specific transcriptional impairment. However, ChIP-seq analyses 
show that the DR4-TRE is the most common TR binding site identified at the promoter regions 
of TH target genes (71-74). Therefore, the exact role of different TRE configurations on 
transcriptional gene regulation is still doubtful.
Figure 5. Consensus TRE half-site and three main TRE configurations. [DR4, direct repeat; IR0, inverted 
repeat; ER6, everted repeat] (Adapted from Cheng SY et al. 2010 (35))
TR-RXR heterodimerization
 As mentioned previously, TRs either form homodimers or heterodimers with RXRs 
to regulate gene expression. However, heterodimerization with RXR is the primary form of 
TR-dimerization for both TRα1 and TRβ1 isoforms. The heterodimerization dramatically 
increases the binding of TRs to TREs, and the T3-induced transcriptional activation (35). 
TRs bind to RXRs via a highly conserved ninth heptad region in H11 of the TR LBD (Leu367-
Leu374 of TRα1 and Leu421-Lue428 of TRβ1) (75). Mutations in this region concomitantly 
decrease heterodimerization and receptor transactivation (34) Although TRs mainly form 
heterodimers, previous studies indicate that TRβ1 may have a greater tendency than TRα1 
to form homodimers on several TREs, suggesting that these two isoforms may have different 
dimerization potentials (34)
T G A C C C C A G C T G A G  G T C A
A G G T C A   C A G G A G G T C A
A G G T C A    T G A C C T
DR4:
IR0:
ER6:
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TR-coregulatory protein interactions
 To control target gene expression, TRs associate with many coregulatory proteins. 
These proteins modify the histone core of nucleosomes by acetylation, methylation, and 
ubiquitination, all of which lead to a change of the chromatin structure (chromatin remodeling) 
and accessibility of target genes (73,76). In case of genes that are positively regulated by TH, 
unliganded TRs recruit corepressor proteins to repress gene transcription, while liganded TRs 
induce coactivator recruitment and consequently stimulate gene transcription. This process is 
called the “classic bimodal switch model” of TR action (Figure 6) (77).
Figure 6. Classic bimodal switch model of TR action. (A) Unliganded-TR heterodimerizes with RXR and 
recruits corepressor proteins, leading to nucleosome packing. (B) Liganded-TR, in combination with 
RXR, recruits coactivator proteins, including histone acetyltransferase (HAT) that acetylate (triangles) 
neighboring histones. This process unpacks the nucleosomes and allows critical enzymes such as RNA-
polymerase II (Pol-II) to approach the target gene and initiate gene transcription.
 The most well-known TR corepressors are NCoR (nuclear receptor corepressor) 
and its homolog, SMRT (silencing mediator of retinoid and thyroid hormone receptors). 
These proteins bind to the corepressor interacting sites in the C-terminal region of TRs and 
recruit other nuclear proteins such as transducing-like protein (TBL1 or TBL1R) and histone 
deacetylase 3 (HDAC3) to form large corepressor complexes (78-80). By removing the acetyl 
group from histones, HDAC3 creates nucleosome compaction, thereby inhibiting the binding 
of RNA polymerase II which results in suppression of target gene transcription.
 Binding of TH to TRs causes a conformational change in H12 of the TR-LBD, in a way 
that favors dissociation of the corepressors from and association of the coactivators with the 
TRs. The main TR-binding coactivators are steroid hormone receptor co-activator 1, 2, and 3 
(SRC-1, -2, and -3) (81,82). SRCs interact with coactivator interaction sites of TRs by using 
the LXXLL motif (NR box) located in the central part of the SRC molecule. After binding to the 
TRs, two activating domains (ADs) located in the C-terminal region of SRC recruit chromatin-
A. B.
20
 Chapter 1 
1
modifying coregulatory complexes such as CBP/p300 processing histone acetyltransferase 
(HAT), which results in chromatin accessibility and activates gene transcription.
 Apart from well-known corepressors and coactivators, other nuclear proteins have 
also been reported as coregulators for TRs. For instance, Hairless (83,84), Alien (85,86), RIP-
140 (87), and Jab1 (88) were identified as corepressors, whereas nuclear receptor-interacting 
factor 3 (NRIF3), as known as integrin subunit beta 3 binding protein (ITG3BP), was identified 
as a coactivator for TRs (89,90). This evidence highlights the complexity of gene transcriptional 
regulation by TRs. In addition, the expression of many nuclear receptor coregulatory proteins 
could be tissue-dependent (40,91-93), and some patterns of coregulatory protein recruitment 
could be isoform-specific (38,91,94). These mechanisms could further explain the various 
transcriptional regulations of TR in different tissues.
Mutation of TRs: Resistance to thyroid hormone
 Resistance to TH (RTH) is a syndrome of reduced sensitivity to TH of target tissues, 
which was firstly described in 1967 (95). Mutations of the gene encoding TRβ (THRB) were 
subsequently identified as a cause of this disease (96). Since then, the term RTH has become 
synonymous with this condition. In 2012, mutations of the gene encoding TRα (THRA) were 
identified (97,98), thereby extending the spectrum of RTH. Today, RTH includes all syndromes 
resulting from dysfunction in TH transport, deiodination and receptor dysfunction (99,100). 
However, in this thesis, we mainly focus on RTH caused by mutations of the TRs (RTHα and 
RTHβ respectively).
RTHβ
 Mutations in the LBD of TRβ1 and TRβ2 lead to RTHβ. Common biochemical 
characteristic includes high serum T3 and T4 concentrations with normal or slightly increased 
TSH level. However, the clinical presentation varies between patients. This is partly dependent 
on the severity of hormonal resistance, but there is also large variation between different family 
members with the same mutation. Goiter is the main clinical finding that prompts patients to 
seek for medical investigations (100,101). Tachycardia, short stature, and attention deficit 
disorders can also be part of the clinical presentation in affected individuals because of the 
effect of high THs in TRα predominant tissues such as heart, brain, and bone. The incidence 
of RTHβ is approximately 1:40,000 live births (102,103).
 RTHβ is usually inherited in an autosomal dominant fashion (100). Single nucleotide 
substitutions leading to amino acid replacement are more common than frameshift or nonsense 
mutations that result in premature protein truncations (104-106). To date, over 160 different 
mutations have been identified as a cause of RTHβ in more than 350 families (101,107). 
These mutations are located in three CpG rich hotspots (cluster 1; codon 426-461, cluster 2; 
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310-353, and cluster 3; codon 234-282) that are prone to mutate in the LBD and the hinge 
region of TRβ (100). Therefore, mutations commonly impair affinity for TH and consequently 
reduce transcriptional activity of the receptor. However, mutations that impair TR dimerization 
or interaction with nuclear co-regulatory proteins have also been reported (70,108-115).
RTHα
 Because of a high degree homology between TRα and TRβ (overall 80% of amino 
acids in their LBD are identical), it was anticipated for many years that mutations in TRα 
would also be able to cause RTH. Therefore, many knock-in and knock-out mouse models 
were generated to predict the clinical phenotype of RTHα (116-119). All of the mutated mice 
showed impaired growth and bone development but near normal TFTs, complicating the easy 
identification of RTHα patients. As a consequence, mutations in THRA as a cause of RTHα 
had not been identified until 2012 (97,98), probably due to this lack of an obvious thyroid 
function abnormality.
Figure 7. Localization of 25 TRα1 mutations identified in RTHα patients. [A/B, A/B domain; DBD, DNA-
binding domain; H, hinge region; LBD, ligand binding domain]
 The clinical phenotype of RTHα patients is distinct from RTHβ and includes growth 
retardation, macrocephaly, constipation, intellectual disability, autistic spectrum disorder, and 
anemia. Their TFTs are typically characterized by high to high-normal (F)T3, low to low-normal 
(F)T4, low rT3 and normal TSH concentrations, resulting in markedly increased (F)T3/(F)T4 
and (F)T3/rT3 ratios. To date, 25 mutations (in a total of 40 patients) have been reported as 
a cause of RTHα, all of which are located in the LBD of TRα1 and impair T3 binding affinity 
(Figure 7). These mutations can be categorized into two groups based on the type of mutation. 
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The first group consists of truncating mutations caused by frameshift or nonsense mutations 
that lead to premature stop codons and shorten the length of the LBD (97,98,120-124). This 
structural alteration abolishes T3 affinity and T3-induced transcriptional activity of TRα1. The 
second group consists of missense mutations that result in single amino acid substitutions in 
the LBD (121,122,125-133). These mutant receptors can still bind T3 but with a lower affinity 
than the WT receptor.
Diverse functional impairment of TR mutants and phenotype variability
 In RTHβ, patients who carry different mutations commonly have differences in 
phenotype severity as well as thyroid dysfunction. Interestingly, these differences are also 
found between individuals that express the same mutation (100,101). This same variety in 
clinical phenotype is also observed in RTHα patients. In general, patients with truncating 
mutations that completely abolish T3 binding affinity have a more severe phenotype than 
patients with missense mutations that have residual T3 binding (128). However, there are 
differences within each group and even between patients carrying the same mutation. For 
instance, in a large RTHα family carrying A263S mutation, the severity of constipation, 
macrocephaly, delay development, and anaemia, are diverse between affected members 
(121). So far, the underlying molecular mechanism to explain this observation has not been 
clearly revealed.
 Since mutations in TRα and TRβ are mainly located in the LBD and affect T3 binding 
affinity of the receptors, it could be anticipated that the severity of T3 binding impairment by 
the different mutants correlates with the degree of transcriptional impairment and the severity 
of the clinical phenotype. However, it has been demonstrated in RTHβ that differences in T3 
binding do not solely explain the diversely impaired transcriptional activation of the mutants. 
Some TRβ mutants have severe transcriptional impairment despite only mild disturbances 
in T3 binding affinity. In vitro studies showed that these mutants either impair dimerization 
(69,108,109,111,134) or TR-cofactor interaction (70,112-115,135). In addition, a small 
group of TRβ mutants impairs transcriptional activation only when associated with certain 
TRE configuration (70). These findings may partly explain the phenotype variability in RTHβ 
patients. Since RTHα has recently been identified, additional patients and studies to explore 
the differences in RTHα are needed.
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Outline of the thesis
 In this thesis, we focus on the complexity of the genomic actions of TH. In chapter 2, 
we describe a novel mutation, TRβ1-L341V, as a cause of RTHβ and emphasize the crucial 
role of the Leu341 in TRβ function. In chapter 3, we unravel the molecular and structural 
mechanism underlying the differences in biological activity of T3 and T4, prompted by the 
identification of a novel TRα1-M256T and previously reported TRβ1-M310T mutations in 
RTHα and β patients, respectively.  In chapter 4, we investigate the factors that contribute 
to the differential impaired transcriptional activity of seven TRα missense mutations, four of 
which are derived from RTHα patients. In chapter 5, we study the difference in neurocognitive 
impairment of RTHα patients carrying various truncating mutations by evaluating the pattern 
of gene expression of stably expressed WT or mutant TRα1 in a human neuronal cell line 
(SH-SY5Y). In chapter 6, we explore the pattern of nuclear coregulatory protein recruitment 
of TRs using interactome analysis. Chapter 6a focuses on the cell-type specific coregulatory 
protein recruitment of TRα1 by performing the experiments in human liver and neuronal 
cell lines (HepG2 vs. SH-SY5Y). Chapter 6b focuses on the isoform-dependent (TRα1 vs. 
TRβ1) coregulatory protein recruitment. In chapter 7, we discuss the findings presented in 
this thesis combining with the currently available literature and the possible implications of 
these studies.
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Abstract
Background: Leucine 341 has been predicted from crystal structure as an important residue 
for thyroid hormone receptor β (TRβ) function, but this has never been confirmed in functional 
studies. Here, we verify the role of Leu341, driven by the identification of a novel L341V 
mutation in a 12-year-old girl with resistance to thyroid hormone β (RTHβ).
Methods: Genomic DNA was sequenced for mutations in the THRB gene. A novel L341V 
mutation as well as three artificial mutations (L341A, L341I, and L341F) were modeled in the 
wild-type (WT) T3-bound TRβ1 crystal structure. T3 binding affinity and transcriptional activity 
of the mutants were determined and compared with WT TRβ1.
Results: A heterozygous missense mutation in THRB (c.1021C>G; p.L341V) was found in 
a patient presented with diffuse goiter, tachycardia, and high serum FT4 and FT3 with non-
suppressed TSH, indicative of RTHβ. Structural modeling of this mutation showed altered 
side-chain orientation and interactions of T3 with receptor. This was confirmed by in vitro 
studies demonstrating reduced affinity for T3 and impaired transcriptional activity of TRβ1-
L341V. In addition, substitution of Leu341 by an alanine (A), isoleucine (I), or phenylalanine 
(F) reduced receptor function to various degrees, depending on their side-chain size and 
orientation and thus ability to maintain important structural interaction.
Conclusion: Leu341 has a critical role in T3 binding and hence TRβ function, and its mutation 
results in the clinical phenotype of RTHβ.
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Introduction
 Thyroid hormone (TH) is crucial for normal growth, development and metabolism. 
It is widely accepted that TH predominantly mediates its effects via transcriptional regulation 
of genes by binding of the active hormone, triiodothyronine (T3), to nuclear thyroid hormone 
receptors (TRs). Three functional TR isoforms, i.e., TRα1, TRβ1 and, TRβ2, are encoded 
by two different genes, THRA on chromosome 17 and THRB on chromosome 3 (1). The 
expression of TRs varies among tissues. TRα1 is mainly expressed in the brain, bone, heart, 
intestine, and skeletal muscle, whereas TRβ1 is principally expressed in the liver, kidney, 
and thyroid gland. TRβ2 is predominantly expressed in the retina, cochlea, as well as the 
hypothalamus and pituitary, where it plays a crucial role in a negative feedback control of the 
hypothalamic-pituitary-thyroid (HPT) axis.
 Mutations in the THRB gene cause resistance to thyroid hormone β (RTHβ), which 
was first described in 1967 (2) and the first mutation was subsequently identified in 1989 
(3). The estimated incidence is approximately 1:40,000 live births (4,5). The biochemical 
characteristics are elevated T4 and T3 with non-suppressed TSH concentrations because 
of impaired TRβ2 function in hypothalamus and pituitary, which consequently alters negative 
feedback control. The clinical phenotype is variable and may include goiter, tachycardia, and 
learning disability with or without hyperactive behavior.
 RTHβ is usually inherited in an autosomal dominant fashion (6,7). Single nucleotide 
substitutions resulting in amino acid replacement are more common than frameshift or 
nonsense mutations that lead to premature protein truncations (8-10). These mutations mainly 
locate in 3 CpG transition and CG rich cluster regions (cluster 1; codon 426-461, cluster 2; 
310-353, and cluster 3; codon 234-282) which encode the ligand binding domain (LBD) and 
the hinge region of TRβ protein (6). Therefore, mutations commonly impair affinity for T3 and 
consequently reduce transcriptional activity of the receptor.
 The affinity for T3 of TRβ is determined by the interactions between the T3 molecule 
and the amino acid residues that form the ligand-binding cavity (11,12). For instance, 
crystallization of the TRβ protein and subsequent in vitro studies revealed that Arg282 and 
His435 play a crucial role in hormone binding (13-17). Another residue that was found to line 
the ligand binding pocket is Leu341 (18,19). A proline substitution at this position (L341P) 
has previously been described in RTHβ patients, supporting the importance of this residue 
(20,21). However, functional studies on the role of this Leu341 for the function of TRβ1 have 
not yet been established.
 In this study, we describe a 12-year-old girl with RTHβ caused by a novel L341V 
mutation in TRβ. In silico studies suggest altered T3 binding of TRβ1-L341V which is confirmed 
by reduced affinity for T3 and impaired transcriptional activity in in vitro studies. In addition, 
substituting Leu341 with other non-polar amino acids also impairs receptor function to various 
degrees, depending on their side-chain size and orientation and thus ability to maintain 
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important structural interactions. These findings emphasize the functional importance of 
Leu341 for TRβ activity.
Materials and methods
Clinical and genetic assessment
 The index patient was referred to our institute because of poorly controlled 
Graves’ disease. Thyroid function tests were evaluated after one month of methimazole 
(MMI) withdrawal using an electrochemiluminescence immunoassay kit (Roche Diagnostic, 
Mannheim, Germany). Informed consent was obtained from the parents of the index patient. 
The study was approved by the Medical Ethics Committee of the Faculty of Medicine, Chiang 
Mai University, Thailand.
 Genomic DNA was extracted from peripheral blood leukocytes by QIAamp® DNA Mini 
Kit (Qiagen, Hilden, Germany). Exons 7-10 of the THRB gene [GeneBank: NM_000461.4], 
including exon-intron boundaries, were amplified (see Supplementary Table S1 for primers). 
Sequencing was performed as described previously (22). The exon carrying the mutation was 
re-amplified and sequenced to exclude a PCR error.
In silico prediction of mutant TRβ1 function
 YASARA Structure Software (YASARA Bioscience GmbH, Vienna, Austria) (23) was 
used to model the TRβ1-L341V patient’s mutation and three artificial mutants (L341A, L341I 
and L341F) into a T3-bound wild-type (WT) TRβ1 crystal structure (PDB-ID: 3GWS) (24) 
using the side-chain substitution tool. Side-chain orientations were optimized using SCWALL 
(Side-Chain conformations With ALL available methods) (25,26), after which the final models 
were minimized without further constraints. All images were created using YASARA Structure 
and Pov-Ray v3.6 software (www.povray.org).
DNA constructs and mutagenesis
 The human TRβ1 cDNA was amplified and subcloned into the EcoRI and XbaI sites 
of the pcDNA3 expression vector fused at the 5’-end to the sequence encoding the FLAG-
epitope tag and downstream of an optimized Kozak sequence (see Supplementary Table S1 
for primers). The TRβ1-L341V patient’s mutation (c.1021C>G) and three artificial mutants, 
including L341A, L341I and L341F, were introduced using the QuickChange II Mutagenesis 
kit (Agilent Technologies, Amstelveen, The Netherlands) according to manufacturers’ protocol 
(see Supplementary Table S1 for primers). Sequences of mutant constructs were confirmed 
by Sanger sequencing.
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[125I]T3 competitive binding assay
 Human FLAG-tagged TRβ1 WT and mutant (L341V, L341A, L341I and L341F) 
receptor proteins were synthesized in reticulocyte lysate using the TnT® T7 Quick Coupled 
Transcription/Translation System (Promega, Leiden, The Netherlands). The protein lysate 
was incubated with 0.02 nM of [125I]T3 in 0.5 mL binding buffer (20 mM Tris, pH 8.0, 50 mM 
KCl, 1 mM MgCl2, 10% glycerol, 5 mM DTT) and 0-10,000 nM unlabeled T3 for 2 hours 
at 30°C. Protein-bound [125I]T3 was captured by filtering through a nitrocellulose filter 
membrane (Millipore HA filters, 0.45 µm) under vacuum. The data was corrected for non-
specific binding (counts bound at 10,000 nM unlabeled T3) and expressed as percentage 
maximal [125I]T3 binding (counts bound at 0 nM unlabeled T3). The [125I]T3 displacement curve 
and the dissociation constant (Kd) were computed by GraphPad Prism program version 5.0 
(GraphPad, La Jolla, CA) and shown as mean ± standard error of the mean (SEM) of three 
independent experiments performed in duplicate.
Cell culture and transfection
 JEG-3 cells were cultured and transfected as previously described (27). In brief, 20 
ng of FLAG-tagged WT or mutant TRβ1 expression vectors and 120 ng of luciferase reporter 
constructs containing either direct repeat (DR4), inverted repeat (IR0) or everted repeat 
(ER6) thyroid hormone response element (TRE) (28), as well as 60 ng pMaxGFP transfection 
control, were transiently transfected into cells in TH depleted medium using Xtreme Gene 9 
transfection reagent (Roche Diagnostics, Almere, The Netherlands). To determine the effect 
of TRβ1-L341V on WT function (dominant-negative effect), we co-expressed WT and TRβ1-
L341V receptors (1:1 equimolar ratio), or either WT or TRβ1-L341V with empty vector (EV) 
(as gene dose control). After 24 hours, cells used for luciferase assays were incubated in 
DMEM/F12 medium supplemented with 0.1% bovine serum albumin and containing 0-10,000 
nM T3 for 24 hours.
Immunoblotting
 To determine the expression of FLAG-tagged TRβ1 WT and mutants in JEG-3 cells, 
nuclear proteins were extracted as described previously with slight modifications (29). Briefly, 
cells were swollen on ice for 15 min in buffer A (10 mM Hepes, 10 mM KCl, 0.1 mM EDTA, 1 mM 
DTT, pH 7.9) supplemented with the Complete Protease Inhibitor cocktail (Roche Diagnostics) 
and were lysed by addition of 0.6% NP40. The nuclei were pelleted by centrifugation for 10 
min at 2500 g and extracted for 45 min in buffer C (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 
1 mM DTT, Complete Protease Inhibitors, pH 7.9) at 4˚C. After centrifugation for 15 min at 
20000 g, the supernatants containing nuclear proteins were collected and diluted in buffer D 
(20 mM HEPES, 1 mM EDTA, Complete Protease Inhibitors, pH 7.9). Immunoblotting was 
performed as previously described (27). The FLAG-tagged TRβ1 and Histone 3 (as loading 
control) were detected by FLAG-M2 antibody (#F1804 Sigma-Aldrich) and Histone 3 (H3; 
1B1B2) antibody (#14269 Cell Signaling Technology), respectively, at a 1:1000 dilution and 
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visualized by Enhanced Chemiluminescence (Thermofisher Scientific) on the Alliance 4.0 
Uvitec platform (Uvitec Ltd).
Luciferase assays
 Luciferase activity of WT and mutant receptors was measured using the Dual 
Glo Luciferase kit (Promega, Leiden, The Netherlands) as previously described (22). The 
ratio between luciferase and GFP was calculated to adjust for transfection efficiency. Data 
were expressed as percentage maximal response of WT and half maximal effective T3 
concentration (EC50) and maximal response calculated using GraphPad Prism program 
version 5.0 (GraphPad, La Jolla, CA). The results are shown as mean ± SEM of at least three 
independent experiments performed in triplicate.
Statistical analysis
 Statistical differences of logKd and logEC50 values between WT and mutants were 
analyzed by student’s t-test. The percentage maximal response of mutants was compared to 
WT by one sample t-test. The statistical difference of logKd and logEC50 values between four 
mutants (L341V, L341A, L341I, and L341F) was determined by one-way ANOVA with Tukey’s 
post-test. Statistical significance was considered when p-values < 0.05.
Results
Clinical and genetic assessment 
 A 12-year-old Thai girl (II.3) born to non-consanguineous parents presented with 
goiter and palpitations for four years. She had been diagnosed erroneously with Graves’ 
disease and treated with methimazole for three years without remission. During treatment, 
she had fluctuating thyroid hormone and increased TSH concentrations. Physical examination 
showed a height of 134 cm (-3.17 SDS), a weight of 27.2 kg, a BMI of 15.1 kg/m2 (-1.83 
SDS), tachycardia (heart rate 144/min) and diffuse thyroid gland enlargement. Her thyroid 
function tests showed high FT4 and FT3 with non-suppressed TSH concentrations (Figure 1, 
Supplementary Table S2). Interestingly, an older sister (II.2) and her mother (I.2) also suffered 
from presumed Graves’ disease, for which the mother had undergone a subtotal thyroidectomy 
and subsequently developed postoperative hypothyroidism, which required high doses of 
levothyroxine (300 µg/day). Because of the high TH with non-suppressed TSH concentrations 
of the index patient and affected family members, Graves’ diagnosis was incorrect and RTHβ 
was suspected in this family.
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Figure 1. (A) The pedigree demonstrates three RTHβ patients in the family. (B-F) The graphs show 
thyroid function tests of affected family members (closed dot [●]: during antithyroid drug treatment and 
normal TSH; open dot [○]: during antithyroid drug treatment with high TSH; triangle [▲]: no treatment; 
[-----]: reference ranges).
 After obtaining informed consent, genomic DNA of exons 7-10 of the THRB gene from 
the index patient and family members was sequenced and a novel heterozygous missense 
mutation at codon 341 leading to a leucine to valine substitution (c.1021C>G, p.L341V) was 
found in the index patient (II.3), the older sister (II.2) and the mother (I.2) (Supplementary 
Figure S1). This mutation was not found in the father (I.1) and is not present in public databases 
(dbSNP, 1000 Genomes, and Exome Aggregation Consortium [ExAC]).
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In silico modeling of the TRβ1-L341V mutant
 Inspection of the crystal structure of the T3-bound WT TRβ1 receptor (PDB-ID: 
3GWS) revealed that Leu341 is located at the TRβ1 ligand-binding pocket (Figure 2A). Its 
aliphatic side-chain is predicted to form a direct hydrophobic interaction with the outer ring of 
the T3 molecule (Figure 2B). In addition, Leu341 interacts with several surrounding residues, 
amongst others the ligand-interacting residues Phe272, Leu330, and Leu346. In this way, 
Leu341 likely determines their orientation towards the T3 molecule and the overall shape and 
integrity of the ligand-binding pocket. Next, the L341V mutant was modeled into the T3-bound 
WT TRβ1 receptor crystal structure (Figure 4A). As a consequence of the shorter side-chain 
length of valine and an altered side-chain orientation as compared to the original leucine 
residue, it is not likely to form a direct interaction with ligand. Moreover, at least part of the 
hydrophobic interactions with surrounding residues, most importantly Leu330, is likely to be 
disturbed, which may impede the structural integrity of the ligand-binding pocket. All together, 
these observations suggest that the L341V mutant may reduce ligand-binding affinity and 
consequently receptor function.
Arg282 His435
Leu330 Phe272 Leu346Leu341
A. B.
Figure 2. (A) Crystal structure of T3-bound WT TRβ1 (PDB-ID: 3GWS) in which the side chain of the 
affected Leu341 is depicted in red. (B) Close-up view of the ligand binding domain showing the side-
chains of ligand-interacting residues. Arg282 and His435 form hydrogen bonds with the carboxyl group of 
the alanine side-chain and phenolhydroxyl group of T3, respectively (purple dashed lines). Together with 
Leu330, Phe272, and Leu346, Leu341 (in red) forms a hydrophobic pocket accommodating the two 
phenolic rings of the T3 molecule through hydrophobic (green lines) and pi-pi (pink-red lines) interactions.
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In vitro functional analysis of TRβ1-L341V
 To understand the effect of the L341V mutation on TRβ1 function, we performed 
[125I]T3 competitive binding assays to determine the T3 binding affinity of the WT and mutant 
receptors. TRβ1-L341V showed a 16-fold higher dissociation constant (Kd) than WT TRβ1, 
indicating an impaired T3 binding affinity for the mutant (Figure 3A, Supplementary Table S3).
 Next, we measured T3-dependent transcriptional activity of overexpressed WT 
or TRβ1-L341V receptors in JEG-3 cells using a luciferase reporter assay. The expression 
of receptor constructs was confirmed by immunoblotting (Figure 3B). The mutant receptor 
showed a significantly higher EC50 compared with WT TRβ1 on all TREs (60-fold on DR4, 40-
fold on IR0, and 90-fold on ER6), reflecting an impaired T3-induced transcriptional activity of 
this mutation. However, the TRβ1-L341V showed similar maximal transcriptional activity with 
WT TRβ1, demonstrating that supra-physiological doses of T3 can rescue the transcriptional 
activity of the TRβ1-L341V (Figure 3C-E, Supplementary Table S3).
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Figure 3. Functional analysis of TRβ1-L341V. (A) The [125I]T3 dissociation curve of mutant shifts to the 
right suggesting an impaired affinity for T3 (data presented as mean ± SEM of three independent 
experiments performed in duplicate). (B) Immunoblotting confirms the expression of WT and TRβ1-L341V 
in JEG-3 cells. (C-E) The TRβ1-L341V shows impaired transcriptional activity on all TRE tested, as 
indicated by the right shift of the T3-induced dose-response curves. Co-transfection of WT with TRβ1-
L341V alters transcriptional activity of WT in a dominant-negative manner (data presented as mean ± 
SEM of four independent experiments performed in triplicate).
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 The effect of TRβ1-L341V on WT TR function or its dominant-negative activity was 
tested by co-expressing WT and TRβ1-L341V. The EC50 of co-expressed WT and TRβ1-
L341V was higher than that of WT only (3-fold on DR4, 5-fold on IR0, and 14-fold on ER6) 
suggesting a dominant-negative effect of the mutant receptor (Figure 3C-E, Supplementary 
Table S4). Together, these in vitro studies support an important role for Leu341 in substrate 
binding and receptor function.
In silico modeling and in vitro functional analysis of artificial mutations at 
341 residue
 To further delineate the function of Leu341, we generated expression constructs in 
which the Leu341 was substituted by an isoleucine (L341I), alanine (L341A), or phenylalanine 
(L341F). All of them have hydrophobic side-chains but of different sizes and structural 
properties (Figure 4A). In case of the isoleucine substitution, the branched chain character 
and the size of the side-chain are maintained, whereas the side-chain of an alanine is smaller. 
In contrast, the side-chain of phenylalanine is more bulky and rigid compared to the original 
isoleucine. Structural modeling of the L341I mutant suggested loss of direct contacts with 
ligand and slight alterations in the interactions with the surrounding residues. Obviously, 
these interactions were predicted to be even more extensively disturbed in case of the L341A 
mutant as a consequence of the size reduction of the side-chain. Although the bulky side-
chain of phenylalanine was predicted to slightly alter the local architecture of the ligand-
binding pocket, most of the essential interactions with the surrounding residues as well as the 
direct interaction(s) with the T3 molecule were preserved.
 In vitro studies confirmed the functional impairment of these artificial mutants. The 
Kd of all three mutants indicating their affinity for T3, was significantly higher than WT. (Figure 
4B, Supplementary Table S5). These results demonstrate that substitution of Leu341 by other 
non-polar amino acids with different side-chain size and orientation results in impaired T3 
binding affinity of TRβ1. Interestingly, the shift in Kd was proportional to the size of the side-
chain that was introduced and hence the distance to the substrate molecule and surrounding 
residues. Substitution by alanine and valine, which have a smaller size of the side-chain than 
isoleucine and phenylalanine, produced the higher shifts in Kd.
 The shift of T3-induced transcriptional activity of the mutant receptors on the DR4 TRE 
showed a similar trend as the shift in affinity for T3. The EC50 of all mutants was significantly 
higher than that of WT TRβ1. In addition, the degree of the shift in EC50 also depended on the 
size and orientation of the side-chain (Figure 4C, Supplementary Table S5).
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Figure 4. (A) Crystal structure of WT TRβ1 (PDB-ID: 3GWS) and structural models of the L341V and 
three artificial mutants (L341A, L341I and L341F) showing the side-chain size and orientation toward the 
T3 molecule and surrounding residues of the different residue side-chains. The WT Leu341 residue forms 
a direct interaction with ligand as well as extensive hydrophobic interactions (green lines) with its 
surrounding residues by which it stabilizes the hydrophobic pocket. All mutants were predicted to disturb 
these interactions to various degrees, with the L341F having the smallest impact. (B) The [125I]T3 
dissociation curve show the diverse severity of T3 binding impairment of the mutants (data presented as 
mean ± SEM of three independent experiments performed in duplicate). (C) Transcriptional activity of the 
mutant receptors is impaired, as indicated by the right-shifted of T3-induced dose-response curves tested 
on DR4 TRE (data presented as mean ± SEM of three independent experiments performed in triplicate). 
(Insert) Immunoblotting confirms the expression of all receptor constructs.
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Discussion
 In this study, we describe the role of Leu341 in TRβ function prompted by the 
identification of a novel TRβ1-L341V mutation in an RTHβ family. In silico modeling of TRβ1-
L341V predicted interference with T3 binding, which was verified by [125I]T3 competitive 
binding assays. Transcriptional impairment and dominant-negative ffect of this mutant was 
confirmed by in vitro studies. Additional artificial mutants (L341A, L341I, and L341F) were 
created based on the in silico predictions, showing different degrees of receptor impairment 
which depended on the side-chain size and exact orientation. With detrimental effects being 
observed even with subtle L341I and L341V mutations, illustrates the importance of Leu341 
for TRβ1 function.
 The novel L341V mutation reported in this study was identified in a patient and 
affected family members that had all been misdiagnosed with Graves’ disease and treated 
with antithyroid drugs without remission. The mutation is located in a commonly mutated 
region (i.e., cluster 2) of TRβ1. Although the other mutation at this position, L341P, has been 
previously described (20,21), functional studies on the role of Leu341 in TRβ are lacking. 
Based on crystallographic analyses (24,30), Leu341 is predicted to be part of the TRβ1 ligand-
binding surface.
 Our in silico models suggest the presence of a direct hydrophobic interaction 
between Leu341 and the outer ring of the T3 molecule. Importantly, Leu341 also interacts with 
several other residues that line the ligand binding pocket, some of which (Phe272, Leu346) 
have been previously suggested to play an important role in ligand binding (15,31). Mutations 
in the latter have indeed been identified in RTHβ patients (20,32). Given its branched-chain 
character, Leu341 may therefore function as an important residue stabilizing the orientation 
of its surrounding residues. Shortening of its side-chain to valine would then affect the direct 
interaction with the T3 molecule, as well as the positioning and hence interactions of this 
residue with surrounding residues. The great impact of removing one side-chain methylene 
group in case of the TRβ1-L341V indeed suggests that the exact side-chain size and 
orientation at this position is of vital importance for substrate binding and hence receptor 
activity. We additionally confirmed this by studying three artificial mutations, L341A, L341I and 
L341F. The side-chains of these three amino acids all have similar hydrophobic properties but 
a different size and orientation, resulting in a variable distance to the T3 molecule.
 The in vitro studies confirmed the results of the in silico modeling. The TRβ1-L341V 
has a reduced affinity for T3, as indicated by the higher Kd compared to WT TRβ1, and 
impaired T3-dependent transcriptional activity, as indicated by the increased EC50 on all TREs 
tested. These data illustrate the resistance of TRβ1-L341V to T3 stimulation, which can, 
however, be overcome in case of higher (supra-physiological) doses of T3. Such rescue of 
function at high T3 concentrations has also been described with other TRβ1 mutations (33-
35) and is probably due to the fact that T3 binding affinity of these mutants is not completely 
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abolished. In addition to the in vitro studies of TRβ1-L341V, the three artificial mutants also 
showed significantly reduced affinity for T3 and impaired transcriptional activity. Interestingly, 
the degree of the shift in EC50 related to the distance between the side-chain and T3. These 
results further confirm that the interaction between T3 and TRβ1 receptor requires a proper 
distance between the amino acid at position 341 and inner ring iodine of T3.
 TRβ1-L341V also showed a dominant-negative effect on transcriptional activity of co-
expressed WT TRβ1 on all TREs tested, but strongest on the ER6 TRE. The strong dominant-
negative effect on this TRE has also been observed in other TRβ1 mutants (34,36). In contrast 
to the DR4 and IR0 TREs, where TRβ1 engages predominantly as a heterodimer with RXR, 
TRβ1 acts on ER6 as a homodimer (37). This means that in the heterozygous situation, only 
25% of homodimers are formed by WT receptors. If both receptors of the homodimer need to 
bind ligand in order to exert transcriptional activity, this may explain the stronger dominant-
negative effects on ER6 TRE.
 To our knowledge, this is the first study showing the role of the Leu341 residue in 
TRβ function, gaining more detailed insight into T3 and TRβ interaction. Taking into account 
the predictive nature of structural modelling, we managed to develop an in silico model 
that correctly predicts the degree of receptor impairment compared with in vitro studies. In 
addition, the creation of artificial mutations based on the in silico modeling proved to be a good 
approach to further explore the role and importance of affected amino acid residues.
 In conclusion, we verify the importance of the Leu341 residue for TRβ function. The 
interactions between Leu341, its surrounding residues, and T3 are required for optimal affinity 
for T3 and transcriptional activity. Mutations at this amino acid residue can reduce affinity for 
T3 and impair transcriptional activity of TRβ.
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Supplementary Materials
Supplementary Table S1. Primers for THRB sequencing, FLAG-TRβ1 cloning, and FLAG-TRβ1 
mutagenesis.
Condition Primers (5’-3’)
Exon 7 THRA Forward: TGCAGCTTGCTGTGTATCTTG
Reverse: CCCAAGGTGATGAGGACTG
Exon 8 THRA Forward: CTTTCTGCAGCAACAGTCC
Reverse: GTATTCCTGGAAACTGATGAAAC
Exon 9 THRA Forward: GAAAACCATGGGCTCAAAG
Reverse: TGAAGCTAAAGGGGGACTG
Exon 10 THRA Forward: TAAAGGCCTGGAATTGGAC
Reverse: TGCTTGGTGCTGGTGAG
FLAG-TRβ1 cloning Forward: GTAGAATTCTGGCCGCAGAAATGGACTACAAAGACGATGACG
                ACAAGATGACTCCCAACAGTATGACAGAAAATG 
Reverse: CTATCTAGACTAATCCTCGAACACTTCCAAGAAC
L341V
(CTG>GTG)
Forward: GACACGGGGCCAGGTGAAAAATGGGGG
Reverse: CCCCCATTTTTCACCTGGCCCCGTGTC
L341A
(CTG>GCG)
Forward: GTGACACGGGGCCAGGCGAAAAATGGGGGTCT
Reverse: AGACCCCCATTTTTCGCCTGGCCCCGTGTCAC
L341I
(CTG>ATC)
Forward: AGTGACACGGGGCCAGATCAAAAATGGGGGTCTTG
Reverse: CAAGACCCCCATTTTTGATCTGGCCCCGTGTCACT
L341F
(CTG>TTC)
Forward: AGTGACACGGGGCCAGTTCAAAAATGGGGGTCTTG
Reverse: CAAGACCCCCATTTTTGAACTGGCCCCGTGTCACT
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Supplementary Table S2. Clinical and biochemical characteristics of index patient and family members.
Parameter Index case (II.3) Sister (II.2) Mother (I.2)
Age (year) 12 23 51
Clinical presentation goiter, tachycardia goiter, tachycardia goiter
Thyroid function tests [normal range]
- TSH (μIU/mL) [0.5-4.8] 3.29 2.45 1.2
- TT4 (µg/dL) [4.2-13.0] N/A 13.5 12
- FT4 (ng/dL) [0.8-2.3] 5.37 N/A N/A
- TT3 (ng/dL) [55-170] N/A 221 190
- FT3 (pg/mL) [2.3-4.2] 14.31 N/A N/A
- Anti-TPO (IU/mL) [<40] 5.0 N/A N/A
- Anti-TG (IU/mL) [<125] 19.9 N/A N/A
- TRAb (IU/L) [0.00-1.75] <0.3 <0.3 N/A
Previous treatment MMI 15 mg/day MMI
MMI then subtotal 
thyroidectomy 
TSH, thyroid-stimulating hormone; TT4, total thyroxine; FT4, free thyroxine; TT3, total triiodothyronine; FT3, 
free triiodothyronine; Anti-TPO, anti-thyroid peroxidase; Anti-TG, anti-thyroglobulin; TRAb, thyrotropin receptor 
autoantibody; MMI, methimazole; N/A, not available
Supplementary Table S3. Functional analysis of WT and TRβ1-L341V. 
Parameter TRE WT TRβ1 TRβ1-L341V
LogKd [Kd(nM)] - -0.51±0.13 [0.31] 0.70±0.06** [5.01]
LogEC50 [EC50(nM)] DR4 -0.45±0.04 [0.35] 1.32±0.04*** [21.1]
IR0 -0.17±0.04 [0.67] 1.69±0.16*** [49.5]
ER6 0.31±0.09 [2.03] 2.43±0.16*** [269]
% WT maximal response DR4 100 106±22.6
IR0 100 107±22.5
ER6 100 83.9±8.41
student’s t-test compared to WT, *p<0.05, **p<0.01, ***p<0.001
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Supplementary Table S4. The dominant-negative effect of TRβ1-L341V on transcriptional activity of WT 
receptor.
Parameter TRE WT+WT WT+EV L341V+ 
L341V
L341V+EV WT+L341V
p-value 
(One way 
ANOVA)
LogEC50
[EC50(nM)]
DR4 -0.45±0.04
[0.35]
-0.47±0.04
[0.34]
1.32±0.04
[21.1]
1.36±0.02
[22.9]
0.05±0.13***, †††
[1.11]
<0.0001
IR0 -0.17±0.04
[0.67]
-0.11±0.15
[0.77]
1.69±0.16
[49.5]
1.53±0.18
[33.7]
0.52±0.13*,†
[3.29]
<0.0001
ER6 0.31±0.09
[2.03]
0.32±0.30
[2.11]
2.43±0.16
[269]
2.43±0.19
[267]
1.46±0.45
[28.9]
<0.0001
Tukey’s post-test compared to WT+WT, *p<0.05, **p<0.01, ***p<0.001, and WT+EV, †p<0.05, ††p<0.01, †††p<0.001
Supplementary Table S5. Functional analysis of artificial mutants at 341 amino acid residue.
Parameter WT TRβ1 TRβ1-L341V TRβ1-L341A TRβ1-L341I TRβ1-L341F
p-value 
(One way
 ANOVA)
LogKd
[Kd(nM)]
-0.51±0.13
[0.31]
0.70±0.06**
[5.01]
0.66±0.06**
[4.54]
0.47±0.10**
[2.94]
0.53±0.11**
[3.42]
0.2606
LogEC50
[EC50(nM)]
-0.47±0.03
[0.34]
1.33±0.04***
[21.38]
1.37±0.04***
[23.12]
1.19±0.35***
[15.35]
0.33±0.06***
[2.14]
0.0113
student’s t-test compared to WT, **p<0.01, ***p<0.001
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Supplementary Figure S1 Sequence analysis of exon 9 of THRB shows a heterozygous missense 
mutation (c.1021C>G) in index case (II.3), older sister (II.2) and mother (I.2), resulting in a valine 
substitution at codon 341 (p.L341V).
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Abstract
Context: The two major forms of circulating thyroid hormones (THs) are T3 and T4. T3 is 
regarded as the biologically active hormone because it binds to TH receptors (TRs) with 
greater affinity than T4. However, it is currently unclear what structural mechanisms underlie 
this difference in affinity.
Objective: Prompted by the identification of a novel M256T mutation in a resistance to TH 
(RTH)α patient, we investigated Met256 in TRα1 and the corresponding residue (Met310) in 
TRβ1, residues previously predicted by crystallographic studies in discrimination of T3 vs T4. 
Methods: Clinical characterization of the RTHα patient and molecular studies (in silico protein 
modeling, radioligand binding, transactivation and receptor-cofactor studies) were performed.
Results: Structural modeling of the TRα1-M256T mutant showed that distortion of the 
hydrophobic niche to accommodate the outer ring of ligand was more pronounced for T3 than 
T4, suggesting that this substitution has little impact on the affinity for T4. In agreement with 
the model, TRα1-M256T selectively reduced the affinity for T3. Also, unlike other naturally 
occurring TRα mutations, TRα1-M256T had a differential impact on T3- vs T4-dependent 
transcriptional activation. TRα1-M256A and TRβ1-M310T mutants exhibited similar 
discordance for T3 vs T4. 
Conclusions: Met256-TRα1/Met310-TRβ1 strongly potentiates the affinity of TRs for 
T3, thereby largely determining that T3 is the bioactive hormone rather than T4. These 
observations provide insight into the molecular basis for underlying the different affinity of TRs 
for T3 vs T4, delineating a fundamental principle of TH signaling.
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Introduction
 Thyroid hormones (THs) are indispensable for normal growth, development, and 
metabolism. T3 and T4 are the two major forms of TH. In 1952, it was recognized that T3 
has greater biological potency than T4 (1-4). This fundamental discovery led to the clinical 
concept that T4, despite being the most abundant circulating iodothyronine, functions as a 
prohormone, with T3 being the biologically active hormone. Since then, this paradigm has 
remained unchanged, although the molecular and structural mechanisms underlying this have 
not been investigated in detail.
 The genomic actions of THs are exerted through binding to the three functional 
isoforms of TH receptors (TRs), namely TRα1, TRβ1, and TRβ2, which are highly homologous 
but have distinctive expression patterns (5-7). Mutations in TRα and TRβ give rise to clinically 
distinct syndromes in humans, termed resistance to TH (RTH) α and β, respectively (8-14). 
RTHβ patients commonly present with goiter and tachycardia with abnormal thyroid function 
tests, including high serum (F)T3 and (F)T4 concentrations with normal or slightly increased 
TSH concentrations. The clinical phenotype of RTHα is distinct from RTHβ and includes 
growth retardation, macrocephaly, constipation, intellectual disability, and anemia. In RTHβ, 
thyroid function tests are typically characterized by high to high-normal (F)T3, low to low-
normal (F)T4, low reverse T3 and normal TSH concentrations.
 The greater biological activity of T3 vs T4 is explained by differences in affinity for 
the functional isoforms of TH receptors (TRs). The binding affinity of T4 to the TRs is 10- to 
30-fold less compared with T3 (15-17). Previous crystallographic studies revealed that the 
ligand-binding pocket of TRβ1 is able to accommodate both T3 and T4, although the helix 
(H)11-H12 loop is more loosely packed in the presence of T4 than T3 (16). These structural 
adaptations of TRβ1, which are required to accommodate the larger T4 molecule, have 
been attributed to possible steric hindrance of its bulky 5’-iodine moiety with the surrounding 
amino acids, especially the methionine residue located at position 310 in TRβ1. Although 
no cocrystallization studies of TRα with T4 are available, a similar role for Met256 in TRα 
(equivalent position of Met310 in TRβ), has been suggested (18). However, no functional 
studies, to support the relevance of these residues for the differences in affinity for T3 and T4, 
have been performed. 
 Therefore, we combined structural modeling and in vitro approaches to determine 
the differential role of these methionine residues in T3 vs T4 binding by TRs and characterized 
a newly identified TRα1-M256T and previously published TRβ1-M310T mutations, which 
naturally occur in patients with RTH (19-21). We showed that these methionine residues 
are of particular importance for the binding of T3, and not T4. This observation provides the 
underlying molecular and structural basis for the role of T4 as prohormone and T3 as bioactive 
hormone in a paradigm for TH physiology and daily clinical practice.
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Materials and Methods
TRα-M256T identification
 The TRα-M256T mutation in an RTHα patient was identified by exome sequencing 
and was confirmed by Sanger sequencing as previously described (12) after obtaining an 
inform consent. This study was conducted following the Declaration of Helsinki principles and 
was  approved by the Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, 
Netherlands (MEC-2015-362).
In silico prediction of TRα1-M256T function
 The TRα1-M256T mutation bound to T3 and T4 was modeled into the wild-type 
(WT) TRα1 crystal structure (PDB-ID: 2H77) (22), and the M256T and M256A mutations were 
introduced using the side-chain substitution tool of the YASARA Structure Software (YASARA 
Bioscience GmbH, Vienna, Austria) (23) and processed as previously described (24). 
DNA constructs and mutagenesis
 The pcDNA3 FLAG-TRα1 and TRβ1 expression vectors containing full-length human 
TRα1 and TRβ1 with 5’ FLAG-tagged (11,24) and the pCMX VP16-TRα1 expression vector 
containing full-length human TRα1 fused with VP16 (25) have been described previously. The 
TRα1-M256T, TRβ1-M310T, as well as the other TRα1 mutations (M256A, A263S, D211G, and 
R384H) were introduced, using the QuickChange II Mutagenesis kit (Agilent Technologies, 
Amstelveen, Netherlands) according to the manufacturers’ protocol. The introduced mutations 
were confirmed by Sanger sequencing.
Radioligand competitive binding assays
 FLAG-TRα1 WT, M256T, and M256A receptor proteins were synthesized using the 
TnT® T7 Quick Coupled Transcription/Translation System (Promega, Leiden, Netherlands). 
The affinity for T3 and T4 of the receptors was determined by competitive binding assays as 
previously described (24) using [125I]T3 and [125I]T4, respectively. The dissociation constant 
(Kd) was analyzed by GraphPad Prism program version 5.0 (GraphPad, La Jolla, CA) and 
shown as a mean ± SEM of three independent experiments performed in duplicate.
Cell culture and transfection
 JEG-3 cells (ECACC Cat# 92120308, RRID:CVCL_0363; Sigma-Aldrich, Munich 
Germany) were cultured and transfected as previously described (24,26). Given the absence 
of 5’-deiodinating activity in this cell-type (27), there is no intracellular deiodination of T4 to T3, 
which allowed us to study the direct effect of T3 and T4 on transactivation. For transcriptional 
activity assays, WT or mutant receptors were coexpressed with luciferase reporter constructs 
containing direct repeat thyroid hormone response elements (DR4-TRE) as well as pMaxGFP 
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as a transfection control. We also coexpressed WT and TRα1-M256T in 1:1 equimolar ratio 
to determine the effect of the mutant on WT function (i.e., the dominant-negative effect). For 
receptor-cofactor interaction (two-hybrid) assays, VP16-fused WT or TRα1-M256T were 
coexpressed with a luciferase reporter construct containing Gal4 binding site (UAStkLuc), 
together with pSG424 expression vectors containing the Gal4DBD fused to the interacting 
domains of NCoR1 or SRC1 (11). After transfection for 24 hours, cells were stimulated with 
0 to 10,000 nM T3 (Cat. No. T2877; Sigma-Aldrich) or T4 (Cat. No. T2376; Sigma-Aldrich) in 
DMEM/F12 medium supplemented with 0.1% bovine serum albumin for 24 hours.
Immunoblotting
 The expression of FLAG-tagged and VP16-fused receptors in JEG-3 cells was 
verified by immunoblotting nuclear extracts as previously described (24,26). FLAG-tagged 
TRα1 and VP16-TRα1 were detected with a 1:1000 dilution of FLAG-M2 (#F1804; Sigma-
Aldrich) and VP16 (sc-7545; Santa Cruz Biotechnology, Heidelberg, Germany) antibodies. 
The Histone 3 protein was detected as loading control with a 1:1000 dilution of a Histone 3 
antibody (H3; 1B1B2) (#14269; Cell Signaling Technology, Leiden, Netherlands). 
Luciferase assays
 Luciferase activity was measured as previously described (12,24). Data were 
expressed as percentage maximal response of WT stimulated by T3. Half-maximal effective 
concentration (EC50), half-maximal inhibitory concentration (IC50), and maximal response were 
calculated using GraphPad Prism program version 5.0 (GraphPad, La Jolla, CA). The results 
are shown as a mean ± SEM of at least three independent experiments performed in triplicate.
Statistical analysis
 Statistical differences of logKd, logIC50, and logEC50 values between groups were 
analyzed by student’s t-test or one-way ANOVA with Tukey’s post-test. The percentage maximal 
response of mutants was compared to WT by one sample t-test. Statistical significance was 
considered when p-values < 0.05.
Results
Clinical characterization
 A de novo heterozygous missense mutation in the THRA gene (c.767T>C), 
resulting in substitution of threonine for methionine at codon 256 (p.M256T), was identified 
in a 19-year-old male presenting with features similar to previously reported RTHα patients, 
including disproportionate ischial leg length (sitting height to height ratio +2.5 SD score), mild 
neurodevelopmental delay, coarse facies, macrocephaly (head circumference 60 cm, +2.5 
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SD score), and high serum T3/T4 ratio with normal TSH concentrations [FT4, 10.6 pmol/L 
(normal range, 11 to 25 pmol/L); total T4, 67 nmol/L (normal range, 58 to 128 nmol/L); total 
T3, 2.9 nmol/L (normal range, 1.4 to 2.5 nmol/L); reverse T3, 0.18 nmol/L (normal range, 0.22 
to 0.54 nmol/L); T3/T4 ratio, 0.043 (normal range, 0.01 to 0.03); and TSH, 1.83 mU/L (normal 
range,  0.4 to 4.3 mU/L)] (Figure 1). This mutation is not present in public databases (dbSNP, 
1000Genome, and Exome Aggregation Consortium [ExAC]).
I
1 2
1 2 3
II
(a)
(b)
c.767T>C
745 atcctcctgaaggggtgctgcatggagatcatgtccctgcgggcg 789
249 I    L   L  K  G   C     C   M  E   I  M  S   L   R   A   263  
745 atcctcctgaaggggtgctgcacggagatcatgtccctgcgggcg 789
249 I    L   L  K   G  C     C   T   E   I  M  S   L   R   A   263  
WT
M256T
Figure 1. (a) Pedigree chart demonstrating that only the index patient (II.1) has the clinical phenotype of 
RTHα. (b) Sequence analysis of exon 8 of THRA gene shows a de novo heterozygous missense mutation 
(c.767T>C) in index patient, resulting in a methionine to threonine substitution at codon 256 (p.M256T).
Protein modeling
 The role of the Met256 in TRα1 function and the potential eff ect of this mutation on 
the affi  nity of T3 and T4 were predicted by in silico modeling. Given the absence of a T4-bound 
TRα crystal structure, we studied the structural organization of the domains surrounding the 
outer ring of TH in the available T3- (PDB ID: 1xzx) and T4-liganded (PDB ID: 1y0x) crystal 
structures of TRβ1. In line with a previous report (16), we observed that the 5’ position of 
the outer ring of both T3 and T4 is fl anked by Ile276 (H3), Met310 and Met313 (H6), His435 
(H11), Phe455 and Phe459 (H12) of TRβ1. Together, these residues form a niche that allows 
the accommodation of T4 despite the presence of its bulky 5’-iodine. The same niche is also 
present within the T3-liganded TRβ1 crystal but is considerably smaller in the absence of the 
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5’-iodine. Met310 (corresponding to Met256 of TRα1) is in closest structural proximity to the 5’ 
carbon of the outer ring and forms an extensive network of (hydrophobic) interactions that link 
H6, H11 and H12.
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Figure 2. Comparison of the architecture of the TRα1 ligand binding pocket in the presence of T3 and T4. 
(a and b) Close-up view of the ligand-binding pocket of the TRα1 crystal structure in complex with (a) T3 
(PDB ID: 2h77) and (b) T4. The residue side-chains lining the niche that accommodates the outer ring of 
T3 and T4 are highlighted, and their molecular surface is shown except for Phe405 for clarity. The 5’ iodine 
group of T4 is represented by the green ball in T4-bound TRα1 model. The hydrophobic contacts between 
Met256 and the phenolic outer ring are depicted as dashed lines. (c and d) Structural models of the TRα1-
M256T mutant in complex with (c) T3 and (d) T4. (e and f) Structural models of the TRα1-M256A mutant 
in complex with (e) T3 and (f) T4. (g and h) Overlay of the structural orientation of the residue side-chains 
that face the (g) T3 and (h) T4 ligands at the 5’ position in WT (gray), M256T (blue) and M256A (red) 
mutant TRα1 models. All fi gures were created in YASARA Structure using PovRay imaging software.
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 We next modeled a T4 molecule into the ligand-binding pocket of the available 
T3-liganded TRα1 crystal structure (PDB-ID: 2H77) [Figure 2(b)]. Compared with the T3-
liganded TRα1 structure [Figure 2(a)], a slight outward shift of H11 and H12 was observed in 
the T4-liganded model, which was accompanied by reorientation of side-chains of residues 
surrounding the 5’ iodine. This resulted in a loss of the direct hydrophobic interactions 
between Met256 and the outer ring and a less tightly packed structural organization of the 
ligand binding pocket. These changes were similar to those observed in the corresponding 
TRβ1 crystal structures, validating the accuracy of the modeling procedure. 
 We subsequently modeled the M256T (shortening of side-chain, hydrophilic moiety) 
mutant in both T3- and T4-bound TRα1 structures and analyzed the impact on the conformation 
of the ligand binding domain and direct substrate interactions [Figure 2(c) and 2(d)]. The 
artificial M256A mutant was also modeled to reduce the side-chain length while maintaining 
the hydrophobic property of the residue [Figure 2(e) and 2(f)]. Due to shortening of side-
chain length in both mutants, direct hydrophobic interaction with the outer ring of T3 was lost 
[Figure 2(c) and 2(e)]. Moreover, both mutants enlarged the niche surrounding the 5’ position 
of T3 due to reorientation of various residue side-chains in H11 and H12 and the subsequent 
outward shift of these helices. As a result, the niche adopts a structural configuration that 
resembles the WT receptor in T4-bound state. These changes were more pronounced for 
the M256T than the M256A, exemplified by the degree of re-orientation of His381, which was 
previously implicated to interact with the phenolhydroxyl group of T3 (18) [Figure 2(g)]. In the 
case of T4, both mutations had little effect on structural organization [Figure 2(d), 2(f), and 
2(h)]. Based on these in silico predictions, we hypothesized that both substitutions would have 
a greater impact on T3 than on T4 binding and action.
Functional studies
 We performd in vitro studies to test this hypothesis. In line with previous literature (15-
17), competitive binding assays showed that the affinity for T4 of WT TRα1 was approximately 
sevenfold lower than for T3, indicating by the higher Kd of T4 than T3 [Figure 3(a); Tabel 1]. 
The TRα1-M256T mutant showed a ~40-fold lower T3 binding affinity than WT, whereas T4 
affinity was unchanged [Figure 3(c); Table 1]. Also, the binding affinity of the TRα1-M256A 
mutant for T3 was selectively reduced (approximately sixfold) [Figure 3(e); Table 1].
 To evaluate the impact of both mutations on the transcriptional activity, WT and mutant 
receptors were cotransfected with a reporter construct in which luciferase expression is under 
control of a TH response element (TRE) into JEG-3 cells with increasing concentrations of T3 
or T4. Equal expression of WT and both mutants was confirmed by immunoblotting nuclear 
extracts with anti-FLAG antibodies [Figure 3(b)]. In line with the binding assays and previous 
studies (16,17), the transcriptional activation assay showed that the EC50 of WT TRα1 induced 
by T4 was ~60-fold higher than that induced by T3 [Figure 3(b); Table 1]. The EC50 of TRα1-
M256T was 100-fold higher for T3 but was unchanged for T4 compared with WT [Figure 3(d); 
Table 1]. The TRα1-M256A also selectively reduced transcriptional activity induced by T3 
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[Figure 3(f); Table 1]. The transcriptional activity was also reduced when WT and TRα1-M256T 
were coexpressed compared to WT expressed alone, suggesting a dominant-negative effect 
of this mutant (data not shown). In mammalian two-hybrid assays compared with WT, the 
TRα1-M256T mutant also affected ligand-dependent interactions with the corepressor NCoR1 
(fold increase IC50: ~80-fold for T3 and ~6-fold for T4) and the coactivator SRC1 (fold increase 
EC50: ~90-fold for T3 and approximately sixfold for T4) [Figure 4(a)-4(d); Table1]. Together, our 
results indicate that the mutations located at the Met256 of TRα1 have a differential impact on 
the binding and activation of the receptor by T4 vs T3.
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Figure 3. (a, c, e) [125I]T3 dissociation curves showing that compared with (a) WT, (c) the TRα1-M256T 
mutation and (e) TRα1-M256A mutation reduces the affinity for T3 (solid line) more than for T4 (dashed 
line) (mean ± SEM of three experiments for WT and M256T and two experiments for M256A performed in 
duplicate). (b, d, f) The TRα1-M256T and TRα1-M256A mutations also had a larger effect on T3- than on 
T4-dependent transcriptional activation (mean ± SEM of three experiments performed in triplicate). The 
effect of the alanine substitution on the ligand binding affinity and the transcriptional activity of TRα1 was 
less than the effect of the threonine substitution. The insert in (b) shows Immunoblots confirming an equal 
expression of WT, M256T, and M256A FLAG-tagged TRα1 and Histone 3 as a loading control in the 
nuclear fraction of JEG-3 cells.
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Table 1. Summary of the results of competitive binding, transcriptional activity, and protein-protein 
interaction assays of WT, TRα1-M256T and TRα1-M256A mutants.
T3 stimulation T4 stimulation
WT M256T M256A WT M256T M256A
LogKd
[Kd(nM)]
-0.91±0.08
[0.12]
0.71±0.10***
[5.14]
-0.16±0.34**,†††
[0.69]
-0.09±0.10
[0.81]
0.22±0.05
[1.67]
-0.18±0.02
[0.66]
LogEC50-DR4
[EC50 (nM)]
-0.60±0.10
[0.25]
1.51±0.16***
[32.3]
0.51±0.08**,††
[3.26]
1.16±0.07
[14.5]
1.67±0.11
[46.6]
1.44±0.25
[27.2]
LogIC50-
NCoR1
[IC50 (nM)]
-1.26±0.04
[0.06]
0.69±0.18***
[4.87]
-
0.02±0.06
[1.05]
0.82±0.14**
[6.64]
-
LogEC50-
SRC1
[EC50 (nM)]
-0.76±0.05
[0.17]
1.19±0.07***
[15.5]
-
0.42±0.07
[2.65]
1.16±0.08**
[14.6]
-
Data are presented as mean ± SEM (one-way ANOVA with Tukey post test, *p<0.05, **p<0.01, ***p<0.001 for WT vs. 
mutant, and †p<0.05, ††p<0.01, †††p<0.001 for M256T vs. M256A). 
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Figure 4. The TRα1-M256T mutation had a larger eff ect on T3- than on T4-dependent (a and b) GAL4-
NCoR1 dissociation, and (c and d) GAL4-SRC1 association (mean ± SEM of at least three experiments 
performed in triplicate). The insert of (a) shows immunoblots confi rming an equal expression of WT and 
M256T VP16 TRα1 fusion proteins and Histone 3 as loading control in the nuclear fraction of JEG-3 cells. 
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 We next investigated if this T3 vs T4 difference is present in other TRα mutants 
located outside the niche surrounding the 5’-iodine position. However, these naturally 
occurring mutations (D211G, A263S, and R384H) had a similar impact on T3 and T4 induced 
transactivation, and, as for WT TRα, the EC50 values for T4 exceeded those for T3 by ~30- 
to 50-fold [Figure 5(a)-5(c)]. These transcriptional activation profiles were in contrast to the 
M256T mutant [Figure 5(d)], strongly indicating that only this mutant has a predominant impact 
on T3 affinity. To extend our findings to TRβ, we also studied the transcriptional activity of a 
corresponding mutation in TRβ1 (TRβ1-M310T). The EC50 of WT TRβ1 induced by T4 was 
~70-fold higher than that induced by T3 [Figure 6(a)], which was similar to WT TRα1. The T3-
induced transcriptional response of TRβ-M310T was greatly reduced, which contrasted with 
the T4-induced transcriptional activity (fold increase EC50: ~350-fold for T3 and approximately 
threefold for T4) [Figure 6(b)].
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Figure 5. (a-c) The T4-induced transcriptional activity of three TRα1 mutations identified in RTHα patients 
is lower than that is induced by T3, which is similar to WT [Figure 3(d)] (mean ± SEM of three experiments 
performed in triplicate). (d) The EC50 of T4 is ~30- to 50-fold higher than the EC50 of T3, except for TRα1-
M256T  ***P < 0.001 (one-way ANOVA with Tukey post test).
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Figure 6. The T3- and T4-induced transcriptional activity of (a) WT and (b) TRβ1-M310T in JEG-3 cells 
shows that the TRβ1-M310T mutation affects T3- more than T4-dependent transcriptional activation 
(mean ± SEM of four experiments performed in triplicate), which is in line with the results of TRα1-M256T 
[Figure 3(d)].
Discussion
 Although the notion of T4 and T3 being the precursor and active hormone, respectively, 
is widely recognized in both the clinical and scientific community, the molecular and structural 
basis of this dogma has received little attention. In this study, we highlight the crucial role of 
residue Met256 of TRα1 and Met310 of TRβ1 in determining the differential bioactivity of T3 
vs T4, using a novel mutant (TRα1-M256T) identified in an RTHα patient and a mutant at the 
corresponding position (TRβ1-M310T) identified in RTHβ patients (19-21). In contrast to WT 
TRα or TRβ and mutations involving other residues, mutations at these methionine residues 
selectively affected binding and transactivation of TR by T3. These observations emphasize 
the key role of these residues in designating T4 as the prohormone and T3 as the major 
bioactive hormone.
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 In line with previous reports (15-17), our results showed that T3 has a higher 
binding affinity for WT TRα1 and stimulates receptor activity with a higher potency than T4. 
Previous structural studies in TRβ1 have suggested that the lower affinity for T4 is caused by 
decreased packing of the ligand binding domain in presence of T4 vs T3, which particularly 
allows oscillation of H12 between liganded and unliganded states, resulting in a higher ligand 
dissociation rate (16). Here, we extend these observations by showing that the ligand binding 
domain of T3-liganded TR has a similar decrease in packing as observed in T4-liganded WT 
receptors upon substitution of Met256 in TRα1 or Met310 in TRβ1 by threonine. In contrast, 
these substitutions hardly changed the predicted structure of T4-liganded mutant receptors. 
Based on these models, we postulated that the extensive (hydrophobic) interactions of 
methionine with surrounding residues are key in stabilizing interhelical interactions (e.g., 
between H6, H11, and H12), which facilitate the tight packing of the ligand binding domain 
as observed in T3-liganded receptors. Moreover, we observed a direct interaction between 
methionine and the 5’ position of the outer ring of T3, which was not formed with T4. This 
suggests that Met256 in TRα1 and Met310 in TRβ1 have a critical role in achieving optimal 
folding and enthalpy in T3-liganded receptors, whereas their role in T4 binding is of less 
importance.
 This in silico prediction was confirmed by in vitro studies indicating that TRα1-M256T 
selectively affected binding affinity for T3 as well as cofactor interactions and transcriptional 
activity of T3-stimulated receptor. These properties seemed specific for the M256T mutant 
because the transactivational potency of T3 and T4 with TRα mutants identified in other RTHα 
patients [D211G (26), A263S, and R384H (28)] was affected equally. Additional testing of the 
naturally occurring mutation at the corresponding residue in the TRβ1 (M310T) (19-21) further 
substantiated the specificity of the findings.
 Threonine substitution at position 256 in TRα1 or 310 in TRβ1 not only alters the 
binding space but also affects the hydrophobicity of the ligand-binding pocket. Therefore, 
we tested the artificial TRα1-M256A mutant, which reduces the size of the side-chain but 
maintains the hydrophobic property of the ligand-binding pocket. Indeed, functional studies 
showed that TRα1-M256A also selectively impairs T3 binding affinity and T3-induced 
transcriptional activity, whereas T4 binding and activity are maintained. Although the effect 
of TRα1-M256T mutation in our functional and structural models was slightly greater than 
that of TRα1-M256A, these findings support the notion that loss of the specific properties 
of methionine, rather than the unfavorable impact of the hydrophilic moiety of threonine on 
the hydrophobic environment, are mainly responsible for the differential impact on T3 vs T4 
signaling. Based on our studies and on a previous report (16), we propose that Met256 in 
TRα1 and Met310 in TRβ1 are crucial residues that determine specific affinity for T3 vs T4. 
Threonine and alanine substitution at these methionine positions significantly affected the 
hydrophobic interactions with T3 and altered the niche accommodating the outer ring of T3 to 
a “T4-bound” configuration, both resulting in a reduced binding affinity of the mutants for T3. 
In contrast, because the ligand binding domain of T4-liganded receptors already exhibit looser 
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packing without direct interaction(s) between methionine and the T4 molecule, mutations in 
the methionine residue are better tolerated. 
 No unique phenotype was discernible in the newly-identified M256T RTHα patient 
when compared to other cases of RTHα harbouring missense mutations in the THRA gene 
(25,26,28-30), or in patients carrying TRβ-M310T (19-21) when compared to other RTHβ 
cases reported in the literature. These findings indicate that although mutations at Met256-
TRα1/Met310-TRβ1 residues preserve T4 binding to mutant receptor proteins, this property is 
not sufficient to prevent patients from developing features of RTH, implying that the phenotype 
of RTH is linked primarily to defective T3 rather than T4 binding by mutant TRs. 
 This study provides in vitro evidence for the importance of Met256 in TRα1 and 
Met310 in TRβ1 in ligand recognition. Our studies highlight the relevance of this methionine 
residue in TRs for discrimination between T3 and T4, providing the molecular basis for the role 
of T4 as prohormone and T3 as bioactive hormone. 
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Abstract
Background: Thyroid hormone (TH) acts on TH receptors (TRs) and regulates gene 
transcription by binding of TRs to TH response elements (TREs) in target gene promoters. 
The transcriptional activity of TRs is modulated by interactions with TR-coregulatory proteins. 
Mutations in TRα cause resistance to thyroid hormone alpha (RTHα). In this study, we 
analyzed if, beyond reduced T3 affinity, altered interactions with cofactors or different TREs 
could account for the differential impaired transcriptional activity of different mutants. 
Methods: We evaluated four mutants derived from patients (D211G, M256T, A263S, and 
R384H) and three artificial mutants at equivalent positions in patients with RTHβ (T223A, 
L287V, and P398H). The in vitro transcriptional activity was evaluated on TRE-luciferase 
reporters (DR4, IR0, and ER6). The affinity for T3 and interaction with coregulatory proteins 
(NCoR1 and SRC1) were also determined. 
Results: We found that the affinity for T3 was significantly reduced for all mutants, except for 
TRα1-T223A. The reduction in the T3 sensitivity of the transcriptional activity on three TREs, 
the dissociation of the corepressor NCoR1, and the association of the coactivator SRC1 
recruitment for each mutant correlated with the reduced affinity for T3. We did not observe 
mutation-specific alterations in interactions with cofactors or TREs. 
Conclusion: In summary, the degree of impaired transcriptional activity of mutants is mainly 
determined by their reduced affinity for T3. 
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Introduction
 Genomic actions of thyroid hormone (TH) are regulated by binding of the active 
form of TH, tri-iodothyronine (T3), to its nuclear TH receptors (TRs), which act predominantly 
as heterodimers with retinoid X receptors (RXRs) on thyroid hormone response elements 
(TREs) in the promoter region of target genes (1,2). TREs usually consist of two-consensus 
half-sites that can be organized in direct repeats (DRs), inverted repeats (IRs), and everted 
repeats (ERs), separated by a stretch of random nucleotides of various lengths, of which the 
DR4-TRE is the predominant TR-binding form (3-6). In the absence of ligand, TRs repress 
target gene transcription by recruitment of corepressors such as nuclear receptor corepressor 
1 (NCoR1). Binding of T3 causes dissociation of the corepressors and allows coactivators, 
such as steroid receptor coactivator 1 (SRC1), to bind to the TR, resulting in activation of gene 
transcription (1,7).
 Mutations in the ligand binding domain (LBD) of TRα1 cause resistance to thyroid 
hormone alpha (RTHα) which was first described in 2012 (8,9). The phenotype of RTHα 
patients includes growth retardation, macrocephaly, constipation, intellectual disability, 
anemia, and a high (F)T3/(F)T4 ratio (10,11). To date, 22 mutations (in a total of 37 patients) 
have been reported as a cause of RTHα. These mutations can be categorized into two groups 
based on the type of mutation. The first group consists of truncating mutations caused by 
nonsense or frameshift mutations that create premature stop codons and shorten the length of 
the LBD (8,9,12-14). This structural alteration completely abolishes T3 affinity and T3-induced 
transcriptional activity of TRα1. The second group consists of missense mutations that result 
in single amino acid substitutions in the LBD (10,13-20). These mutant receptors can still bind 
T3 but with a lower affinity than wild-type (WT) receptors. 
 There is a variety in the clinical phenotype of RTHα patients. Patients with truncating 
mutations generally have a more severe phenotype than patients with missense mutations 
(9,12-14). Within the latter group, there are notable differences in the neurocognitive 
features (14,17,20). At present, it is unclear whether these differences are solely explained 
by differences in T3 binding. In RTHβ, mutation-specific effects on particular TREs and 
differences in interaction with coactivators versus corepressors have been described (21-
24). Here, we studied if mutation-specific effects on TRE or cofactor binding are present in a 
selected series of seven specific TRα1 missense mutations. 
Materials and methods
Plasmid constructs
 The coding sequence (cDNA) of full-length TRα1 fused at the 5’ end to the FLAG 
epitope or to VP16 were cloned into the pcDNA3 (9) and the pCMX expression vectors (18), 
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respectively, as previously described. Selected TRα1 missense mutations were introduced 
into pcDNA3-FLAG TRα1 and pCMX-VP16 TRα1 expression vectors using the QuickChange 
II Mutagenesis kit (Align Technologies, Amstelveen, The Netherlands) (see Supplementary 
Table S1 for primers) and confirmed by Sanger sequencing. 
 The luciferase reporter constructs containing either direct (DR4), inverted (IR0), or 
everted repeat (ER6) TRE configurations (TRE-tkLuc) (25), the luciferase reporter construct 
containing Gal4 binding site (UAStkLuc), and the pSG424 expression vector constructs 
containing the Gal4 DNA-binding domain (GAL4-DBD) fused to the interacting domains of 
NCoR1 or SRC1 (8) have all been described elsewhere.
[125I]T3 competitive binding assays
 [125I]T3 competitive binding assays were performed as previously described (26). 
In brief, WT and mutant FLAG-TRα1 proteins were synthesized using the TnT® T7 Quick 
Coupled Transcription/Translation System (L1170, Promega, Leiden, The Netherlands). The 
proteins were incubated with 0.02 nM of [125I]T3 (prepared in-house as previously described 
(27)) and 0-10,000 nM unlabeled T3 (Cat. No. T2877, Sigma-Aldrich) at 30°C for 2 hours. The 
input of WT and mutant FLAG-TRα1 proteins lysate was adjusted to obtain 10-20% maximal 
[125I]T3 binding, in order to prevent ligand-depletion effect. TR bound [125I]T3 was measured 
and calculated as a percentage [125I]T3 input. The dissociation constant (Kd) was computed 
by GraphPad Prism 5.0 (GraphPad, La Jolla, CA) 
In silico model prediction
 The various TRα1 mutations were introduced into the WT T3-bound TRα1 crystal 
structure (PDB-ID: 2H77 (28)) using the side-chain substitution and optimization tools of 
the YASARA Structure Software (YASARA Bioscience GmbH, Vienna, Austria) (29). The 
structural models of the TRα1 mutants have been processed and compared to the WT TRα1 
structure as previously described (20). Given their location outside the ligand-binding pocket, 
the D211G, T223A, R384H, and P398H mutant models were compared to WT after additional 
molecular dynamic simulations in an AMBER force field with water as a solvent to investigate 
their impact on the structural integrity of the receptor.
 Ligand-binding energy was calculated using the BindEnergy command implemented 
in YASARA Structure Software, which calculates the in vacuo binding energy in a NOVA force 
field without considering solvation effects (30). As such, this approach is suitable for detecting 
changes in binding energy by mutations that affect substrate interactions directly, and not for 
those having indirect effects. A high value indicates a favorable T3 binding.
Cell culture and transfection
 JEG-3 cells (ECACC Cat# 92120308, RRID:CVCL_0363, Sigma-Aldrich) were 
cultured in 24-well plates using the growth medium (DMEM/F12 supplemented with 9%FBS, 
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100 nM Na2SeO3, 100 U/mL penicillin, and 100 µg/mL streptomycin) and transfected as 
previously described (19,26). Briefly, 20 ng of FLAG-TRα1 plasmid was co-transfected with 
120 ng TRE-tkLuc reporter construct for transcriptional activity assays. For protein-protein 
interaction (mammalian two-hybrid) assays, 20 ng of TRα1 fused to the transcriptional 
activator VP16 (VP16-TRα1) plasmid was co-transfected with 20 ng of NCoR1 or SRC1 
fused to the DNA binding domain of Gal4 (GAL4-NCoR1 or GAL4-SRC1) and 120 ng of UAS-
tkLuc. In both assays, 20 ng pMaxGFP plasmid was co-transfected to monitor the transfection 
efficiency. All of the transfection processes were performed in TH-depleted medium (DMEM/
F12 supplemented with 9% charcoal-stripped FBS) using Xtreme Gene 9 transfection reagent 
(Roche Diagnostics, Almere, NL). After 24-hour transfection, cells were stimulated for 24 hours 
with 0-10,000 nM T3 in DMEM/F12 supplemented with 0.1% bovine serum albumin (BSA).
Immunoblotting
 The expression of FLAG- and VP16-TRα1 proteins in cells was verified by 
immunoblotting nuclear extracts of JEG-3 cells transfected with WT or mutant TR expression 
constructs as previously described (19,26). The receptors were probed with 1:1000 dilution 
of FLAG-M2 antibody (#F1804 Sigma-Aldrich) or 1:1000 dilution of VP16 antibody (sc-7545, 
Santa Cruz Biotechnology). Histone 3 protein was detected with 1:1000 dilution of Histone 
3 (H3; 1B1B2) antibody (#14269 Cell Signaling Technology) to verify comparable protein 
input. Bands were visualized on the Alliance 4.0 Uvitec platform (Uvitec Ltd) by Enhanced 
Chemiluminescence (Thermofisher Scientific).
Electrophoretic mobility shift assays (EMSA)
 A double-stranded overlapping oligonucleotide probe containing DR4-TRE was 
obtained by annealing 25 ng of sense and antisense oligonucleotides 5’end labeling with 
fluorescence dye (5’IRDye®700) (Integrated DNA Technologies, Leuven, Belgium) at 80°C for 
5 minutes (sense oligonucleotides: 5’-AGGACGTTGGGGTTAGGGGAGGACAGTGGAC-3’, 
antisense oligonucleotides: 5’-GTCCACTGTCCTCCCCTAACCCCAACGTCCT-3’). The DR4-
TRE probe was diluted to a final concentration of 1 ng/µL in 50 µL 1xTE buffer (10mM Tris 
HCl pH 8.0, 1 mM EDTA). FLAG-TRα1 and RXRα proteins were synthesized by the TnT® T7 
Quick Coupled Transcription/Translation System (L1170, Promega, Leiden, The Netherlands). 
Since equal amounts of in vitro translated receptors were detected on an immunoblot (data 
not shown), we decided to use 1 µL of in vitro translated WT or mutant FLAG-TRα1 and 2 
µL of in vitro translated RXRα. TR and RXRα were co-incubated in the dark with 0.5 µL of 
DR4-TRE probe, and 2 µg of poly(deoxyinosinic-deoxycytidylic) acid sodium salt (SC-286691, 
Santa Cruz Biotechnology) in a final 10 µL of binding buffer (10x binding buffer: 100mM Tris, 
10 mM EDTA, 1M KCl, 1 mM DDT, 50% glycerol, 0.1 mg/mL BSA) for 30 minutes at room 
temperature. Gel electrophoresis was performed on 6%DNA retardation gel (EC6365BOX, 
Invitrogen). The TR-DNA complexes and residual unbound probe were visualized using an 
Odyssey® imaging system (LI-COR, Leusden, The Netherlands).
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Luciferase assays
 Luciferase activity was determined using the Dual Glo Luciferase kit (E2940, 
Promega, Leiden, The Netherlands). Luciferase and GFP activities were measured by a 
luminometer (VictorTM X4, PerkinElmer, Groningen, The Netherlands). Half-maximal effective 
T3 concentration (EC50), half-maximal inhibitory T3 concentration (IC50), and %WT maximal 
response were analyzed using GraphPad Prism 5.0 (GraphPad, La Jolla, CA) 
Statistical analysis
 The statistical differences between WT and mutants were analyzed by One sample 
T-tests. The statistical differences of fold changes of logKd, logEC50, and logIC50 between 
WT and mutants were determined by one-way ANOVA with Tukey’s post-test. Statistical 
significance was considered at p-values < 0.05.
Results 
Selection of mutants 
 We tested seven TRα1 mutants, of which four were derived from RTHα patients 
(D211G (19), M256T (20), A263S, and R384H (14)). These mutations covered the three CpG-
rich regions of the LBD of TRα1 that are equivalent to the mutation-prone hotspots of the 
TRβ1 receptor, namely R384H in cluster 1, M256T and A263S in cluster 2, and D211G in 
cluster 3. The other three mutations were derived from RTHβ patients. TRα1-P398H (cluster 
1), the equivalent of TRβ1-P452H, gave rise to an unusual phenotype that included obesity 
and marked metabolic disturbances in a murine model for RTHα (31). TRα1-T223A (cluster 
3) is the equivalent of TRβ1-T277A, which was previously shown to specifically impair 
transcriptional activity on an ER6-TRE and diminish affinity for SRC-1 (24). Finally, TRα1-
L287V (cluster 2) is the equivalent of TRβ1-L341V, a recently identified mutation that causes 
a strong decrease in T3-binding affinity and a concomitant reduction in the T3-sensitivity of 
transcriptional activity and cofactor recruitment (26).
T3 binding affinity of the TRα1 mutants
 We first determined the binding affinity of in vitro translated mutant receptors using 
a [125I]T3 competitive binding assay. The [125I]T3 binding curves were shifted to the right for 
most mutants (Figure 1A), which reflects a higher required dose of T3 to saturate binding 
and hence a lower binding affinity. The dissociation constant (Kd) which is the concentration 
of T3 at which half the binding sites are occupied, varied between mutants (Figure 1B and 
Supplementary Table S2). TRα1-M256T showed the lowest affinity, as is illustrated by the 
highest Kd of all mutants (160-fold higher than WT). Binding of T3 was similarly affected for 
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TRα1-D211G (Kd 25-fold higher than WT), -R384H (25-fold), -L287V (19-fold), and -P398H 
(17-fold), but significantly less impaired for TRα1-A263S (Kd 5-fold higher than WT) whereas 
the Kd of TRα1-T223A was not different from WT. These data indicate that the binding affinity 
is reduced to a different extent for the different mutants. 
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Figure 1. (A-B) [125I]T3 competitive binding assays of the TRα1 WT and mutants. (A) The dissociation 
curves of all mutants are shifted to the right, indicative of a reduced T3 binding affinity. (B) The fold 
increase of the Kd are various between mutants (One-sample T-test, *P<0.05, **P<0.01, ***P<0.001). 
Data presented as mean ± SEM from four independent experiments performed in duplicate. (C-F) 
Mammalian two-hybrid assays demonstrating TRα1-cofactor interactions. (C) T3-induced GAL4-NCoR1 
dissociation and (E) GAL4-SRC1 association curves show a various degree of reduced T3-dependent 
NCoR1 release and SRC1 recruitment of mutants, respectively. These are indicated by the right shift of 
the curves and higher IC50-NCoR1 or EC50-SRC1 than that of WT. (D) The fold increases in IC50 for the 
NCoR1 dissociation are similar to (E) the fold increase in EC50 for the SRC1 association for each mutation 
(the fold increases IC50-NCoR1 and EC50-SRC1 of the mutants were compared to WT by One-sample 
T-test; *P<0.05, **P<0.01, ***P<0.001). Data presented as mean ± SEM from at least four independent 
experiments performed in triplicate.
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Figure 2. (A) The WT TRα1 crystal structure in complex with T3 (PDB ID: 2H77) in which the locations of 
the mutated residues studied are highlighted. (B) Close-up view of the TRα1 ligand-binding pocket, 
presented as an overlay of the WT crystal (grey) and indicated mutant models (colored). The side-chains 
of the mutant residues are displayed in blue (M256T, left panel), orange (A263S, middle panel), and red 
(L287V, right panel) and of the corresponding WT residues in grey. Hydrophobic interactions between WT 
residues and T3 are indicated with a red dashed line. The interaction between mutant residues and T3 are 
not observed. For clarity, the small deviations in the carbon-backbone structure are not displayed. (C) 
Close-up view of the overlay of the WT TRα1 structure and models with indicated mutations that aff ect 
residues outside the ligand-binding pocket. Mutant models are displayed in blue (D211G, left upper 
panel), green (T223A, right upper panel), pink (R384H, left lower panel), and purple (P398H, right lower 
panel), and WT TRα1 in grey. The T3 ligand is displayed in all panels in element color. All fi gures were 
created in YASARA Structure using PovRay imaging software.
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In silico model of mutant TRα1
 Structural modeling was used to validate our in vitro studies. The side-chains of 
Ala263, Met256, and Leu287 face to the ligand-binding pocket (Figure 2A and 2B) and are 
predicted to make direct interactions with T3 (Supplementary Figure S1). The hydrophobic 
interaction between the side-chain of Ala263 and the inner ring of T3 is lost in the A263S 
mutant. As previously reported (20), the M256T abrogates the direct interactions of Met256 
with T3 and simultaneously disturbs the structural niche accommodating the outer ring of T3. 
In analogy to the predicted in silico effects of the L341V mutant in TRβ1 (26), the L287V mutant 
disrupts the direct hydrophobic interaction of Leu287 with T3. In agreement with our in vitro 
studies, all three mutations reduced the calculated T3-binding energy compared to WT TRα1 
in the order M256T>L287V>A263S (Supplementary Figure 1D). Due to their location outside 
the binding pocket, the side-chains of Asp211, Arg384, Pro398 (facing other internal domains), 
and Thr223 (facing the external protein surface), do not make direct contact with T3 (Figure 2A 
and 2C), which prevents reliable in silico prediction of their impact on binding affinity. Structural 
modeling revealed extensive structural changes for the D211G (predominantly within the loop 
connecting H2 and H3), R384H and P398H (predominantly H11 and H12) mutants, whereas 
the T223A mutant displayed only minor local structural changes of the backbone configuration 
(Figure 2C). These observations may well explain the differential effects of these mutations on 
in vitro binding affinity. 
Heterodimerization of TRα1 mutants with RXRα
 To determine whether the dimerization of the mutants with RXR and binding of the 
dimer to DNA was affected, we performed electrophoretic mobility shift assays (EMSAs) 
with in vitro translated WT or mutant TRα1 and RXRα on a fluorescently labeled DR4-TRE 
(Supplementary Figure S2). The result showed that only a co-incubation of TRα1 and RXRα 
could shift the DR4-TRE oligonucleotide probe upward. The upward shift of the probe was not 
observed in an incubation of WT TRα1 or RXRα alone. These findings indicate that the WT 
receptors exclusively bound to the DR4-TRE as heterodimers with RXRα, which is in contrast 
to the TRβ1 isoform that can bind as both homo- and heterodimers (32,33). The intensity of 
the heterodimer band was similar to WT for all mutants. In addition, heterodimer binding to the 
DR4-TRE was independent of the presence of T3 for WT and mutants. These results show 
that heterodimerization with RXRα and binding to the DR4-TRE is not affected in any of the 
mutants.
Receptor-cofactor interaction of the TRα1 mutants 
 To determine whether cofactor recruitment of the mutants was impaired, we next 
evaluated the interaction of the mutants with the corepressor NCoR1 and the coactivator 
SRC1, which directly bind to TRs and play a crucial role in receptor function (1,7). In a 
mammalian two-hybrid assay, VP16-TRα1 activates a luciferase reporter (UAS-tkLuc) 
only when it interacts with GAL4-NCoR1 or -SRC1. As a measure for T3-dependence, we 
82
Chapter  4
4
determined the concentration that gave half-maximum dissociation of NCoR1 (IC50) and half-
maximum association of SRC1 (EC50). Stimulation of WT TRα1 with low concentrations of T3 
(0.1-1 nM) already resulted in dissociation of GAL4-NCoR1 (IC50 0.08 nM) and association of 
GAL4-SRC1 (EC50 0.28 nM). Most mutants required higher T3 concentrations to dissociate 
from NCoR1 (Figure 1C) and recruit SRC1 (Figure 1E). Consistent with the affinity for T3, 
TRα1-M256T showed the highest IC50 for NCoR1 dissociation (60-fold higher than WT) 
and EC50 for SRC1 association (200-fold) (Figure 1D, 1F, Supplementary Figure S3, and 
Supplementary Table S3). The TRα1-D211G, L287V, R384H, and P398H mutants showed 
higher IC50-NCoR1 dissociation and EC50-SRC1 association than WT but lower than TRα1-
M256T. The fold increase IC50 and EC50 of these four mutations were similar. The IC50-NCoR1 
dissociation and EC50-SRC1 association of A263S-TRα1 mutation were approximately two-
fold higher than WT, corresponding to the changes of its Kd in competitive binding assays. 
For TRα1-T223A, the T3-induced NCoR1 dissociation and SRC1 association were similar to 
the WT receptor. We did not observe major differences in maximal binding of either NCoR1 
or SRC1 to mutants compared to WT, indicating that the affinity of the mutants for these 
cofactors is not markedly disturbed. 
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Figure 3. The T3-induced transcriptional activity of TRα1 WT and mutants tested on three different TRE-
luciferase reporter constructs. (A-C) The dose-response curves show a various degree of impaired 
transcriptional activity of mutants, as indicated by the right shift of the curves and higher EC50 than WT. 
(D) The fold increases of mutants’ EC50 are various between mutations. The shift of EC50 on three TREs 
generally follows a similar trend for each mutation. Data presented as mean ± SEM from at least three 
independent experiments performed in triplicate. (E) Immunoblot confirms the expression of WT and 
mutant FLAG-TRα1 in JEG-3 cells.
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Transcriptional activity of the TRα1 mutants 
 We then tested the mutants for transcriptional activity using a reporter assay. For 
this, we co-transfected WT or mutant receptors into JEG-3 cells with constructs in which the 
coding sequence for firefly luciferase is under control of a DR4, IR0 or ER6-TRE. 
 The T3-induced transcriptional activity on the DR4-TRE was impaired for most 
mutant receptors, as indicated by a rightward shift of the dose-response curves as compared 
to WT and a concomitant increase in EC50, representing the T3 dose that is needed to achieve 
a half-maximal response. (Figure 3A and Supplementary Table S4). TRα1-M256T had the 
highest EC50 (100-fold higher than WT). The EC50 of TRα1-D211G, L287V, R384H, and P398H 
was approximately 10 to 20-fold higher than that of WT. In contrast, the EC50 of TRα1-A263S 
and T223A was not significantly different from WT. The fold increase in EC50 tested on the IR0- 
and ER6-TREs of each mutant was not significantly different from that tested on the DR4-TRE 
(Figure 3B-D), suggesting that the effects of these mutations are not TRE-specific. Most of 
the mutants showed a similar maximal transcriptional activity as WT at supraphysiological T3 
concentrations, with the exception of TRα1-T223A on DR4-TRE and TRα1-P398H on DR4- 
and IR0-TRE that were significantly lower than that of WT.
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Figure 4. Fold increases of Kd, IC50-NCoR1 dissociation, EC50-SRC1 association and EC50 of T3-induced 
transcriptional activity on the DR4-TRE. These fold increases are various among mutants but generally 
follow a similar trend for each mutant, except for M256T and R384H (One-way ANOVA with Tukey’s post-
test *P<0.05).
Correlation between T3-affinity, cofactor binding, and transcriptional activity 
of TRα1 mutants
 Finally, in order to determine whether certain aspects of receptor regulation were 
proportionally stronger affected than that would be expected from the effect of the mutation 
on T3-binding, we correlated the fold increase of parameters for binding affinity, and T3-
dependent activity and cofactor recruitment (Figure 4). The fold increases in IC50-NCoR1, 
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EC50-SRC1, and EC50 on DR4-TRE generally followed the same trend as the fold increase in 
Kd of each mutant with two exceptions. First, the fold increase in EC50-SRC1 of TRα1-M256T 
was slightly but significantly higher than its IC50-NCoR1, which would suggest a marginally 
stronger effect of the mutation on T3-dependent SRC1 recruitment than NCoR1 release. 
Second, the fold increase in Kd of TRα1-R384H was slightly higher than its IC50-NCoR1. In 
both cases, however, this did not result in a significant effect on the EC50-DR4 TRE, indicating 
that these differences do not majorly contribute to the degree of functional impairment. 
Discussion
 In the current study, we report in vitro functional studies of seven TRα1 missense 
mutations. The main purpose was to investigate if other factors, beyond disturbed T3 binding, 
contribute to the functional impairment of TRα1 mutations. According to our results, the reduced 
affinity for T3 is the main factor that determines both the severity of impaired transcriptional 
activity as well as impaired TR-cofactor interaction of the mutants. In our series, we did not 
find evidence for mutation-specific effects on different TREs or coregulatory protein binding.
 Our selection of mutants covered the equivalents of the three mutation-prone 
hotspots in TRβ1. We evaluated the effect of the mutations on the transcriptional activity by 
overexpressing WT or mutant receptors with a reporter gene under control of TREs. Since 
some TRβ1 mutants display TRE selective defects, we included all three reported half-site 
configurations (DR4, IR0, and ER6). As expected, the mutants had an impaired T3-dependent 
transcriptional activity, as illustrated by their dose-response curves with a clear shift to the 
right side of the WT curve and corresponding higher EC50 than WT. The degree of impaired 
transcriptional activity varied among the mutants and correlated with the reduced T3-binding 
energy of the mutants predicted by the in silico modeling and the reduction in T3-affinity from 
the in vitro binding assays. This finding is in line with previous reports of the other mutants 
derived from RTHα patients (8,12,15,25). In addition, the degree of impaired transcriptional 
activity seemed to be related to the severity of the phenotype of the RTHα patients, especially 
the delayed motor development which is much more prominent in the patients carrying TRα1-
D211G and -R384H mutations than in the patient carrying a TRα1-A263S mutation. This is in 
agreement with a previous report by Moran et al. that showed that the functional properties 
of two TRα1 mutations (A263V and L274P) correlate with the clinical features of the patients 
(18). 
 There was no TRE-selective reduction in T3-dependent receptor activity since the 
fold increase in EC50 on all three TREs was similar for each mutant. Of note, the T223A-
TRα1 mutant did not show any differential effect on different TREs, which is in contrast with 
its equivalent TRβ1-T277A, which is selectively affected on an ER6-TRE (24). However, 
the maximal response of T223A and P398H were lower than that of WT on the DR4- and 
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IR0-TRE. This TRE-specific submaximal response has been previously reported in TRβ1-
T277A (24); however, in these studies the submaximal response was found on the DR4- 
and ER6-TRE. The TRE-specific transcriptional impairment may be caused by different 
patterns of dimer formation and cofactor recruitment among TREs (34,35). Nevertheless, 
since numerous chromatin occupation studies have suggested that the DR4-TRE is the most 
important TRE playing a role in the in vivo TR transcription (3-6), the pattern of TR-regulating 
gene transcription is more likely to follow the in vitro result of DR4-TRE rather than IR0- and 
ER6-TRE. Therefore, selective transcriptional impairment of the mutants on IR0- and ER6-
TRE found in vitro may not have a large contribution in the severity of phenotypes in RTH 
patients.
 It has been shown that submaximal response of mutant receptors can be caused 
by impaired TR-cofactor interactions. For instance, the reduced maximal response of TRβ1-
T277A was due to a reduced affinity for SRC1, which could be rescued by overexpression 
of SRC1 (24). Mutations at the residues adjacent to the Pro452 of the TRβ1 (homologous 
to Pro398 of TRα1), Pro453 and Leu454, were also unable to reach WT maximal response 
and have been shown to have a defective TR-cofactor interaction that consequently affects 
transcriptional activity to a greater extent than what would be expected based on their reduced 
affinity for T3 (25,36,37). We, therefore, evaluated the interaction of selected TRα1 mutants 
with the NCoR1 corepressor and the SRC1 coactivator. Except for T223A, the mutants 
required higher T3 levels than WT to dissociate from NCoR1 and to associate with SRC1, 
illustrating the impaired T3-dependent TR-cofactor interaction of these mutants. However, 
the degree of impaired TR-cofactor interaction was similar to the reduced affinity for T3 for all 
selected mutants. In addition, the maximum binding of TRα1-T223A and -P398H was similar 
to WT. These findings suggest that these mutations alter the T3-dependent TRα1-cofactor 
recruitment via their reduced T3 affinity, but that the submaximal response is likely explained 
by another mechanism such as impaired interaction of the mutants with other nuclear 
cofactors. For this reason, we also studied the heterodimerization property of the selected 
TRα1 mutants and found that none of them disturbed heterodimer formation on the DR4-
TRE, suggesting that the submaximal response of these mutant receptors is not explained by 
altered heterodimerization with RXR. 
 To our knowledge, our study reports the in vitro functional impairment at different 
levels of the largest series of TRα1 mutants to date, including four mutations derived from RTHα 
patients which cover all three CpG-rich clusters of TRα1 that correspond with the mutation-
prone hotspots of TRβ1. However, the transcriptional activation of mutants in this study was 
only tested on the most abundant TRE configuration, DR4 (3-6), and the other two well-known 
TRE configurations, IR0 and ER6, which do not cover all natural TREs. Therefore, the results 
should be interpreted and applied cautiously. Our study also did not explore some issues that 
might complicate the phenotype of RTH patients, for instance, the negative transcriptional 
gene regulation by TRs and the effect of mutant TRs on WT receptor function, as known 
as a dominant-negative effect. In addition, our experiments were performed exclusively in 
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vitro and mainly by the overexpressing system in the JEG-3 cells which might not be entirely 
comparable to the in vivo situation. Although JEG-3 cells comprise a well-established model 
to study the impact of TRs mutations, the results of which correlating with the severity of the 
clinical phenotype, it may not represent the situation in other cell types or tissues. Therefore, 
studies in different TR-overexpressing cell lines, or in models that rely on endogenously 
expressed mutant TRs (such as CRISPR-Cas9 genome editing or primary cells derived from 
patients) may substantiate our findings. 
 RTHα patients are currently treated with levothyroxine (LT4) to normalize FT4 levels 
and reduce the hypothyroid state of tissues that predominantly express TRα1, which in 
some cases has been shown to ameliorate the developmental delay and chronic symptoms 
(15,18,19), however, the working mechanism is yet unclear. Since FT4 and T3 levels are only 
marginally increased, it seems unlikely that this treatment results in a significant occupation of 
receptors that have 10 to 100-fold reduction in ligand affinity, but rather increases the number 
of activated WT receptors. Given that the functional defects of TRα1 missense mutants are 
driven by their reduced ligand-affinity, agonists that provide a better fit to the altered ligand-
binding pockets could, therefore, be a tailor-made treatment. Although such agonists are 
currently lacking, the finding that some TRβ1 mutants are more efficiently dissociated from 
NCoR1 by the natural T3 analogue triiodoacetic acid (TRIAC), which is sometimes used to 
suppress FT4 levels in RTHβ patients, and the TR antagonist NH-3 (38), shows that such an 
approach may be viable.
 In summary, this study demonstrates that the severity of impaired transcriptional 
activity of mutant TRα1 receptors is mainly determined by the reduced affinity for T3. These 
mutations also alter TR-cofactor interactions to the same magnitude as the T3 binding defect. 
However, further studies are required to extensively evaluate the in vivo consequences of the 
TRα1 mutations.
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Supplementary Materials
Supplementary Table S1. Primer used for TRα1 mutagenesis.
Mutations Bases change Primers (5’-3’)
D211G GAC>GGC
Forward: TGAAGGCTTCCAGGCCCACCTTGTCTCCG
Reverse: CGGAGACAAGGTGGGCCTGGAAGCCTTCA
T233A ACC>GCC
Forward: CGAGTTTACCAAGATCATCGCCCCGGCCATCAC
Reverse: GTGATGGCCGGGGCGATGATCTTGGTAAACTCG
M256T ATG>ACG
Forward: CTGAAGGGGTGCTGCACGGAGATCATGTCCC
Reverse: GGGACATGATCTCCGTGCAGCACCCCTTCAG
A263S GCG>TCG
Forward: GCGGACAGCCGACCGCAGGGACA
Reverse: TGTCCCTGCGGTCGGCTGTCCGC
L287V CTC>GTC
Forward: CAAGCGGGAGCAGGTCAAGAATGGCGG
Reverse: CCGCCATTCTTGACCTGCTCCCGCTTG
R384H CGC>CAC
Forward: CATGTGGAGGAAGTGGCTGGCGTGGCA
Reverse: TGCCACGCCAGCCACTTCCTCCACATG
P398H CCC>CAC
Forward: CACCGAACTCTTCCACCCACTCTTCCTCG
Reverse: CGAGGAAGAGTGGGTGGAAGAGTTCGGTG
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Supplementary Table S2. Affinity for T3 of TRα1 WT and mutants from the [125I]T3 competitive binding 
assay. 
TRα1
LogKd
[Kd (nM)]
LogKd(MT/WT)
[Fold Kd]
WT -0.87±0.10
[0.1]
-
D211G 0.52±0.15
[3.3]
1.39±0.11**
[24.5]
T223A -0.52±0.15
[0.3]
0.35±0.17
[2.2]
M256T 1.34±0.22
[21.9]
2.21±0.15***
[161]
A263S -0.15±0.24
[0.7]
0.72±0.17*
[5.2]
L287V 0.41±0.09
[2.6]
1.28±0.06***
[19.0]
R384H 0.55±0.16
[3.5]
1.41±0.11***
[25.8]
P398H 0.39±0.07
[2.4]
1.25±0.07***
[17.9]
P valueᶲ <0.001
Data are means ± SEM from four independent experiments (duplicate). *P<0.05, **P<0.01, ***P<0.001 compared with 
WT=0, One-sample T-test. ᶲP value of One-way ANOVA compared between mutants.
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Supplementary Table S3. T3-dependence of GAL4-NCoR1 dissociation and GAL4-SRC1 association of 
TRα1 WT and mutants. 
TRα1
NCoR1 SRC1
LogIC50
[IC50 (nM)]
LogIC50(MT/WT)
[Fold IC50]
Max 
response
(%)
LogEC50
[EC50 (nM)]
LogEC50(MT/WT)
[Fold EC50]
Max 
response
(%)
WT -1.09±0.07
[0.1]
-
100 -0.55±0.08
[0.3]
-
100
D211G -0.02±0.09
[1.0]
1.13±0.07***
[13.6]
98.6±23.9 0.38±0.15
[2.4]
0.95±0.16**
[8.9]
103±16.0
T223A -0.99±0.04
[0.1]
0.15±0.08
[1.4]
84.0±9.2 -0.32±0.11
[0.5]
0.21±0.07
[1.6]
92.2±7.3
M256T 0.78±0.08
[6.0]
1.77±0.10***
[59.5]
77.7±12.3† 1.69±0.08
[48.6]
2.30±0.10***
[200]
79.3±7.3†
A263S -0.79±0.07
[0.2]
0.37±0.05**
[2.3]
89.9±3.6† -0.19±0.10
[0.7]
0.38±0.11*
[2.4]
89.1±9.8
L287V 0.16±0.07
[1.5]
1.30±0.11**
[20.1]
115±5.2 0.70±0.08
[5.1]
1.23±0.16**
[17.2]
83.4±10.5
R384H -0.26±0.06
[0.6]
0.90±0.08***
[7.9]
71.7±11.4†† 0.36±0.18
[2.3]
0.92±0.18**
[8.4]
76.7±14.0
P398H -0.27±0.11
[0.5]
0.87±0.12**
[7.4]
91.7±3.3 0.17±0.10
[1.5]
0.70±0.06**
[5.1]
77.3±13.9
P valueᶲ <0.001 <0.01 <0.001 NS
Data are means ± SEM from at least four independent experiments (triplicate). *P<0.05, **P<0.01, ***P<0.001 
compared with WT=0, and †P<0.05, ††P<0.01, †††P<0.01 compared with WT=100, One-sample T-test. ᶲP value of One-
way ANOVA compared between mutants (NS=not significant).
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Supplementary Figure S1. (A-C) Close-up views of the wild-type (WT) TRα1 structure (left) and indicated 
mutant (right) structural models in which the side-chains of all ligand-interacting residues are displayed. 
The side-chains of the aff ected residues are indicated with an arrow. WT residues are shown in grey, and 
mutant residues are highlighted in color. H-bonds are indicated with a purple dashed line, pi-pi interactions 
with a solid pink line, and hydrophobic interactions with a solid green line. The T3 ligand is displayed in 
ball-stick style in element colors. All fi gures were created in YASARA Structure using PovRay imaging 
software. (D) The bar chart shows reduced T3-binding energy of the mutants predicted by the in silico 
modeling.
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RXRα
T3 (100 nM)
EV WT D211G T223A M256T WT A263S L287V R384H P398H
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TR/RXRα →
DR4-probe →
Supplementary Figure S2. Electrophoretic mobility shift assay (EMSA) showing the TR/RXRα 
heterodimer complex on the DR4-TRE. The heterodimer formation of all mutants is similar to WT and 
independent of T3 stimulation. 
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Supplementary Figure S3. Immunoblot confirms the expression of VP16-TRα1 WT and mutants in JEG-
3 cells.
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Abstract
 Thyroid hormone receptor (TR) α1 is the predominant TR isoform in the brain and 
plays a vital role in neurodevelopment. Mutations in TRα1 that reduce or abolish T3 binding 
to the receptor are the cause of the syndrome of resistance to thyroid hormone alpha (RTHα), 
which is characterized among others by motor and cognitive impairment in RTHα patients. 
Although a genotype-phenotype relation has been reported, it is clear that the severity of the 
neurological phenotype does not always correlate with the degree of T3 binding impairment 
of mutant receptors. However, the mechanism underlying this phenotypic difference is 
unclear. To understand the differences of the neurological phenotype in RTHα patients, we 
analyzed gene regulation by two TRα1 truncating mutations, C380fsx387 and F397fsx406, 
both of which exhibited negligible T3 binding but create a different degree of cognitive 
impairment in patients. RNA was extracted from human-derived neuronal (SH-SY5Y) cells 
stably expressing FLAG-HA-tagged (FH) wild-type (WT) or mutant TRα1 after stimulation 
with vehicle or 10 nM T3. Transcriptomes were analyzed by RNA sequencing. The results 
showed that, in contrast to WT, cells expressing the mutant receptors lacked any T3-induced 
gene expression. Unstimulated gene expression was also different in cell expressing mutant 
versus WT receptors. This difference was more pronounced in FHTRα1-C380fsx387 than 
in -F397fsx406 expressing cells, indicating a differential effect of these mutants on baseline 
gene expression. Many genes that are specifically dysregulated by FHTRα1-C380fsx387 
but not -F397fsx406 compared to both WT are involved in the nervous system development 
and neuronal migration. These findings may explain the more severe neurological phenotype 
found in the patient carrying the C380fsx387-TRα1 mutation. 
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Introduction
 Thyroid hormone (TH) is indispensable for proper neurodevelopment. Impaired TH 
action during brain development can lead to various degrees of psychomotor retardation and 
neurological impairment (1-3). The genomic actions of TH are regulated by thyroid hormone 
receptors (TRs). The TR isoform α1 (TRα1) is broadly expressed in the brain and is considered 
the major isoform to be involved in brain development (4-7).
 Mutations in the ligand binding domain (LBD) of TRα1 cause resistance to 
thyroid hormone alpha (RTHα). The clinical phenotype of RTHα patients includes growth 
retardation, macrocephaly, constipation, and anemia (8-10). Patients also present with 
neurodevelopmental defects, including cognitive and motor impairment, autistic spectrum 
disorder (ASD), and epilepsy (8,11), confirming the importance of TRα1 for a proper brain 
development. To date, 25 mutations (in a total of 40 patients) have been identified as a cause 
of RTHα. These mutations can be categorized into two groups. The first group consists of 
truncating mutations that create premature stop codons and shorten the length of the LBD. 
These mutations abolish the T3 binding affinity and T3-induced transcriptional activity of TRα1 
(12-19). The second group consists of missense mutations that result in single amino acid 
substitutions in the LBD. These mutants bind T3 but with a lower affinity than wild-type (WT) 
receptors (8,15,17,20-27).
 The neurological phenotype of patients with truncating mutations is generally more 
severe than that of patients with missense mutations (8). Interestingly, there is also a striking 
diversity in the severity of the neurological phenotype within the group of patients carrying 
truncating mutations. For instance, patients with a TRα1-F397fsx406 mutation have a relative 
mild neurological phenotype with borderline cognitive and motor impairment (IQ score 90) 
(13,14), whereas the patients with a TRα1-C380fsx387 and -A382fsx388 mutations have 
severe mental retardation (TRα1-C380fsx387 patient was unable to walk and communicate 
at 12 years of age and TRα1-A382fsx388 patient has IQ score 52) (16,17). Since all TRα1 
truncating mutants exhibited negligible T3 binding (13,17), other mechanisms than impaired 
T3-affinity must be involved that are causing this differences in the neurocognitive phenotype.
 In order to better understand the diversity of neurocognitive impairment of RTHα 
patients carrying truncating mutations, we studied the pattern of neuronal gene expression 
regulated by WT TRα1 and two truncating TRα1 mutants (C380fsx387 and F397fsx406) of 
patients with two very distinct neurocognitive phenotypes. 
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Materials and Methods
Plasmid constructs
 A lentiviral bicistronic vector to drive expression of N-terminal FLAG and 
Hemagglutinin (HA) tagged (FH) WT human TRα1 together with the puromycin resistance 
marker, and green fluorescent protein (GFP) (pLentiFHTRα1 WT) was created as previously 
described (Chapter 6a). The TRα1-C380fsx387 (pLentiFHTRα1-C380fsx387) or -F397fsx406 
(pLentiFHTRα1-F397fsx406) mutations were generated using the Quik Change II kit according 
to the manufacturer’s protocol (Agilent Technologies, Amstelveen, The Netherlands). An 
empty vector (EV; pLentiMCS) expressing only the puromycin resistance marker and GFP 
was used to create an EV control cell line. The pMD2.G and psPAX2 packaging vectors 
(Chapter 6a) were used to produce lentiviruses in 293FT cells. The pdV-L1 luciferase-renilla 
reporter construct containing the luciferase reporter gene under control of a thyroid hormone 
response element (TRE) (22) was used to study the T3-induced transcriptional activity of TRs 
in TR-expressing cell lines.
Stable expression of TRs in SH-SY5Y cells
 Lentivirus production and viral transduction have been previously described 
(Chapter 6a). Briefly, lentiviruses containing pLentiFHTRα1 WT, pLentiFHTRα1-C380fsx387, 
pLentiFHTRα1-F397fsx406, and pLentiMCS were produced in 293FT cells seeded in 10 cm 
tissue culture dishes by co-transfecting 4 µg of lentiviral constructs with 4 µg of psPAX2 and 
pMD2.G plasmids using Xtreme Gene 9 transfection reagent according to the manufacturer’s 
protocol (Roche Diagnostics, Almere, NL). SH-SY5Y cells were grown in 6-well plate using 
growth medium (DMEM/F12 supplemented with 9%FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 100 nM Na2SeO3) and infected with lentivirus at 25% confluency. After 48 hours, 
infected cells were selected with 2 µg/mL of puromycin. Puromycin-resistant SH-SY5Y cells 
(SH-SY5Y/FHTRα1 WT, -C380fsx387, -F397fsx406, and MCS) were expanded in selection 
medium (growth medium supplemented with 2 µg/mL puromycin). After two passages, cells 
were subcultured at a 1:10,000 dilution ratio into 10 cm culture dishes in order to growth of 
separate clones. The clones were selected and screened for TR expression by immunoblotting 
before expanding for subsequent experiments.
Immunoblotting
 The expression of FH-TRα1 WT and mutants in monoclonal SH-SY5Y cells was 
verified by immunoblotting of nuclear extracts (NEs) as previously described (22,28), using 
1:1,000 dilution of a HA-Tag antibody (C29F4) Rabbit mAb (#3724, Cell Signaling Technology, 
Leiden, NL). Histone 3 protein was detected as a loading control using a 1:1,000 dilution of a 
Histone 3 (H3; 1B1B2) antibody (#14269, Cell Signaling Technology, Leiden, NL).
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Transfection and luciferase assays
 T3-induced transcriptional activity of FH-TRα1 WT and mutants in monoclonal SH-
SY5Y cells was determined by transfecting 200 ng of the pdV-L1 luciferase-renilla reporter 
construct into cells at 80% confluency in 24-wells tissue culture plates in TH-depleted medium 
(DMEM/F12 supplemented 9% charcoal-treated FBS) using Xtreme Gene 9 transfection 
reagent (Roche Diagnostics, Almere, NL) according to the manufacturer’s protocol. After 
24 hours transfection, cells were stimulated with 0-1,000 nM T3 for 24 hours in DMEM/F12 
supplemented with 0.1% bovine serum albumin (BSA). Luciferase and renilla activities in 
cell lysates were measured as previously described (13) using the Dual Glo Luciferase kit 
(Promega, Leiden, NL). The luciferase to renilla ratio was calculated to adjust for transfection 
efficiency and was shown as mean ± standard error of the mean (SEM) of four independent 
experiments performed in triplicate. 
T3 stimulation and RNA isolation for transcriptome analysis and qRT-PCR
 The monoclonal transduced SH-SY5Y cells were plated in 6-well culture plates in 
selection medium. At 80% confluency, the cells were cultured for 24 hours in DMEM/F12 
supplemented with 9% charcoal-stripped FBS to deplete TH and subsequently stimulated 
for 6 hours with 0 or 10 nM T3 in DMEM/F12 supplemented with 0.1% BSA. RNA was then 
isolated from the cells using Trizol reagent (TRI Reagent®, Sigma-Aldrich, Zwijndrecht, NL) 
and further purified with EchoCLEAN RNA CleanUp kit (020-002-050-050, BioEcho, Cologne, 
Germany), according to the manufacturer’s protocol. RNA samples of three independent 
experiments performed in triplicate for each receptor and T3 concentration were collected. 
One sample of each triplicate was sent for RNA sequencing, and the other two samples were 
used for qRT-PCR.
Next-generation RNA sequencing (RNA-seq) 
 Purity and quality of isolated RNA were assessed by Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). The RNA was prepped with the Illumina TruSeq 
Stranded mRNA Library Prep Kit (Illumina, Eindhoven, NL). The resulting DNA libraries were 
sequenced according to the Illumina TruSeq Rapid v2 protocol on an Illumina HiSeq2500 
sequencer. Reads were generated of 50 base-pairs in length. Subsequently, adapter 
sequences were trimmed off, and the trimmed reads were matched against the requested 
reference (GRCh38 version of the human reference genome) using HiSat2 (version 2.1.0). 
Gene expression values were called using HTseq-count (version 0.9.1).
Differential gene expression analysis 
 Gene expression values from HTseq-count were analyzed using the R program. 
Read counts were first normalized with the DEseq2 package from R (29) and filtered for genes 
that had a false discovery rate (FDR) above 0.05 and low normalized count (<10 reads in 
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more than 21 samples). Principle component analysis (PCA) and pairwise distance heat map 
were performed to visualize the clustering of the samples. Pairwise comparisons of differential 
expression were determined using the DEseq2 package from R (29). A p-value adjusted 
for multiple comparisons < 0.05 was considered significant. Subset of genes that have at 
least a 4-fold difference in expression (log2 fold change ≥ ±2) for each pairwise comparison 
was defined as highly differentially expressed genes (H-DE genes). Gene Ontology terms 
(molecular function, MF; biological process, BP; cellular component, CC) enrichment analysis 
was performed by DAVID functional annotation chart (DAVID Bioinformatics Resources 6.8, 
NIAID/NIH: https://david.ncifcrf.gov/) using default setting (count 2, ease 0.1). Statistical 
significance was considered when p-values of modified Fisher’s exact test (EASE score) with 
Benjamini post-test < 0.05.
Quantitative real-time polymerase chain reaction (qRT-PCR)
 RNA was reverse transcribed using the transcriptor high fidelity cDNA synthesis 
kit (05091248001, Roche Diagnostics, Almere, NL) according to the manufacturer’s 
protocols. qRT-PCR was performed on 25 ng cDNA using TaqMan probes for KLF9 
(Hs00230918_m1), HR (Hairless) (Hs00218222_m1), and Cyclophilin A (Cat. No. 4310883E, 
ThermoFisher Scientific, Landsmeer, NL), and qPCR Core kit for SYBR® Green (Eurogentec, 
Maastrich, NL) with GAPDH (forward primer: 5’-GAGTCCTTCCACGATACCAAAG-3’, 
reverse primer: 5’-GGTGTGAACCATGAGAAGTATGA-3’) and THRA (forward primer: 
5’-AGACCAGATCATCCTCCTGAA-3’, reverse primer: 5’-CCGCTTGACAGCCATCTC-3’) 
primers. The expression of KLF9, HR and THRA were quantified by the ddCt method using 
the geometric means of two house-keeping genes (Cyclophilin A and GAPDH) expression 
for normalization. Data are presented as mean ± SEM of three independent experiments 
performed in duplicate.
Results
Expression and transcriptional activity of FH-TRα1 WT and mutants in SH-
SY5Y cells 
 To study the effect of TRα1 truncating mutations on gene expression in neuronal 
cells, we introduced WT TRα1 and two truncating mutants, C380fsx387 and F397fsx406, 
into SH-SY5Y cells using lentiviral transduction. Monoclonal cell strains were selected 
to get a genetically homogenous and clonal population. The mRNA expression of THRA 
in all three TRα1 expressing cell lines was substantially higher than the MCS control cells 
(approximately 100-fold for SH-SY5Y/FHTRα1 WT, 60-fold for -C380fsx387, and 90-fold for 
-F397fsx406 cells), confirming a low level of endogenous TRα1 expression in SH-SY5Y cells 
and the success of FH-TRα1 transduction (Supplementary Figure S1A). Immunoblots of NEs 
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from SH-SY5Y cells confi rmed that all three FHTRα1 are effi  ciently expressed in the cells, 
albeit with slightly lower expression levels for FHTRα1-C380fsx387 than for FHTRα1 WT 
and FHTRα1-F397fsx406 (Supplementary Figure S1B). WT TRα1 showed normal T3-induced 
transcriptional activity in luciferase assays (Supplementary Figure S1C). In contrast, the two 
truncating mutants showed no response to T3-stimulation at any of the concentrations tested, 
indicating a complete loss of T3-induced transcriptional activity for these mutants.
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Figure 1. (A) Principal component analysis (PCA) of the top 500 genes of RNA sequencing data from 
SH-SY5Y/FHTRα1 WT, -C380fsx387, -F397fsx406, and MCS control cells (after 6 hours 0 or 10 nM T3 
stimulation) clearly demonstrates the clustering of biological replicates from a similar TR and T3 condition. 
The samples from cells expressing WT receptor are separated into two clusters, depending on the T3 
concentration. In contrast, samples from cells stimulated by 0 and 10 nM T3 are clustered together in 
MCS control and the two mutants, suggesting a small eff ect of T3 on their transcriptomes. (B) The 
heatmap illustrates the pairwise distance between samples clustered by hierarchical clustering analysis. 
The key color on the top left indicates the distances between samples. In agreement with the PCA plot, 
samples from the same cell type and T3 condition are clustered together.
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Overall gene expression 
 RNA sequencing was performed to evaluate the different patterns of gene expression 
elicited by WT and the two TRα1 truncating mutants in SH-SY5Y cells. At least 23 million 
reads were generated for each sample, and more than 95% of these reads were aligned with 
the reference sequence. After normalization and filtering, 17,788 genes remained for analysis. 
The PCA plot and pairwise distance heat map showed a high degree of clustering of the three 
biological replicates for each TR and T3 condition (Figure 1). The cluster of T3-stimulated 
SH-SY5Y/FHTRα1 WT was separated from unstimulated WT (0 nM T3), indicating global 
changes in the pattern of gene expression elicited by the liganded WT TRα1. In contrast, 
the six biological replicates of the SH-SY5Y/FHTRα1-C380fsx387 and -F397fsx406 were 
clustered together, regardless of T3, indicating that these two mutants did not respond to 
T3. The fold increase in RNA reads of two known TH responsive genes, KLF9 and HR, were 
similar to the results of qPCR (independent samples) (Supplementary Figure S2), confirming 
the reliability of the RNA sequencing.
 We then analyzed the effect of 10 nM T3 stimulation on gene expression of each 
cell line. The relatively short 6-hour T3 incubation was chosen to minimize the chance that 
differentially expressed genes were not directly controlled by T3-TRα1 but rather secondarily 
via a T3-induced transcription factor (30-32). The results showed that, in the presence of 
WT TRα1, the expression of 5,688 genes was significantly changed by 10 nM T3 (2,999 T3-
upregulated genes and 2,689 T3-downregulated genes) (Figure 2). In contrast, only 43 genes 
were differentially expressed between unstimulated and 10 nM T3 stimulated in the MCS 
control group. In SH-SY5Y/FHTRα1-C380fsx387 or -F397fsx406 cells, T3 did not significantly 
alter the expression of any gene.
 Since T3 did not affect the pattern of gene expression in SH-SY5Y/FHTRα1-
C380fsx387 and -F397fsx406 cells, we from here on only focused on unstimulated gene 
expression to study the difference between the two mutants. The expression heat map 
showed that the overall pattern of unstimulated gene expression of the SH-SY5Y/FHTRα1-
F397fsx406 cells was more similar to WT than to -C380fsx387 cells (Figure 2). We set stringent 
criteria of a minimal 4-fold difference in gene expression levels, designated highly differentially 
expressed (H-DE) genes, to ensure that the differences are likely to have a biological impact. 
The number of H-DE genes between unstimulated SH-SY5Y/FHTRα1-F397fsx406 and WT 
cells was also much smaller than between unstimulated SH-SY5Y/FHTRα1-C380fsx387 and 
WT cells (Figure 3), confirming that the C380fsx387 mutant creates a more distinct pattern of 
baseline gene expression compared to WT than the F397fsx406 mutant.
Differential gene expression of FHTRα1-C380fsx387 versus -F397fsx406
 We performed pairwise comparison to determine which genes are differentially 
expressed between unstimulated SH-SY5Y/FHTRα1-C380fsx387 and -F397fsx406 cells. 
Overall, 4,629 genes were differentially expressed between the two cell lines, of which 721 
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were H-DE genes. Of those, 342 genes were T3 responsive genes, i.e., genes that had a 
signifi cantly diff erent expression level after 10 nM T3 stimulation in the WT cells (Figure 4A).
WT
10 nM
WT
0 nM
C380fsx387MCS F397fsx406
Z-score of norm
alized count
Figure 2. The expression heat map of the normalized RNA sequencing data illustrates the pattern of gene 
expression of all samples. Data are shown as a Z-score of normalized counts per gene (key color on the 
right). The dendrogram shows hierarchical clustering of genes (row) and samples (column) (analyzed by 
average linkage clustering and Pearson distance measurement methods). The heat map is clearly 
diff erent between unstimulated and 10 nM T3 stimulation in WT cells. In contrast, there is no clear 
diff erence in the heat map of SH-SY5Y/FHTRα1-C380fsx387 and -F397fsx406 cells after 10 nM T3 
stimulation (all samples are clustered together). In addition, the heat map of SH-SY5Y/FHTRα1-
F397fsx406 cells is more similar to unstimulated WT than that of -C380fsx387 cells, suggesting a stronger 
eff ect of the C380fsx387 mutation than the F397fsx406 mutation on gene expression of unstimulated 
cells.
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Figure 3. The bar chart shows number of H-DE genes between unstimulated SH-SY5Y/FHTRα1-
C380fsx387 and WT cells (888 genes, black bar) and between SH-SY5Y/FHTRα1-F397fsx406 and WT 
cells (471 genes, grey bar).
Figure 4. 721 H-DE genes between unstimulated SH-SY5Y/FHTRα1-C380fsx387 and -F397fsx406 cells. 
(A) Pie chart shows that 342 genes (47%) are T3-responsive genes, i.e., genes that had a significantly 
different expression level after 10 nM T3 stimulation in the WT cells (189 genes are T3-upregulated 
and 153 genes are T3-downregulated), whereas 379 genes (53%) are T3-independent (the expression 
level does not change after 10 nM T3 stimulation). (B) The result of the gene ontology (GO) enrichment 
analysis showed that the genes were significantly enriched (Benjamini p value < 0.05) with 18 GO terms, 
most of which are related to the physiology of neurons.
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Figure 5. Expression of selected individual genes that are significantly enriched for at least one GO term. 
These genes encode (A) neuronal guidance molecules, (B) cell adhesion molecules, and (C) neurotrophic 
factors, which play an important role in nervous system development and neuronal growth and migration. 
(Data are shown as mean ± SEM of three biological replicates of normalized count from RNA sequencing.)
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Gene ontology (GO) enrichment analysis of FHTRα1-C380fsx387 highly 
differential genes
 Next, we analyzed whether the H-DE genes between unstimulated SH-SY5Y/
FHTRα1-C380fsx387 and -F397fsx406 cells were associated with specific GO terms. The 
result showed that 328 genes were significantly enriched for at least one GO term. The genes 
were enriched for 18 terms, including one molecular function, four biological processes, and 
thirteen cellular components, most of which are related to the physiology of neurons (Figure 
4B and Table 1). Many genes that significantly enriched with these GO terms encode neuronal 
guidance molecules, cell adhesion molecules, and neurotrophic factors, which play important 
roles in nervous system development and neuronal growth and migration (Figure 5 and Table 
2). Interestingly, in addition to the genes that were enriched, the expression of two genes that 
are vital for neuronal differentiation, ASCL1 and NEUROG2, was also remarkably different 
between SH-SY5Y/FHTRα1-C380fsx387 and SH-SY5Y/FHTRα1 WT or -F397fsx406 (Figure 
6 and Table 2). 
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Figure 6. The disparate expression of (A) ASCL1 and (B) NEUROG2 in SH-SY5Y/FHTRα1-C380fsx387 
cells compared to the SH-SY5Y/FHTRα1 WT and -F397fsx406 cells. (Data are shown as mean ± SEM of 
three biological replicates of normalized count from RNA sequencing.)
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Table 1. Significant Gene Ontology enrichment analysis by DAVID Bioinformatics Resources 6.8, NIAID/
NIH (https://david.ncifcrf.gov/).
GO term Gene list
Fold 
enrichment
FDR
Benjamini
p value
Biological Process (BP)
Axonal 
fasciculation
(GO:0007413)
CNR1, CNTN2, CNTN4, CRTAC1, NDN, NRCAM, SEMA3A 13.1 0.015 0.007
Axon guidance
(GO:0007411)
ANOS1, CNTN2, CNTN4, EFNB2, EPHA8, FEZ1, GFRA3, 
LGI1, NGFR, NR4A3, NTN4, RELN, SEMA3A, SEMA3C, 
SLIT1, SLIT2, TENM2, TGFB2, TNR, UNC5A, UNC5D
4.46 <0.001 <0.001
Cell adhesion
(GO:0007155)
ADAM12, ADGRE2, ADGRE5, AJAP1, ANOS1, AZGP1, CD9, 
CNTN2, CNTN4,CNTN6, CNTNAP4, CNTNAP5, COL6A3, 
EDIL3, EFNB2, ENG, EPHA8, FEZ1, FREM2, ISLR, ITGA8, 
ITGA9, ITGB5, JCAD, KITLG, LPP, MYBPC2, NLGN4X, NTM, 
PCDH17, PRKCA, PTPRK, PTPRT, RELN, SIRPA, SORBS2, 
SPOCK1, SPON1, SSPO, THY1, TNFAIP6, TNR
3.09 <0.001 <0.001
Nervous system 
development
 (GO:000739)
CNTN4, CSGAL, NACT1, ENC1, FEZ1, FOS, FUT9, GFRA1, 
GFRA2, GFRA3, HES4, ITM2A, JAG1, LGI1, MAB21L2, 
MAFB, MPPED2, NDN, PCDH1, RGS9, SOX14, SPOCK1, 
ST8SIA4, ZIC5
2.71 0.080 0.025
Molecular Function (MF)
Calcium ion 
binding
(GO:0005509)
ADGRE2, ADGRE5, ASTN2, CACNA1E, CAPN13, CCBE1, 
CPS1, CRTAC1, DGKB, DGKG, EDIL3, EYS, FAT3, FBLN2, 
FSTL4, GUCA1A, HPCAL4, JAG1, KCNIP1, LRP1B, LRP4, 
MATN3, MCTP1, MCTP2, ME1, MMP17, NID1, PCDH1, 
PCDH17, PCDHGB7, PHF24, PLA2G4A, PRRG1, RPH3A, 
S100A10, S100A11, SCGN, SLIT1, SLIT2, SMOC1, SNCB, 
SPOCK1, SPOCK3, SYT17, SYT2, SYT4, TENM2, TLL2
2.35 <0.001 <0.001
Cellular Component (CC)
Anchored 
component of 
membrane
(GO:0031225)
ART4, CD177, CNTN2, CNTN4, CNTN6, GFRA1, GFRA2, 
GFRA3, GPC5, LYPD1, LYPD6B, MMP17, NT5E, NTM, 
PRNP, TFPI
4.92 0.001 <0.001
Axon
(GO:0030424)
CNR1, CNTN4, COBL, FEZ1, GRIK3, HTR2A, IGF2BP1, 
IRX3, KCNA2, KCNA3, KCNB1, KIF21B, MME, NEFL, NEFM, 
PRSS12, PTPRK, SEMA3A, STMN4, SYT4, TGFB2
3.29 0.009 <0.001
Cell junction
(GO:0030054)
CADPS, CAMK2N1, CBLN4, CNTNAP4, CXCR4, DACT1, 
FAIM2, GABRA5, GABRB1, GABRB3, GABRG3, GCOM1, 
GRIA2, GRIA3, GRIK3, GRIK4, GRIK5, KCNA2, KCNB1, 
LGI1, LRRC7, LRRTM3, MYZAP, NLGN4X, PRIMA1, RIMS3, 
RPH3A, SDK2, SIPA1L1, STXBP5, SV2B, SYN3, SYNPR, 
SYT2, SYT4, TENM2, TMEM163, TRIM9
2.80 <0.001 <0.001
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GO term Gene list
Fold 
enrichment
FDR
Benjamini
p value
Dendrite
(GO:0030425)
BRINP2, BRINP3, CAMK2N1, CNTNAP4, COBL, FEZ1, 
GABRA5, GABRB1, GNG3, GRIK3, GRIK5, HTR2A, KCNA2, 
KCNB1, KCNIP1, KIF21B, LRP4, MME, NLGN4X, P2RY1, 
PRSS12, PSD2, PTPRK, RELN, SEMA3A, SLC32A1, SYT4, 
TENM2, THY1, TRIM9, ZNF385A
3.22 <0.001 <0.001
Extracellular 
region
(GO:0005576)
A2M, ADAM12, ADAMTS3, ADAMTS5, ALKAL2, ANOS1, 
AOAH, APLN, APOL4, AZGP1, BCHE, BRINP2, BRINP3, 
C1orf54, C1QTNF1, C6, C7, CLUL1, CNTN4, COL14A1, 
COL24A1, COL2A1, COL6A3, COLEC11, DBH, DMBT1, 
FAM19A5, FBLN2, FGF22, FGF7, FSTL4, GPC5, GREM2, 
IGFBP3, IL13RA2, INHBE, ISLR, JAG1, KITLG, KNG1, 
LGI1, LYPD1, MATN3, MR1, NGFR, NID1, NPY, NRCAM, 
NRG3, NTN4, NTS, NXPH1, OAS1, OTOR, PRRG1, PTX3, 
RBP3, RSPO4, SCGN, SEMA3A, SERPINA5, SLIT1, SLIT2, 
SUSD4, TAC3, TFPI, TGFB2, TIMP3, TLL2, TNFRSF1A, 
TNR, TUBA4A, TULP2, VEGFD, VIP, VSTM2A, WNT11, 
WNT16, XYLT1
1.71 0.004 <0.001
Extracellular 
space
(GO:0005615)
ADAMTS3, ADAMTS5, ADGRE5, ANGPTL2, ANOS1, 
APLN, APOL4, AZGP1, C1QTNF1 ,CBLN4, CCBE1, CD9, 
COL14A1, COL2A1, COL6A3, CPB1, CPNE9, DBH, 
DMBT1, ENG, FGF22, GLDN, GPC5, GREM2, GSDMD, 
HIST1H2BF, IGFBP3, IL13RA2, INHBE, KIT, KITLG, KNG1, 
LGI1, NLGN4X, NPY, NRG3, PTGIS, PTX3, RBP3, RELN, 
S100A11, SEMA3A, SEMA3C, SERPINA5, SERPINB6, 
SEZ6, SLIT1, SLIT2, SPINK13, SPOCK1, SPOCK3, SPON1, 
SSPO, TAC3, TFPI, TGFA, TGFB2, TIMP3, TNFAIP6, 
TNFRSF1A, VEGFD, WNT11, WNT16
1.63 0.196 0.004
Integral 
component 
of plasma 
membrane
(GO:0005887)
ABCB4, ABCG1, ADGRE5, AGTR1, APCDD1, AQP10, 
AQP3, ASIC1, C1QTNF1, CACNB2, CALCRL, CALY, 
CD9, CNR1, CNTN2, EFNB2, EPHA8, ESYT3, GABRA5, 
GABRB1, GABRB3, GPC5, GPR1, GRIA2, GRIK3, GRIK4, 
HAS2, HTR2A, INSRR, JAG1, KCNA2, KCNJ9, KCNK3, 
KCNK9, LIFR, MME, MMP17, NGFR, NLGN4X, NRCAM, 
NRG3, NTRK3, P2RX3, P2RY1, PCDH1, PLPPR4, PLPPR5, 
PLXNA2, PRKD1, PROKR2, PRRG1, PTGER2, PTH1R, 
PTPRK, RHBG, SLC18B1, SLC6A16, SLC7A14, SLITRK6, 
SSTR1, TENM2, TGFA, THY1, TLR1, TNFRSF1A, TRHDE, 
TSPAN2, TSPAN8, VIPR1
1.70 0.024 <0.001
Perikaryon
(GO:0043204)
ASS1, ASTN1, ASTN2, GRIK3, GRIK5, ITGA1, ITGA8, 
KCNA2, KCNAB1, KCNB1, NDN, TMEM100
3.94 0.316 0.006
Proteinaceous 
extracellular 
matrix
(GO:0005578)
ADAMTS16, ADAMTS3, ADAMTS5, ANOS1, CCBE1, 
COL14A1, COL24A1, COL6A3, CRTAC1, FBLN2, GLDN, 
GPC5, MATN3, MMP17, RELN, SLIT1, SLIT2, SMOC1, 
SPOCK1, SPOCK3, SPON1, TFPI2, TIMP3, TNR, WNT11, 
WNT16
3.37 <0.001 <0.001
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GO term Gene list
Fold 
enrichment
FDR
Benjamini
p value
Postsynaptic 
membrane
(GO:0045211)
CAMK2N1, FAIM2, GABRA5, GABRB1, GABRB3, GABRG3, 
GRIA2, GRIA3, GRIK3, GRIK4, GRIK5, KCNB1, LRRC7, 
LRRTM3, NLGN4X, P2RY1, SIPA1L1, TENM2
2.97 0.177 0.004
Plasma 
membrane
(GO:0005886)
ABCB1, ABCB4, ABCG1, ABCG4, ADAM12, ADCY8, 
ADGRE2, ADGRE5, AGTR1, ANO3, ANOS1, AQP10, 
AQP3, ARHGEF28, ART4, ASIC1, ATP10A, AZGP1, 
BAMBI, CA14, CACNA1E, CACNA1G, CACNB2, CACNG2, 
CALCRL, CARD11, CD177, CD9, CERK, CNR1, CNTN2, 
CNTN4, CNTN6, COBL, COLEC12, CSMD2, CXCR4, 
DGKB, DGKG, DGKK, DOCK5, EFNB2, ELMO1, EPHA8, 
FAM155B, FAM84B, FAT3, FEZ1, FGFRL1, FREM2, 
GABRA5, GABRB1, GABRB3, GABRG3, GFRA1, GFRA2, 
GFRA3, GLDN, GLP1R, GNG3, GPBAR1, GPC5, GPR160, 
GPR37L1, GRIA2, GRIA3, GRIK3, GRIK4, GRIK5, GSDMD, 
GUCA1A, HEPH, HTR2A, IFNLR1, ITGA1, ITGA8, ITGA9, 
ITGB5, ITM2A, JAG1, KCNA2, KCNA3, KCNAB1, KCNB1, 
KCNIP1, KCNJ3, KCNJ9, KCNK3, KCNK9, KCNN3, KCNQ3, 
KIRREL1, KIT, KITLG, KNG1, LIFR, LPP, LYPD1, LYPD6B, 
ME1, MME, MR1, MYOF, NFATC2, NGFR, NLGN4X, 
NRCAM, NT5E, NTM, NTN4, P2RX3, P2RY1, PANX2, 
PCDH1, PCDH17, PCDHGB7, PHACTR2, PIK3AP1, PLCE1, 
PLPPR4, PLPPR5, PLXNA2, PRIMA1, PRKCA, PRKD1, 
PRNP, PROKR2, PRSS12, PTGER2, PTH1R, PTPRT, PYGL, 
RAP1GAP2, RELN, RGS9, RHBG, RPH3A, SCN1A, SDK2, 
SEZ6, SGK1, SHB, SIRPA, SLC27A6, SLC32A1, SLIT2, 
SSTR1, STXBP5, SV2B, SYT17, SYT2, SYT4, TBC1D30, 
TENM2, TFPI, TGFA, THY1, TLR1, TMEM100, TMEM119, 
TMEM204, TNFRSF19, TNFRSF1A, UNC5A, UNC5D, VIM, 
VIPR1, VSTM2A
1.42 <0.001 <0.001
Receptor 
complex
(GO:0043235)
ENG, GPR160, GPR37L1, INSRR, ITGB5, LIFR, LRP1B, 
NTRK3, P2RX3, PEX5L, PTH1R, TNFRSF1A, VDR, VIPR1
3.83 0.101 0.003
Synapse
(GO:0045202)
ASIC1, CBLN4, CNTN2, DACT1, GABRA5, GABRB3, 
LGI1, MME, MYO7A, NLGN4X, NRCAM, PPFIA2, PRIMA1, 
RPH3A, SCGN, SDK2, SNCB, TENM2
3.46 0.026 <0.001
FDR, false discovery rate
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Table 2. Selected genes with different expression levels in the FHTRα1-C380fsx387 regulated compared 
to FHTRα1 WT and -F397fsx406, and with known functions in neuronal growth and migration (the gene 
descriptions are extracted from GeneCards: www.genecards.org).
Gene 
symbol
Protein Description
Guidance molecules
SEMA3A Semaphorin 3A Protein can function as either a chemorepulsive (inhibiting outgrowth of axon), 
or a chemoattractive agent (stimulating the growth of axon) 
SEMA3C Semaphorin 3C Functions as attractant for growing axons, and thereby plays an important role in 
axon growth and axon guidance
SLIT1 Slit guidance ligand 1 SLIT1 and SLIT2 together seem to be essential for midline guidance in the 
forebrain by acting as repulsive signal preventing inappropriate midline crossing 
by axons projecting from the olfactory bulb
EFNB2 Ephrin B2 Cell surface transmembrane ligand for Eph receptors which are crucial for 
migration, repulsion and adhesion during neuronal development
UNC5A UNC-5 netrin receptor A Protein belongs to a family of netrin-1 receptors thought to mediate the 
chemorepulsive effect of netrin-1 on specific axons
UNC5D UNC-5 netrin receptor D Receptor for the netrin NTN4. Plays a role in axon guidance by inhibit axon 
growth cones in the nervous system development upon ligand binding
Cell adhesion molecules
NRCAM Neuronal cell adhesion 
(Immunoglobulin 
superfamily, IgSF)
Involved in neuron-neuron adhesion and directional signal during axonal growth
CNTN4 Contactin 4 
(Contactin family of 
immunoglobulin)
Function in neuronal network formation and plasticity
CNTNAP5 Contactin associated 
protein like 5 
(Neurexin family)
Function as cell adhesion molecules in the vertebrate nervous system
THY1 Thy-1 cell surface 
antigen 
(IgSF superfamily)
Involved in cellular adhesion of the immune and nervous systems
PCDH1 Protocadherin 1
(Cadherin superfamily)
Involved in neural cell adhesion, suggesting a possible role in neuronal 
development
PCDH17 Protocadherin 17
(Cadherin superfamily)
Protein may involve in the cellular connections in the brain
FAT3 FAT atypical cadherin 3 May play a role in the interactions between neurites derived from specific 
subsets of neurons during development
ITGA1 Integrin subunit alpha 1
(integrin superfamily)
The protein heterodimerizes with the beta 1 subunit and involved in cell-cell 
adhesion
ITGA9 Integrin subunit alpha 9
(Integrin superfamily)
The protein heterodimerizes with the beta chain and mediates cell-cell and cell-
matrix adhesion
ITGB5 Integrin subunit beta 5 
(Integrin superfamily)
Combines with different alpha chains to form a variety of integrin heterodimers 
and participates in cell adhesion and cell surface mediates signaling
ASTN2 Astrotactin 2 Protein is expressed in the brain and may function in neuronal migration
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Gene 
symbol
Protein Description
Neurotrophic factors
NGFR Nerve growth factor 
receptor
Low affinity receptor which binds to multiple neurotrophic factors and regulates 
neuronal cell survival and cell death 
NTRK3 Neurotrophic receptor 
tyrosine kinase 3
Binds to its ligand neurotropin 3 (NT-3) and involved in nervous system 
development
GFRA2 Glial-derived 
neurotrophic factor 
(GDNF) family receptor 
alpha 2
Encoded protein acts preferentially as a receptor for neurturin (NTN), potent 
neurotrophic factors for neuron survival and differentiation
Neuronal differentiation
ASCL1 Achaete-Scute family 
bHLH transcription 
factor 1
Protein plays a role in the neuronal cell commitment and differentiation
NEUROG2 Neurogenin 2 Protein is expressed in neural progenitor cells within the developing central and 
peripheral nervous systems to specify a neuronal fate
Discussion
 In this study, we evaluated the differences in the transcriptomes controlled by two 
TRα1 truncating mutants (C380fsx387 and F397fsx406) and WT TRα1 in a neuronal cell model 
(SH-SY5Y) in order to gain a better understanding of the differential effects of these mutations 
on the neurological phenotype of RTHα patients. The results showed that the transcriptomes 
of SH-SY5Y cells overexpressing FHTRα1-C380fsx387 and -F397fsx406 mutants were very 
different from the T3-stimulated but also the unstimulated transcriptome of WT TRα1. This 
suggests that the presence of these two mutants alters both baseline and T3-induced gene 
transcription. In addition, the transcriptomes of the two mutants were very different from each 
other, suggesting a differential effect of these two different mutations on gene transcription. 
 Previous studies showed that the phenotype of RTHα patients is mainly caused by 
the reduced T3 binding affinity of TRα1 mutants. However, patients that carry different TRα1 
truncating mutations, all of which exhibited negligible T3 binding, display a striking variation 
in the cognitive phenotype. For instance, the patient who carries TRα1-C380fsx387 mutation 
was severely handicapped and unable to communicate at 12 years of age, suggesting severe 
cognitive impairment (17). Patients who carry TRα1-A382fsx388 and C392X mutations also 
had a low IQ score (IQ score 52 and 22, respectively) (15,16). In contrast, patients who 
carry TRα1-F397fsx406 and E403X mutations had borderline cognitive impairment (IQ score 
90 and 70, respectively) (13-15). This suggests that other effects of the mutation that are 
independent from T3-binding can contribute to the phenotype as well (8,12,13,15-17,33). 
TRα1-C380fsx387 and -F397fsx406 were selected because of the marked differences in the 
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severity of the cognitive impairment in the patients harboring these mutations. In agreement 
with previous reports (13,17), both mutants had no response to T3 in luciferase experiments, 
confirming that T3 could not stimulate transcriptional activity for these mutants.
  In SH-SY5Y/FHTRα1 WT cells, the expression of a substantial number of genes 
(5,688 genes) was regulated by T3 in contrast to SH-SY5Y/MCS controls cells (43 genes). 
The T3-induced response of WT receptor can be divided into two groups. The first group 
is a positive regulation in which the level of gene expression is increased in the presence 
of T3 (2,999 genes, 53%). The second group is a negative regulation in which the level of 
gene expression is decreased in the presence of T3 (2,689 genes, 47%). Interestingly, the 
number of genes in both groups is similar. The number of T3 negatively regulated genes in the 
brain varies (15-60%) between reports, depending on the cellular context and experimental 
technique (34-38). So far, the molecular mechanisms underlying the negative regulation by T3 
have not yet been clearly established.
 In contrast to the WT receptor, the transcriptomes regulated by FHTRα1-C380fsx387 
and -F397fsx406 were not significantly altered by 10 nM T3 stimulation for any gene, which 
is in line with negligible T3 binding of these two mutants. Since we were interested in the 
differential effect of these two mutants on gene transcription, we then studied whether these 
mutants alter unstimulated gene expression compared to the WT receptor in a different way. 
The results indicate that the number of H-DE genes between SH-SY5Y/FHTRα1-C380fsx387 
and WT cells was higher than that between -F397fsx406 and WT cells (888 vs. 471 genes). 
This finding suggests that the effect of these two mutants on gene expression is beyond 
their loss of affinity for T3. In addition, the much larger impact of the C380fsx387 mutant on 
unstimulated gene transcription compared to the F397fsx406 mutant likely contributes to the 
difference in the neurological phenotype of the patients. 
 We performed gene ontology (GO) term enrichment analysis to understand the 
functions of the genes that are differentially expressed between unstimulated SH-SY5Y/
FHTRα1-C380fsx387 vs. -F397fsx406 cells. We only selected the H-DE genes that had 
at least a 4-fold difference in expression between the two mutants for the analysis since 
a difference in expression of these genes is likely to have an impact on the difference in 
phenotype of patients. The results showed that approximately 50% of the selected genes 
were significantly enriched for at least one GO term. Most of the significant terms were related 
to neurons (axon, dendrite, synapse) and physiology of the neurons (axon guidance, axon 
fasciculation, cell adhesion, calcium ion binding, and cell junction). These findings further 
support the hypothesis that a differential effect of the C380fsx387 and F397fsx406 mutants on 
gene expression may disturb the pathways that are critical for the brain and neurons. 
 One of the most significant terms in our GO analysis is axon guidance. Genes 
enriched for this term encode proteins that act as extracellular guidance cues for neuronal 
growth and migration. These cues can either attract or repulse axon growth. SEMA3A and 
SEMA3C encode Semaphorin 3A and 3C that bind to the plexin and neuropillin receptor and 
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inhibit axon growth (39-42). SLIT1 encodes Slit1 that signals through Roundabout (Robo) 
family receptors and controls midline guidance of axons (42-45). EFNB2 encodes Ephrin B2, 
which is a membrane-bound ligand that binds to EphB tyrosine kinase receptors, and mediates 
cell to cell communication and neuronal development (42,46-48). UNC5A and UNC5D encode 
UNC-5 homolog proteins A and D which function as receptors for axonal attractive molecule, 
Netrin (42,49,50). In addition to the axonal growth, these cues are involved in dendrite 
development (51,52) and cortical migration of the neurons (53). By responding to appropriate 
signals, the neurons grow into the correct paths, which leads to proper neurodevelopment. 
Since the expression of these genes in SH-SY5Y/ FHTRα1-C380fsx387 cells was significantly 
different from both SH-SY5Y/ FHTRα1 WT and -F397fsx406 cells, it is likely that these genes 
may have contributed to the more severe neurodevelopmental impairment found in the patient 
carrying the C380fsx387 mutation.
 Apart from the genes that were enriched for GO terms, the expression of ASCL1 and 
NEUROG2 was also markedly different in SH-SY5Y/FHTRα1-C380fsx387 cells compared 
to SH-SY5Y/FHTRα1 WT and -FHTRα1-F397fsx406 cells (Figure 6). These genes encode 
Achaete-scute homolog 1 (ASCL1) and Neurogenin 2 (NEUROG2), respectively, which are 
master regulators of neuronal differentiation. Many studies using murine models suggest that in 
cortical brain development, Neurog2 expression commits progenitor cells to become excitatory 
(glutamatergic) neurons, whereas Ascl1 expression commits cells to become inhibitory 
(GABAergic) neurons (54-58). In addition, highly expressed Ascl1 keeps neuron progenitor 
cells in the proliferative phase rather than enter the differentiation process (55). Therefore, the 
relatively high expression of the ASCL1 and low expression of the NEUROG2 in SH-SY5Y/
FHTRα1-C380fsx387 cells (Figure 6) are likely to affect progenitor cell differentiation and the 
balance between excitatory and inhibitory neurons, which may relate to the severe cognitive 
impairment found in the TRα1-C380fsx387 patient.  
 Although our study showed that TRα1-C380fsx387 and TRα1-F397fsx406 have a 
differential effect on gene transcription, the underlying mechanism explaining this differential 
effect remains unclear. It has been shown that the C-terminal region of TRα1 protein is 
important for the interaction with corepressor and coactivator proteins (59-62). Since the 
location of the frameshift and premature stop codon of TRα1-C380fsx387 is proximal to 
that of TRα1-F397fsx406 mutant, the C-terminal region of the TRα1-C380fsx387 mutant is 
likely more distorted. The C380fsx387 mutation alters both Helix [H] 11 and 12, whereas the 
F397fsx406 mutation only alters H12. The more prominent structural changes in the TRα1-
C380fsx387 mutant might result in more exposure to the corepressor docking surface than in 
case of the TRα1-F397fsx406 mutant. This would allow corepressor proteins to bind stronger 
to the TRα1-C380fsx387 mutant than to the TRα1-F397fsx406 mutant and lead to stronger 
gene repression. Alternatively, since TRs can associate with and be regulated by multiple 
coregulatory proteins, different binding surfaces of the mutants may result in the recruitment 
of a different repertoire of proteins that ultimately affects the expression of target genes. 
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 It is important to emphasize that our experiments were performed by overexpressing 
WT or mutant TRα1 in SH-SY5Y cells, which creates a non-physiologic level of TRα1 
expression. A high level of mutant TRα1 in the cells against a background of low levels of 
endogenous WT TRα1 expression may not mimic the actual situation in which both WT and 
mutant THRA alleles are expressed at equal levels. Therefore, the effect of the mutants may 
be under or overestimated in our system. Although the lentiviral transduction with subsequent 
clonal selection is widely used to create a stable cell line of interest, it has a (tiny) chance that 
viral DNA that integrates into the cell genome disrupts a vital region of the genome, which 
may have complicated the result. Therefore, experiments in more physiologic systems such 
as CRISPR-Cas9 genome editing, primary cells derived from patients, or knock-in animals are 
needed to independently confirm our findings. Last, since neuronal development is a highly 
dynamic process, data from one snap-shot in a neuroblastoma cell line may represent only a 
small part of the whole neurodevelopmental process. 
 In summary, the transcriptome regulated by the two TRα1 truncating mutants, TRα1-
C380fsx387 and -F397fsx406, in SH-SY5Y cells are widely different. Unstimulated gene 
expression controlled by the TRα1-C380fsx387 mutant is more different from WT than that 
controlled by the TRα1-F397fsx406 mutant. Interestingly, this involves many genes that have 
a vital role in neuronal development. These findings may, at least in part, explain the more 
severe neurological phenotype found in the patient carrying the TRα1-C380fsx387 mutation.
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Supplementary Figure S1. (A) The qPCR analysis shows a high expression of the THRA in all three 
FHTRα1 expressing cell lines (SH-SY5Y/FHTRα1 WT, -C380fsx387, and -F397fsx406), confirming the 
success of FHTRα1 transduction. (B) The FHTRα1 protein expression (detected by 1:1,000 dilution of a 
HA antibody) showed that all three FHTRα1 are expressed in the cells with a slightly lower expression 
level for FHTRα1-C380fsx387 than for WT and -F397fsx406. (Relative protein expression (band intensity) 
of three independent blots is quantified by ImageJ program and showed as mean ± SEM, One-sample 
t-test compared to WT **p<0.01.) (C) The T3-induced transcriptional activity of FHTRα1 WT is increased 
in the presence of T3. In contrast, the two truncating mutants showed no response to T3-stimulation, 
indicating a complete loss of T3-induced transcriptional activity (data are shown as mean ± SEM of three 
independent luciferase assay experiments performed in triplicates, Student’s t-test compared to 0 nM T3 
**p<0.01). 
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Supplementary Figure S2. qRT-PCR analysis (left panel) and RNA sequencing (right panel) of the (A) 
KLF9 and (B) HR (Hairless) show a similar pattern between the two methods. The data are shown as 
mean ± SEM of the fold induction (adjusted MCS 0 nM T3 = 1).
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Abstract
 Thyroid hormone receptors (TRs) recruit cofactor complexes to regulate their 
transcriptional activity. Mutations in the TRα1 isoform result in a syndrome of resistance 
to thyroid hormone α (RTHα) that is characterized amongst others by growth retardation, 
and intellectual and motor disabilities. However, the severity of the phenotype differs widely 
between patients. To fully understand the impact of mutations in the RTHα syndrome beyond 
the effect on binding of T3 to TRα1, a comprehensive elucidation of the profiles of TRα1-
associated cofactors in different tissues is required. In this study, we used a tandem-affinity 
purification method to identify TRα1-interactomes from a liver cell model and a neuronal cell 
model in the presence or absence of the ligand T3. The interactomes differed extensively 
between liganded and unliganded receptors. However, they mostly overlapped between the 
different cell types, suggesting that the general regulatory mechanisms are rather conserved 
in different cells. The presence of known cofactors, such as NCoR1, SRC1 and the mediator 
complex confirmed the validity of the approach. In addition, we identified novel putative binding 
partners including transcription factors and chromatin remodelling proteins. We confirmed 
the findings by co-immunoprecipitations. The identification of these novel binding partners of 
TRα1 expands the understanding of the molecular regulation of TRα1 and allows subsequent 
studies on the mechanisms how specific TRα1 mutations contribute to the RTHα phenotype.
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Introduction
 Thyroid hormone receptors (TRs) are ligand-dependent transcriptional regulators 
that are pivotal for the control of development, metabolism and tissue homeostasis (1,2). 
TRs are encoded by two genes (THRA and THRB) that yield three nuclear hormone-binding 
isoforms, TRα1, TRβ1, and TRβ2, which have high homology but differ in their tissue-specific 
distribution. TRs predominantly bind as heterodimers with Retinoid X Receptors (RXR) to 
thyroid hormone response elements (TREs) to regulate the expression of target genes. 
 Mutations in TRs can cause syndromes of resistance to thyroid hormone (RTH) with 
distinct clinical outcomes. RTHα, caused by mutations in THRA, was recently identified and is 
characterized by intellectual disability, growth and psychomotor retardation, and developmental 
delay (3). The severity of the phenotype and the panel of traits differ widely between patients. 
Apart from ligand binding affinity, this may be explained by impaired recruitment of specific 
cofactors, some of which may be expressed or associated in a tissue-specific pattern. A 
thorough identification of tissue-specific interactomes of liganded and unliganded TRα1 will 
therefore contribute to better understanding the molecular regulation of TRα1 action in health 
and disease.
 Similar to other nuclear receptors (NRs), TR activity is regulated via recruited 
cofactors that determine the local chromatin structure and thereby facilitate the accessibility to 
the promoter region of target genes (4). In the absence of triiodothyronine (T3), the biologically 
active form of thyroid hormone (TH), TRs are bound to members of the nuclear corepressor/
silencing mediator for retinoid and thyroid hormone receptors (NCoR/SMRT) proteins that 
recruit a complex of proteins that favour histone deacetylation, which renders the local 
chromatin in a closed confirmation. Binding of T3 induces conformational changes of the TRs 
that cause the NCoR/SMRT complex to dissociate and results in the recruitment of members 
of the Nuclear Coactivator (NCoA) family, also known as steroid receptor coactivators (SRCs), 
which are complexed with histone acetyl transferases (HATs). This results in acetylation 
of histones, which turns the local chromatin in an open and accessible state allowing the 
subsequent recruitment of the Mediator complex, which recruits general transcription factors 
(GTFs) and the RNA polymerase II complex to initiate gene transcription (5-7). Apart from 
these classical cofactors, numerous proteins have been identified that can directly bind to 
TRs and modulate their transcriptional activity, including other scaffolding and chromatin 
remodeling proteins, transcription factors, signaling proteins, and structural proteins (8-11). 
Some of these non-classical cofactors exhibit isoform preference, (11,12), adding to the 
complexity of TH action.
 Previous studies that identified TR-interacting proteins and protein complexes used 
two-hybrid (8), GST-pull downs (11), and affinity purification methods (5,12). Fozzatti and 
coworkers developed a tandem-affinity purification (TAP) method to purify isoform-specific 
interacting proteins from HeLa cells (12). However, their study was limited to proteins associated 
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with TR mutants deficient in T3-binding and returned only a limited number of proteins that 
were isolated from SDS-PAGE gels. In the current study, we optimized their method to purify 
TRα1-interactomes from models for liver cells and neuronal cells in the presence or absence 
of ligand, and subsequently to co-purify proteins of the intact complexes that were identified 
by LC-MS/MS without prior separation. The interactomes mostly overlapped between the 
two cell types, but differed strongly between liganded and unliganded receptors. Importantly, 
we identified novel interacting proteins and multisubunit complexes with yet to be identified 
regulatory functions in TH action.
Materials and methods
Cell culture
 293FT (Thermofisher, #R70007), human HepG2 (ATCC® HB-8065™) hepatocellular 
carcinoma and human SH-SY5Y (ATCC® CRL-2266™) neuroblastoma cells were grown in 
DMEM/F12 medium (Lonza), supplemented with 9% FBS (Lonza), 100 U/ml penicillin, 
100 µg/ml streptomycin (Lonza), and 100 nM Na2SeO3 at 37 °C and 5% CO2. Cells were 
routinely passaged and medium refreshed twice a week. Before transfections, the medium 
was first replaced with hypothyroid Ct-medium (DMEM/F12, 9% charcoal-treated FBS without 
penicillin/streptomycin). 
Constructs
 The plasmid pCDNA3-FLAGTRα1 was used to transiently express FLAG-tagged 
human TRα1 as described previously (13).  A lentiviral construct was used to stably express 
N-terminal FLAG and hemagglutinin (HA) double-epitope tagged human TRα1 (from 
hereon called FHTRα1). To select cells, we used a construct that produces a bicistronic 
messenger from which FHTRα1 is translated together with the puromycin selection marker 
coupled to GFP by a cleavable 2A peptide (Supplementary Figure S1). The entry vectors 
pENTL1-MCS-R5, pENTL5-IRESPuro2AGFP-R2, the lentiviral vector pWCAGpCasC, and 
the packaging vectors pMD2.G and psPAX2 were all kindly gifted by Dr. Lammert Dorssers 
(Department of Pathology, Erasmus MC, Rotterdam). Please see the supplemental methods 
for the generation of the plasmids pWCAGpCasC-MCS-IRESPuro2AGFP and pWCAGpCasC-
FHTRα1-IRESPuro2AGFP (from hereon called pLentiMCS or pLentiFHTRα1) (14).
Lentivirus production and transduction
 To generate lentiviral particles, 293FT cells were seeded into 10 cm dishes and 
transfected with 4 µg of pLentiMCS or pLentiFHTRα1, 4 µg psPAX2, and 4 µg pMD2.G at 
~90% confluency in growth medium without antibiotics, using Xtreme Gene. Supernatants 
were harvested at 48 and 72 hour after transfection and subsequently, filtered through 0.45 µm 
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PES filters to obtain cell-free lentiviral stocks. For infections, HepG2 and SH-SY5Y cells were 
seeded in growth medium in 6-wells dishes and infected at ~25% confluency with different 
amounts of viral stocks. After 2 days, infected cells were selected with 2 µg/ml puromycin. The 
medium was refreshed every 2-3 day and wells with similar number of puromycin resistant 
cells were expanded and used for further analysis. 
Luciferase assay
 HepG2 and SH-SY5Y cells stably expressing FHTRα1 were seeded in 24 wells 
plates and grown in growth medium to 70-80% confluency. The cells were transfected with 
Xtreme Gene (Roche) using the manufacturer’s protocol in Ct medium with 200 ng of the 
plasmid pdV-L1 that contains firefly luciferase under control of a direct and inverted repeat 
TRE, and renilla luciferase as described previously (15). Results are presented as the means 
± SEM of three experiments performed in triplicate.
Tandem-affinity purification (TAP)
 FHTRα1 expressing or MCS control cells were seeded in growth medium in 10 
(HepG2) or 20 (SH-SY5Y) 145 mm dishes per cell line per condition. At 80-90% confluency, 
the cells were incubated overnight with DMEM/F12 supplemented with 0.1% BSA and 
subsequently incubated for 4 hours with vehicle or 100 nM T3. FHTRα1-containing protein 
complexes in nuclear extracts were sequentially purified on anti-FLAG and anti-HA resins as 
described previously with adaptations (12). A detailed protocol of the purification and LC-MS/
MS analysis of the enriched proteins is provided in the supplementary material section (14).
Co-immunoprecipitations
 HepG2 or SH-SY5Y cells were transfected with the plasmids pCDNA3-FLAGTRα1 
or pCDNA3 as empty vector control in Ct medium with Xtreme Gene (Roche) according to the 
manufacturer’s protocol. After overnight incubation in DMEM/F12 supplemented with 0.1% 
BSA, the cells were stimulated with vehicle or 100 nM T3 for 4 hours. Cells were collected in 
buffer A (10 mM Hepes.NaOH, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, cOmpleteTM protease 
inhibitors (Roche), pH 7.9) and lysed by adding 0.6% NP40.  Nuclei were extracted in buffer 
C (20 mM HEPES.NaOH, 400 mM NaCl, 1 mM EDTA, 1 mM DTT, cOmpleteTM protease 
inhibitors, pH 7.9) and diluted in buffer D (20 mM HEPES.NaOH, 1 mM EDTA, cOmpleteTM 
protease inhibitors, pH 7.9) to restore NaCl concentrations to 150 mM. Nuclear extracts were 
incubated overnight with 10 µl bed volume of FLAG-agarose beads (clone M2; Sigma). The 
beads were washed 4 times with 1 ml wash buffer (20 mM HEPES.NaOH, 150 mM NaCl, 
1 mM EDTA, 1 mM DTT, pH 7.9) and eluted with 200 µg/ml FLAG peptide in wash buffer. 
Nuclear extracts and immunocomplexes were denatured in 1x NuPAGE LDS sample buffer 
supplemented with 10 mM DTT at 70 °C for 10 minutes.
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Immunoblotting
 Nuclear extracts and immunocomplexes were separated on 4-15% Mini-Protean 
TGX gels (Bio-rad) and transferred to Immobilon PDVF membranes (Whatmann). Membranes 
were probed with 1:1000 dilutions (unless stated otherwise) of the following antibodies: FLAG 
M2 clone (F1804, RRID:AB_262044), Prox1 (1:2000) (P7124, RRID:AB_1079691) (both 
Sigma Aldrich), HA (clone C29F4, #3724, RRID:AB_10693385), CHD4 (clone D8B12, #11912, 
RRID:AB_2751014), NCoR1 (#5948, RRID:AB_10834809), RXRα (clone D6H10, #3085, 
RRID:AB_11140620), SRC-1 (clone 128E7, #2191, RRID:AB_2196189), HDAC3 (clone 
7G6C5, #3949, RRID:AB_10986336), MED26 (clone D4B1X, #14950, RRID:AB_2798656), 
Histone 3(clone 1B1B2, #14269, RRID:AB_2756816), Brg1 (clone D1Q7F, #49360, 
RRID:AB_2728743), KIF11/Eg5 (#7625, RRID:AB_10860412) (all Cell Signaling Technology). 
Blots were then probed with 1:3000 dilutions of horse radish peroxidase (HRP)-conjugated 
goat anti-mouse or goat anti-rabbit (Biorad) and proteins were visualized by Enhanced 
Chemiluminescence (ECL).
Results
Stable expression of FHTRα1 in HepG2 and SH-SY5Y cells
 HepG2 and SH-SY5Y cell lines that stably expressed FHTRα1 transcribed from a 
bicistronic messenger RNA that also encodes the puromycin selection marker and GFP for 
selection of transduced cells (Supplementary Figure S1 (14)) were successfully generated. 
Cells transduced with the empty vector (MCS) that only expresses the puromycin selection 
marker and GFP were also generated as a control. Equal amounts of nuclear extracts prepared 
from all stable cell lines were analysed by immunoblotting. By probing with HA antibodies, 
specific bands at the predicted size of ~49 kD were visualized for both HepG2 and SH-SY5Y 
cells (Figure 1A). A dose-dependent increase in luciferase activity was found in both HepG2 
and SH-SY5Y cells expressing FHTRα1 after 24 hours T3 incubation, confirming that the FH-
tag did not interfere with receptor activation (Figure 1B).  
Tandem-affinity purifications (TAP)
 To confirm the effectiveness of our TAP protocol, we first purified FHTRα1 from 
HepG2 cells that had been stimulated for 4 hours with 100 nM T3 or vehicle. A third of the 
final eluate was separated by SDS-PAGE. After visualization by Colloidal Coomassie Blue 
staining, the bait as well as additional bands were shown in lanes with eluates from HepG2/
FHTRα1 but not control (MCS) cells, confirming that our method is effective to purify TRα1 and 
associated proteins (Supplementary Figure S2 (14)). In addition, the staining pattern differed 
between cells incubated in the presence or absence of T3, indicating that the association of 
many proteins depended on the occupation state of the receptor. 
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Figure 1. FHTRα1 has T3-stimulated activity. (A) Western blot showing expression of FHTRα1 in HepG2 
and SH-SY5Y cells. Equal amounts of nuclear proteins extracted from HepG2 and SH-SY5Y cells with 
stable integration of FHTRα1 or empty vector (MCS) as control were immunoblotted with an HA antibody. 
(B) Luciferase reporter assay showing T3-dependent transcriptional activity of FHTRα1. HepG2 and SH-
SY5Y cells with stable integration of FHTRα1 or empty vector (MCS) as control were transfected with a 
reporter construct in which the gene encoding fi refl y luciferase is under control of a TRE and constitutively 
expresses renilla luciferase as transfection control, incubated with increasing concentrations of T3 and 
lysates measured for luciferase and renilla activity. Data represent mean ± SEM of three independent 
experiments performed in triplicate.
General composition of the interactomes
 An additional purifi cation from HepG2 cells, and two independent purifi cations from 
SH-SY5Y cells were performed, and all eluates were subjected to LC-MS/MS analysis. Proteins 
that were identifi ed with an FDR of 1% in any of the control purifi cations were excluded. A total 
number of 252 proteins were identifi ed in all purifi cations combined (Supplementary Table 
1 (14)). Gene enrichment analysis for cellular compartments using DAVID showed that 148 
were nuclear proteins (Benjamini corrected p value for enrichment 2.0x10-20, Supplementary 
Figure S3 (14)). Proteins generally overlapped between purifi cations for the same cell type 
and condition (Table 1), although the second HepG2 purifi cation returned a larger number of 
hits many of which were not present in the fi rst purifi cation. This may be due to impurity of 
the enriched complex, which is underscored by the relatively large number of ribosomal and 
ribonuclear proteins (Table 2, Supplementary Table 1 (14)).
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Figure 2. Enrichment of GO terms in the profile. Proteins that were replicated in for at least one cell line 
and condition (see Table 2) were analysed for enrichment of (A) cellular compartments, (B) biological 
processes or (C) molecular function using DAVID (minimum count 2, ease 0.1). The top 30 most significant 
GO terms are displayed. P values were adjusted for false discovery rates using the Benjamini correction.
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Table 1: Total number of hits and replication between purifications
Cell/condition Purification 1 Purification 2 Overlap
HepG2 vehicle 22 130 11
HepG2 T3 58 76 37
SH-SY5Y vehicle 21 21 9
SH-SY5Y T3 20 65 14
Proteins and peptides were compared with Scaffold version 4.8.3. FDR was set at 1% for proteins and peptides. 
Probability scores that met criteria were 5% for proteins and 78% for peptides and 2 peptides minimum for HepG2 
purification and 99% and 91% with 1 peptide for the other purifications. Proteins found in control purifications were 
excluded.
Many copurifying proteins belong to protein complexes and are involved in 
gene regulation
 Of the total number of proteins, 55 were replicated for at least one cell type plus 
condition, and are listed with probability scores and coverage (exclusive unique peptides and 
percentage coverage) in Table 2. For global analysis of the functional relevance of these 
proteins, we used DAVID for gene enrichment analysis (Figure 2). For biological processes 
and molecular functions, we found enrichment of transcriptional regulation via the RNA 
polymerase II complex, nuclear receptor signalling and regulation, histone modification, 
chromatin remodelling and cofactor binding, all confirming a strong association of the profile 
with gene regulation. Enrichment for cellular components showed that the profile is strongly 
enriched for nuclear chromatin binding proteins and/or proteins associated with complexes that 
are involved in gene regulation, such as Mediator complex, histone deacetylation complexes, 
RNA polymerase II complex, and the nuclear remodelling and deacetylase (NuRD) complex. 
Screening of the entire profile of 252 proteins for cellular components identified enrichment of 
additional chromatin remodelling complexes with lower coverage and significance, including 
the strongly overlapping SWItch/Sucrose Non-Fermentable (SWI/SNF), neuron-specific 
BRG1 or HBRM-associated factor (nBAF) and neural progenitor BAF (npBAF) complex, and 
the mixed-lineage leukemia 4 (MLL4) complex (Supplementary Figure S3 (14)). 
Dependence of ligand state and cell lineage on composition of TRα1-
interactomes 
 To characterize the protein complexes in our profiles and the effect of T3-binding, we 
built an interaction network based on experimentally proven interactions using the STRING 
database where we separated between proteins found in the presence or absence of T3 
(Figure 3). In addition, we listed proteins by complexes and/or function by cell-type and ligand 
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state (Table 3). Since there were differences in recovery between HepG2 and SH-SY5Y cells 
and because distant interactions of some members of the complexes may have been so weak 
that they were close to the limit of detection, we included here proteins that were found in a 
single purification, when they belonged to a specific protein complex. As expected, TRα1 is 
associated with RXRs in the presence or absence of T3. In the absence of T3, the receptor 
is associated with the NCoR1-complex that further contains HDAC3 and the F-Box/WD40 
repeat-containing proteins TBL1X and TBL1XR1. Both the corepressor nuclear receptor 
interacting protein 1 (NRIP1) and the Mediator complex were found under both conditions 
but strongly upregulated by T3, as indicated by the higher number of peptides and number 
of subunits for Mediator in the presence of T3, whereas the RNA polymerase II complex was 
only found in the presence of T3 (Figure 3 and Table 2). Surprisingly, we only found NCoAs 
in a single purification in the presence of T3 from HepG2, namely NCoA1/SRC1 and NCoA3/
SRC3 (Supplementary Table 1 (14)), and no HATs. The NuRD complex was also present 
under both conditions, but slightly enriched by T3 (Table 3). Like NRIP1, the association of 
prospero homeobox 1 (Prox1) was increased by T3, whereas the phosphoserine/threonine 
phosphatase PPM1G was only found in the absence of T3. 
 The profiles extensively overlapped between cell lines. Both HepG2 and SH-SY5Y 
cells yielded the NCoR/SMRT, Mediator, and NuRD complexes (Tables 2 and 3). A number 
of hits appeared specific for a single cell line. NRIP1 was abundantly present in purifications 
from T3-treated HepG2 cells only (Table 2). In SH-SY5Y cells, we found a higher number of 
SWI/SNF complex members and specific association of transcription factor 4 (TCF4), and 
the protein encoded by the open reading frame C11orf84 (Table 3). In addition, the structural 
proteins KIF11 (also known as thyroid hormone receptor interacting protein 5 (TRIP5) and 
Eg5) and CLASP2 were only found in from SH-SY5Y cells. Other proteins that copurified 
with FHTRα1 in a cell-type specific manner appear less relevant for gene regulation, such as 
extracellular proteins, mitochondrial enzymes or membrane transport. 
Co-immunoprecipitations confirm LC-MS/MS profiles
 To validate selected hits from our profiles, we immunoprecipitated FLAG-TRα1 from 
transiently transfected HepG2 and SH-SY5Y cells using FLAG antibodies and immunoblotted 
the immunocomplexes (Figure 4). In both cell types, NCoR1 and HDAC3 were only detected 
in cells treated with vehicle, and SRC1 and MED26 (as representative of the Mediator 
complex) in T3-treated cells, whereas the association of RXRα was modestly increased by 
T3. Chromodomain helicase 4 (CHD4) was chosen as representative of the NuRD complex 
and specifically copurified with FLAG-TRα1 from both cell types. The transcription Prox1 
copurified with FLAG-TRα1 from both cell types as well, and the association was strongly 
increased by T3, consistent with the increased coverage of Prox1 with T3 in the LC-MS/MS 
profiles (Table 2). Only BRG1 (also known as SMARCA4 and belonging to SWI/SNF and BAF 
complexes) and KIF11 were also present in immunoprecipitations from cells transfected with 
the empty vector and thus are likely false positives (results not shown).
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Figure 3. Protein networks in the protein profi le and the eff ect of ligand state. Proteins that were replicated 
in at least one cell line and condition (see Table 2) were mined for existing experiment-based protein 
interactions, using STRINGS with minimum required interaction scores set at medium (0.400). Profi les 
found for the (A) absence or (B) presence of T3 were analysed separately. Dashed circles indicate protein 
complexes.
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Figure 4. Immunoprecipitation confi rms association of selected proteins from the profi les with FHTRα1. 
Representative immunoblots showing co-immunoprecipitation of selected hits with FHTRα1 from HepG2 
and SH-SY5Y cells. Nuclear extracts from HepG2 and SH-SY5Y cells transfected with FLAG-TRα1 
or empty vector (EV) as control were subjected to immunoprecipitation with anti-FLAG resin, proteins 
eluted with the FLAG peptide and the immunocomplexes or 10% of the nuclear extracts as input control 
subjected to western blotting. Segments of the blot around the expected molecular weight of the targeted 
proteins were immunoblotted with the indicated antibodies. Histone 3 was used as control for equal input.
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Table 3: Proteins by complexes and/or molecular function
Complex
HepG2 SH-SY5Y
vehicle T3 vehicle T3
Nuclear receptors THRA, RXRA, 
RXRB
THRA, RXRA, 
RXRB
THRA, RXRB THRA, RXRB
NCoR/SMRT NCoR1, NCoR2, 
HDAC3,TBL1X, 
TBL1XR1, TBL1Y
NCoR1, TBL1XR1
Other corepressors NRIP1 NRIP1 C11orf84 C11orf84
Mediator MED1, MED12, 
MED21
MED1, MED4, 
MED6, MED7, 
MED8, MED9, 
MED10, MED11, 
MED12-17, 
MED13L, MED19-
20, MED21-24, 
MED26-28, 
MED29, MED31, 
CCNC, CDK8
MED1, MED6, 
MED12, MED14-
17, MED24, 
MED28
RNA polymerase II POLR2A-C, 
POLR2D, 
POLR2E, 
POLR2H, POLR2I, 
PAF1, RECQL5, 
RPAP2
NuRD CHD4, MTA1, 
MTA2
CHD4,  GATAD2A, 
GATAD2B, 
HDAC2, MBD3, 
MTA1, MTA2, 
MTA3, RBBP4, 
RBBP7
GATAD2B, HDAC2, 
MTA1, MTA2, 
RBBP4
SWI/SNF
nBAF
npBAF
SMARCC2 SMARCB1 ACTL6A, PBRM1, 
SMARCA4/
BRG1, SMARCB1, 
SMARCE1
Histones H1FX H1FX
Transcription factor PROX1 PROX1 PROX1, TCF4 PROX1, TCF4
Phosphatases PPM1G PPM1G
Methylosome complex WDR77 WDR77 WDR77
Membrane transport SLC25A5 SLC25A5
Enzyme HADHA, CPVL HADHA CPVL
Structural LMNB1 KIF11 CLASP2, KIF11
Extracellular APCS
Proteins that were replicated for a cell line and condition are in bold. Proteins that were not replicated were included 
when they were replicated for another cell line and condition or when they belong to a protein complex (normal font).
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Discussion
 In this study, we purified TRα1 from two cell models in the presence and absence 
of the natural ligand T3 and identified several unknown binding partners of TRα1 by LC-
MS/MS. Our approach revealed that the composition of TRα1-interactomes mostly overlaps 
between the two studied cell-types and strongly depends on ligand-state. In addition, we found 
novel putative binding partners, most notably transcription factors and proteins belonging to 
chromatin remodelling complexes. 
 Two important aims of our approach were to determine the effect of ligand and 
cell background on the composition of TRα1-interactomes. As expected, the interactomes 
varied clearly between unliganded and liganded receptors. This was confirmed by co-
immunoprecipitations for members of the NCoR1, NCoA/SRCs and Mediator complexes, but 
also for potentially novel candidates such as the transcription factor Prox1. Whether these 
novel partners act as global regulators of T3-dependent TR activity or are involved in the 
regulation of a subset of genes at the cross-road of TH and other signalling pathways remains 
to be elucidated. The analysis of cell specificity dependence was complicated by the fact 
that recoveries of the bait and number of co-purifying proteins were consistently lower from 
SH-SY5Y cells than from HepG2 cells. As a result, interactions that are weakly preserved 
or are only incorporated in a subset of transcriptional complexes could have fallen below 
the detection limit in purifications from SH-SY5Y cells. This is underscored by the recovery 
of substantially less members of conserved protein complexes like Mediator from SH-SY5Y 
cells than from HepG2 cells. The lower recovery is likely due to the lower amount of input from 
SH-SY5Y cultures, even though we used twice the amount of tissue culture plates. Despite 
this, a number of hits were replicated in a single type, for example NRIP1 in HepG2 cells and 
TCF4 in SH-SY5Y cells, suggesting a cell-type specific association with TRα1 which could 
contribute to cell-type specific gene regulation. However, since according to the human protein 
atlas (https://proteinatlas.org) both proteins are expressed in liver and brain, but NRIP1 only 
in HepG2 and TCF4 only in SH-SY5Y cells, it cannot be proven whether the association is 
specific for the cellular context or merely a consequence of expression in the cell models. 
 Several proteins in our profiles belong to multisubunit chromatin remodelling 
complexes. Chromatin remodelling complexes combine different enzymatic activities that alter 
the local chromatin architecture by affecting the state of histone acetylation and methylation 
and repositioning nucleosomes.  Most notably, we found many members of the NuRD complex, 
including CHD4, GATA zinc finger domain containing 2A and 2B (GATAD2A/GATAD2B), 
metastasis-associated factors (MTA1/MAT2/MTA3), histone binding proteins (RBBP4 and 
weakly RBBP7) and methyl-CpG domain binding protein (MBD3). The NuRD complex is a 
chromatin remodelling complex that facilitates predominantly transcriptional repression by 
combining helicase and histone deacetylase activities (16) and has been shown to repress 
TR activity in a Xenopus oocyte model (17). CHD4 was previously shown to co-purify with 
mutant TRs (12), and here co-immunoprecipitated with WT TRα1 in HepG2 and SH-SY5Y 
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cells (Figure 4). Interestingly, CHD4 directly binds to the nuclear receptor Retinoid Orphan 
Receptor gamma (RORγ) and inhibits its transcriptional activity (18). 
 Members of SWI/SNF complexes, also known as the BAF (BRG1/BRM-associated 
factors) complex, were weakly present in our profiles. BAF complexes are ATP-dependent 
chromatin remodelling complexes that confer epigenetic regulation of gene expression by 
altering the positioning of nucleosomes, and altered activity is associated with developmental 
disorders and cancer (19,20). Studies using TRβ1 and reporter construct injected Xenopus 
oocytes showed T3-stimulated recruitment of BRG1/SMARCA4 to chromatin (21). BAF 
proteins were predominantly found in SH-SY5Y cells treated with T3, but also in HepG2 
cells treated with vehicle. However, immunoblotting against BRG1/SMARCA4 showed the 
presence of BRG1 in immunocomplexes of both control and FLAG-TRα1 transfected HepG2 
and SH-SY5Y cells, leaving a TRα1-specific interaction questionable (results not shown). A 
third chromatin remodelling complex, the mixed-lineage leukemia 4 (MLL4) complex, was 
found in a single purification from HepG2 cells, and represented by the methylosome protein 
50 (WDR5) in vehicle and T3-treated cells, and the histone lysine N-methyltransferase MLL4/
KMT2D (sometimes also addressed as MLL2) and the lysine-specific histone demethylase 
UTX/KDM6A in T3-treated cells only. Mutations in MLL4/KMT2D and UTX/KDM6A cause 
the Kabuki syndrome, which is characterized by intellectual disability and distinct facial 
characteristics (22). 
 One of the strongest hits in our profiles was Prospero homeobox 1 (Prox1). Prox1 was 
associated with TRα1 in both HepG2 and SH-SY5Y cells and binding was enhanced by the 
presence of T3, as indicated by the higher coverage and confirmed by co-immunoprecipitation 
(Figure 4). Prox1 is a transcription factor that has important functions in cell fate specification 
and metabolism (23-25). Prox1 interacts with several other NRs, such as COUP-TFII in 
lymphatic endothelial cells, and hepatic nuclear factor 4 (HNF4α), liver receptor homologue-1 
(LRH-1) and Retinoid Orphan Receptor (ROR) α and γ in liver (26-29). A recent systematic 
study of in vitro binding of peptides from coregulators to NRs showed that the Prox1 peptide 
bound to nearly all of the 24 NRs tested, including both TRs, which indicates that Prox1 may 
well be a general cofactor for NRs (30). In liver, Prox1 inhibits reverse cholesterol transport 
and represses HNF4α and LRH-1 mediated expression of CYP7A1, an important enzyme for 
the conversion of cholesterol into bile acid (25,27,28,31), processes that are also regulated by 
TH (32). 
 The advantage of the TAP-purification method used is that the bait is incorporated 
into the protein complexes in the intact cell and purified under native condition. This approach 
therefore preserves the natural composition of the complexes. In addition, the two consecutive 
purification steps ensured recovery of highly pure complexes with limited background. We 
adopted a TAP-method that was previously used to isolate proteins associated with ligand-
binding defective TRα1 and TRβ1 mutants form HeLa cells (33), and improved on the 
method by i. using wt TRα1 as bait, which allowed us to compare interactomes of liganded 
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and unliganded receptors, ii. instead of first separating proteins by SDS-PAGE and proteins 
subjecting the final eluate directly to LC-MS/MS to identify all proteins irrespective of their 
visualization on an SDS-PAGE gel, and iii. replicating the purifications for each condition 
to minimize the number of false positive hits. Our profiles partially overlap with the study of 
Fozzatti and coworkers, but returned a larger number of proteins that associate with TRα1. 
For example, their study only returned CHD4, but we also found several additional proteins of 
the NuRD complex. 
 Our method was further validated by the recovery and co-immunoprecipitation of 
several known transcriptional co-regulators of TRs, such as RXR isoforms, the NCoR/SMRT 
corepressor complex in the absence of T3 and the Mediator and RNA polymerase II complexes 
in the presence of T3 (Table 3). Furthermore, the fact that we found many if not most subunits 
for these complexes shows that our method not only finds binary binding partners, but is 
mild and sensitive enough to preserve the complexes and identify indirect binding partners of 
TRα1. This is for example demonstrated by the fact that from the RNA polymerase complex 
II, which only associates with TRα1 via the large multisubunit Mediator complex, we also 
identified the regulatory kinase CDK9 (34) and phosphatase RPAP2 (35). One exception were 
the NCoA/SRC coactivator complexes, which were underrepresented in our purifications. We 
found NCoA1/SRC1 and NCoA3/SRC3 only in one HepG2 purification in the presence of T3 
(Supplementary Table 1 (14)) and did not detect any HAT proteins. Co-immunoprecipitations, 
however, showed T3-dependent binding of SRC1 in both HepG2 and SH-SY5Y cells (Figure 
4). Most likely, the SRC1 binding is sensitive to the prolonged purification procedure of the 
tandem versus the single affinity purification method. 
 In conclusion, we successfully and efficiently purified cell-type and ligand state 
specific TRα1-interactomes using a simple tandem-affinity purification method and identified 
potentially novel interactions with signalling proteins, transcriptional regulators and chromatin 
remodelling complexes. Future studies will need to elucidate how these novel binding partners 
contribute to TRα1-mediated gene regulation by TH and how specific mutations in TRα1 affect 
the repertoire of recruited cofactors and downstream gene regulation, and ultimately the RTHα 
phenotype in patients.
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Supplementary Materials
Supplementary Figures
Supplementary Figure S1. Structure of expression cassette of the FLAG-HA tagged TRα1 (FHTRα1) 
construct. The second codon of the full length coding sequence of TRα1 is fused at the 5’-end to 
consecutive sequences encoding the FLAG and hemagglutinin (HA) epitope tags (B). To select cells 
expressing FHTRα1, the construct is expressed from a bicistronic messenger RNA, due to the inclusion 
of an internal ribosome entry site (IRES) sequence, together with a selection marker consisting of the 
sequences encoding the puromycine resistrance gene (PURO) and green fl uorescent protein (GFP), 
fused by the sequence encoding the 2A self-cleaving peptide (A).
Supplementary Figure S2. SDS-PAGE of FHTRα1-containing protein complexes from HepG2 cells. 
HepG2 cells expressing FHTRα1 or empty vector (MCS) as control were stimulated for 4 hrs with vehicle 
or 100 nM T3 and subjected to TAP purifi cations. One third of the fi nal eluates were separated on a 4-12% 
Bis-Tris gel and protein bands visualized by Colloidal Coomassie staining.
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Supplementary Figure S3. Enrichment for cellular compartments of the total profile. Proteins that 
specifically co-purified with FHTRα1 in any purification (Supplementary Table 1) were analysed for 
enrichment of cellular compartment using DAVID (minimum count 2, ease 0.1). The top 40 most significant 
GO terms are displayed. P values were adjusted for false discovery rates using the Benjamini correction.
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Supplementary Methods
Construction of lentiviral vectors pWCAGpCasC-MCS-IRESPuro2AGFP and 
pWCAGpCasC-FHTRα1-IRESPuro2AGFP 
 To add the sequence encoding the FLAG and HA epitope to the 5’-side of TRα1, the 
full length coding sequence for TRα1 was amplified using Pfu polymerase (Thermofisher) by 
which the start codon was replaced with consecutive sequences for the FLAG and HA epitope 
tag (Supplementary Figure S1). The resulting fragments was cloned into the pCR2.1TOPO 
vector (Invitrogen) and subsequently excised and ligated into the HindIII and BamHI sites 
of pENTL1-MCS-R5 to yield the plasmid pENTL1-FHTRα1-R5. The correct sequence was 
confirmed by Sanger sequencing. The MCS (multiple cloning site) or FHTRα1 fragments were 
next fused to the IRESPuro2AGFP-fragment from pENTL5-IRESPuro2AGFP-R2 and inserted 
into pWCAGpCasC by multiple gateway cloning using the LR II Clonase Plus (Invitrogen) 
according to the manufacturers protocol.
Tandem affinity purification
 Throughout the procedure, buffers were supplemented with 100 nM T3 or vehicle, 
and cOmpleteTM protease inhibitors cocktail (Roche). Cells were washed twice with ice-cold 
DPBS, scraped into 2 ml DPBS per plate, pelleted in a table-top centrifuge at 1200 round per 
minute (rpm) for 5 minutes at 4 °C and resuspended in 5 ml buffer A (10 mM Hepes.NaOH, 
10 mM KCl, 0.1 mM EDTA, 1 mM DTT, pH 7.9). After 15 min on ice, 0.6% NP40 was added 
and the cells were vortexed for 30 seconds to lyse the cells. Phosphatase inhibitors (5 mM 
NaF and 1 mM NaPPi) were added and nuclei pelleted by centrifugation at 2000 rpm for 10 
minutes at 4 °C. Nuclear proteins were extracted by nutating the nuclei in 1.88 ml buffer C 
(20 mM HEPES.NaOH, 400 mM NaCl, 1 mM EDTA, 1 mM DTT, 5 mM NaF, 1 mM NaPPi, 
pH 7.9) for 20 minutes at 4 °C.  The nuclei were spun down in a microfuge at 15000 rpm. 
The supernatant was transferred to a 15 ml conical tube, the salt concentration reduced by 
addition of 3.12 ml buffer D (20 mM HEPES.NaOH, 1 mM EDTA, 5 mM NaF, 1 mM NaPPi, 
pH 7.9) and NP40 added to a final concentration of 0.1%. Next, FHTRα1-containing protein 
complexes were bound overnight at 4 °C to 20 µl bedvolume of anti-FLAG agarose (clone 
M2; Sigma), washed 1 time with 10 ml and 4 times with 1 ml of ice-cold washbuffer (20 mM 
HEPES.NaOH, 150 mM NaCl, 1 mM EDTA, 5 mM NaF, 1 mM NaPPi, 0.1% NP40, pH 7.9) 
and eluted twice with 50 µl of 200 µg/ml FLAG peptide (Sigma) in washbuffer for 30’ at 4 °C in 
spin columns (Biorad). Eluates were combined, 500 µl of washbuffer was added to the eluates 
and FHTRα1-containing protein complexes were bound overnight at 4 °C to 20 µl bedvolume 
of anti-HA agarose (Sigma), after which the resin was washed 4 times with 1 ml ice-cold 
washbuffer. For the first purification from HepG2 cells, the resin was subsequently washed 1 
time with 1 ml washbuffer without NP40, transferred into a spin column and protein complexes 
eluted once at 4 °C and once at room temperature with 25 µl 400 µg/ml HA peptide (Sigma), 
after which the eluates were pooled. For the other purifications, 0.1% RapiFest SF (Waters) 
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was added to the final washbuffer and elution buffer, to improve bead handling. Elutes were 
pooled and subjected to LC-MS/MS for protein identification. For the first purification from 
HepG2 cells, 1/3 part of the eluate was denatured in 1x NuPAGE LDS sample buffer (Thermo 
Fisher Scientific) supplemented with 10 mM DTT at 70 °C for 10 minutes, separated by SDS-
PAGE on a 4-12% Bis-Tris gel (Novex, Invitrogen) and bands visualized with a  Colloidail Blue 
Staining Kit (Invitrogen). 
In-solution digestion
 Eluates from two independent purifications from each cell line were precipitated 
using acetone and then resuspended in 0.1% Rapigest in 50 mM NH4HCO3. The solution 
was reduced with 100 mM dithiothreitol (DTT) at 60 °C for 30 minutes. After the mixture was 
cooled down to room temperature, it was alkylated in the dark with 300 mM iodoacetamide 
at ambient temperature for 30 minutes, and digested overnight with 0.4 µg trypsin (Promega, 
Madison, WI). Five percent trifluoroacetic acid was added, to obtain a final concentration of 
0.5% trifluoroacetic acid (pH < 2). After 45 minutes of incubation at 37 °C, the samples were 
centrifuged at 13,000 x g for 10 minutes.
NanoLC data dependent mass spectrometry measurements
 Digested samples were subjected to LC-MS/MS analysis. Samples were analyzed 
by nano-LC (Ultimate 3000RS, Thermo Fisher Scientific, Germering, Germany). After pre-
concentration and washing of the samples on a C18 trap column (1 mm × 300 μm i.d., Thermo 
Fisher Scientific), they were loaded onto a C18 column (PepMap C18, 75 mm ID × 150 
mm, 2 μm particle and 100 Å pore size, Thermo Fisher Scientific) using a linear 15 minutes 
gradient (4-38% ACN/H20; 0.1% formic acid) at a flow rate of 250 nL/min. The separation of 
the peptides was monitored by a UV detector (absorption at 214 nm). The integrated area of 
the UV chromatogram is used to determine the maximum injection volumes for the LC-MS 
analyses. For the LC-MS the same type of LC system is used connected to a nanospray 
source. The LC system was equipped with a PepMap C18 column (75 mm ID × 250 mm, 2 
μm particle and 100 Å pore size, Thermo Fisher Scientific) and a 30 or 90 minutes gradient 
(4-38% ACN/H20; 0.1% formic acid) at a flow rate of 300 nL/min coupled to either an Orbitrap 
Fusion or to a Orbitrap Fusion Lumos (Thermo Fisher Scientific, San Jose, CA, USA). The 
Orbitrap Fusion Lumos was operated in the data dependent acquisition (DDA) mode. Full scan 
MS spectra (m/z 375-1,500) in profile mode were acquired in the orbitrap with a resolution of 
120,000 after accumulation of an AGC target of 400,000. A top speed method with a maximum 
duty cycle of 3 seconds was used. In these 3 seconds, the most intense peptide ions from 
the full scan in the orbitrap were fragmented by HCD (normalized collision energy 28%) and 
measured in the iontrap with a AGC target of 10,000. Maximum fill times were 50 ms for the 
full scans and 50 ms for the MS/MS scans. Precursor ion charge state screening was enabled 
and only charge states from 2-7 were selected for fragmentation. The dynamic exclusion was 
activated after the first time a precursor was selected for fragmentation and excluded for a 
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period of 60 seconds using a relative mass window of 10 ppm. Lock mass correction was 
activated to improve mass accuracy of the survey scan. In the Orbitrap Fusion the following 
settings were used; DDA mode, Full scan MS spectra (m/z 400-1,600) in profile mode with 
a resolution of 120,000 and an AGC target of 400,000. A top speed method with a maximum 
duty cycle of 3 seconds was used. In these 3 seconds, the most intense peptide ions from 
the full scan in the orbitrap were fragmented by CID (normalized collision energy 30%) and 
measured in the iontrap with a AGC target of 10,000. Maximum fill times were 100 ms for 
the full scans and 40 ms for the MS/MS scans. The rest of settings were the same as for the 
measurements on the Orbitrap Fusion Lumos. From the data files of both systems the MS/
MS spectra were extracted and converted into mgf files by using MSConvert of ProteoWizard 
(version 3.0.06245). All mgf files were analyzed using Mascot (version 2.3.02; Matrix Science, 
London, UK). Mascot was used to perform database searches against the human subset 
of either uniprot_sprot download November 2015 (20194 entries) or download September 
2014 (20196 entries), using Mascot version 2.3.02. Monoisotopic fragment tolerance was 
set to 0.50 Da and parental tolerance at 10 ppm. Carbamidomethylation of cysteine was 
specified as fixed modification and oxidation of methionine as variable modification for all, and 
n-terminal acetylation for the first HepG2 purification. 
 Version 4.8.3 of the Scaffold platform was used to validate proteins and peptides. 
Stringency settings allowed FDRs of 1% for proteins and peptides when screened against 
a decoy database. This allowed probability scores of 5% and 78% for proteins and peptides 
respectively with a minimum of 2 peptides for the first purification from HepG2, and 99% 
and 91% for proteins and peptides with a minimum of 1 peptide for the other purification. 
Proteins that were present in any of the control purifications were excluded from our final 
profile. The uniprot_sprot database contains the TRα isoform 2 (P10827-1) instead of our bait 
TRα1 (P10827-2). These isoforms differ in their C-terminal domain (371-410 in TRα1), which 
has high homology between TRα1 and TRβ. Therefore, a peptide (sequence MIGACHASR; 
position 376-384 in TRα1, position 440-448 in TRβ1) that is conserved between TRα1 and 
TRβ was scored as an exclusive unique peptide for the C-terminus of TRβ. Apart from one 
peptide with a probability score of 85% (sequence KLIEENR; position 190-196 in TRβ1), in 
HepG2 purification 1 from vehicle treated cells, we did not find any peptides that are unique 
for TRβ as well as TRα2. As such, we decided that all peptides are derived from TRa1 and 
assigned the C-terminal peptide and spectra to TRα1 in Table 2 and Supplementary Table 1. 
Gene enrichment analysis was performed using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID), version 6.8 (https://david.ncifcrf.gov/) using default settings 
(count 2, ease 0.1) and p-values adjusted using the Benjamini correction. Existing protein 
interaction networks were searched using STRINGS (https://strings-db.org) with minimum 
required interaction scores set at medium confidence (0.400).
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Abstract
 Thyroid hormone (TH) binding to its nuclear TH receptors (TRs) alters coregulatory 
protein recruitment of the TRs to regulate gene transcription. Considering the crucial role of 
TH in brain development and function, we aimed to identify the coregulatory proteins that are 
involved in neuronal TR activity by elucidating the interactomes for wild-type TRα1 and TRβ1 
in a human-derived neuronal cell line (SH-SY5Y). TR-interacting proteins were purified from 
nuclear extracts of SH-SY5Y cells stably expressing epitope-tagged TRα1 and TRβ1 (FH-
TRα1 and -TRβ1) by tandem-affinity purification and analyzed by LC-MS/MS. One hundred 
one proteins were co-purified with TRs, including the known TR-interacting proteins, such as 
retinoid X receptors (RXRs) (regardless of T3, the presence or absence of T3), NCoR1/SMRT/
HDAC3 repressor complex (in the absence of T3), and SRCs and the Mediator complex (in 
the presence of T3). Several chromatin remodeling complexes that have not previously been 
described as coregulators of TRs were identified, for instance the nucleosome remodeling 
deacetylase (NuRD) and the Spt-Ada-Gcn5-Acetyltransferase (SAGA) complexes. Most of 
the proteins were shared between the two TR isoforms. However, we identified nine proteins 
that only associated with FH-TRα1 and two proteins with FH-TRβ1. These findings suggest 
that TRs not only interact with classical coregulatory proteins in SH-SY5Y cells but also with 
several potential novel binding partners. In addition, we identified a subset of distinct nuclear 
proteins that seem to interact with TRs in an isoform-specific manner. 
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Introduction
 Thyroid hormone (TH) is indispensable for proper neurodevelopment (1). TH 
regulates gene transcription by binding of the bioactive TH form, triiodothyronine (T3), 
to thyroid hormone receptors (TRs). Impaired action of TH in the brain is associated with 
intellectual disability and psychomotor retardation in many conditions, including prolonged 
untreated congenital hypothyroidism patients (2,3), impaired TH transport to the brain in 
monocarboxylase transporter 8 (MCT8) deficiency (due to a mutation in MCT8) (4,5), and 
impaired function of TRα due to a mutation in this receptor leading to resistance to TH alpha 
(RTHα) (6,7). 
 Three TR isoforms, TRα1, β1, and β2 that have extensive structural similarity are 
capable of binding to T3. TRα1 is encoded by THRA gene on chromosome 17 whereas TRβ1 
and TRβ2 are encoded by THRB gene on chromosome 3 (8). It has been shown that TRα1 
is the most abundantly expressed in the brain and plays a crucial role in brain development 
(9-13). TRβ1 is also expressed in many regions of the brain but the distribution is more 
restricted compared to TRα1 (9,11). TRβ2 is predominantly expressed in the hypothalamus, 
pituitary, retina, and cochlea (11,14,15). These differential expression patterns suggests that 
TR isoforms could play different functional roles during development.
 TRs mainly form heterodimers with retinoid X receptors (RXRs) on thyroid hormone 
response elements (TREs) and interact with many nuclear coregulatory proteins to regulate 
local chromatin structure and gene transcription. In the absence of T3, TRs recruit corepressor 
proteins, including nuclear receptor corepressor 1 (NCoR1), silencing mediator for retinoid or 
thyroid hormone receptors (SMRT), and histone deacetylases (HDACs), to modify the histone 
core of nucleosomes and create a closed chromatin conformation. Binding of T3 induces 
conformational changes in TRs, which favor recruitment of coactivator proteins, including 
steroid receptor coactivators (SRCs) and histone acetyltransferases (HATs), to create an 
open chromatin configuration and accessibility of target genes for general transcription factors 
(GTFs) and the RNA polymerase II complex (8,16). In addition to the classical TR coregulators, 
other nuclear proteins have been described that can have a direct or indirect interaction with 
TRs (17,18) and are involved in transcriptional regulation. 
 There is evidence indicating that the coregulatory protein recruitment by nuclear 
receptors is tissue-dependent, which may lead to diverging receptor functions in the 
different tissues (14,17,19,20). In addition, some studies showed that TRs recruit a subset 
of coregulatory proteins in an isoform-specific manner (17,18), adding to the complexity of 
transcriptional gene regulation by TRs. In order to gain more insight into the transcriptional 
gene regulation by TRs in the brain, we identified the coregulatory proteins that are involved in 
neuronal TR activity by interactome analysis for wild-type (WT) TRα1 and TRβ1 in a human-
derived neuronal cell line (SH-SY5Y). We found that TRs interact with several nuclear proteins, 
some of which have not previously been described as TR interacting partners. In general, both 
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TR isoforms shared the same coregulatory proteins; however, a subset of proteins seemed to 
interact in an isoform-specific manner. 
Materials and Methods
Plasmid constructs
 Lentiviral constructs containing N-terminal FLAG and Hemagglutinin (HA) double-
epitope tagged human WT TRα1 and TRβ1 and a bicistronic messenger RNA that allows the 
simultaneous expression of TRs, puromycin resistance marker, and green fluorescent protein 
(GFP) (pLentiFH-TRα1 and pLentiFH-TRβ1) were created as previously described (Chapter 
6a). An empty vector construct (pLentiMCS) expressing only the puromycin resistance marker 
and GFP was also used to generate an empty vector control cell line. The packaging vectors, 
pMD2.G and psPAX2 (Chapter 6a), were used to produce TR containing lentiviruses as 
described below. 
Stable expression of TRs in SH-SY5Y cells
 FH-TRα1, -TRβ1 and empty vector (MCS) were stably expressed in SH-SY5Y 
human-derived neuroblastoma cells using lentiviral transduction as previously described 
(Chapter 6a). In brief, lentiviruses containing pLentiFH-TRα1, pLentiFH-TRβ1, and pLentiMCS 
were produced in HEK293FT cells by co-transfecting 4 µg of pLenti-CMV-FH-TRα1, -TRβ1, 
or -MCS constructs with 4 µg of psPAX2 and pMD2.G plasmids using Xtreme Gene 9 
transfection reagent (Roche Diagnostics, Almere, NL). SH-SY5Y cells were transduced with 
lentiviruses for 48 hours in 6-well plates (at 25% confluency) and subsequently selected with 
2 µg/mL of puromycin. Puromycin-resistant SH-SY5Y cells were expanded in growth medium 
(DMEM/F12 supplemented with 9%FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 100 
nM Na2SeO3) and 2 µg/mL puromycin for subsequent experiments. SH-SY5Y cells stably 
expressing FH-TRα1, -TRβ1 or -MCS were designated as FH-TRα1, FH-TRβ1, or MCS cells, 
respectively.
Luciferase assays
 To determine T3-induced transcriptional activity of stably expressed receptors, FH-
TRα1, FH-TRβ1, and MCS cells were cultured in 24-well plates. At 80% confluency, cells were 
transfected for 24 hours with 200 ng pdV-L1 luciferase-renilla reporter construct (21) in TH 
depleted medium (DMEM/F12 supplemented with 9% charcoal-stripped FBS) using Xtreme 
Gene 9 transfection reagent (Roche Diagnostics, Almere, NL). After that, cells were stimulated 
with 0-10,000 nM T3 for 24 hours in DMEM/F12 medium supplemented with 0.1% bovine 
serum albumin (BSA). Luciferase and renilla activities were determined using the Dual Glo 
Luciferase kit (Promega, Leiden, NL) as previously described (7). The ratio between luciferase 
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and renilla was calculated to adjust for transfection efficiency. The results were shown as 
mean ± SEM of three independent experiments performed in triplicate. Dose-response curves 
were created by GraphPad Prism version 5.0 (GraphPad, La Jolla, CA).
Tandem-affinity purification 
 The FH-TRs and TR-interacting proteins were purified from SH-SY5Y cells as 
previously described (Chapter 6a). Briefly, the FH-TRα1, FH-TRβ1, and MCS cells were 
cultured until near confluency. Then, the cells were starved of TH for 24 hours in TH depleted 
medium and incubated for 4 hours with 0 (vehicle) or 100 nM T3 in DMEM/F12 supplemented 
with 0.1% BSA. After that, the cells were harvested, and nuclear proteins were extracted as 
previously described (22) (Chapter 6a). Nuclear extracts were incubated overnight with anti-
Flag M2 affinity gel (#A2220, Sigma Aldrich) at 4°C to purify the TRs. The bound proteins were 
eluted with 200 µg/mL Flag peptide (#F3290, Sigma Aldrich) and subsequently incubated for 
4 hours with EZview red anti-HA affinity gel (#E6779, Sigma Aldrich) at 4°C for the second 
purification. The proteins were eluted from HA-resin with 400 µg/mL HA peptide. The purified 
products (final HA eluates) of two independent tandem-affinity purifications per conditions 
were subjected for analysis by LC-MS/MS. 
Immunoblotting
 The expression of TRs in nuclear extracts prepared from FH-TRα1, FH-TRβ1, and 
MCS cells and FLAG and HA eluates from two tandem-affinity purification were verified by 
immunoblotting as previous described (21,22) using 1:1000 dilution HA-Tag (C29F4) Rabbit 
mAb (#3724, Cell Signaling Technology, Leiden, NL).
Proteomic analysis (Orbitrap LC-MS/MS)
 Isolated proteins in the purified products were identified by Orbitrap LC-MS/MS as 
previously described (Chapter 6a). The peptide sequences identified by LC-MS/MS were 
mapped onto the reference amino acid sequences to determine individual proteins using 
Scaffold Viewer version 4.8.9 (Proteomic Software Inc., Oregon, USA). Proteins with at 
least two unique peptides assigned to them with 1% false detection rate (FDR) protein and 
peptide threshold were accepted as true identifications. Only proteins that were present in 
the two replicates of at least one TR and T3 conditions but absent in MCS control eluates 
were selected for further analysis. Individual proteins were clustered and presented as an 
expressing heat map using the Heatmapper online software (http://www.heatmapper.ca) (23). 
Pathway enrichment analysis was performed by DAVID functional annotation chart (DAVID 
Bioinformatics Resources 6.8, NIAID/NIH: https://david.ncifcrf.gov/) using default setting 
(count 2, ease 0.1). The gene-term enrichment was analyzed based on molecular function 
Gene Ontology terms. Statistical significance was considered when p-values of modified 
Fisher’s exact test (EASE score) with Benjamini post-test < 0.05. The known protein-protein 
interactions (from curated databased and experimentally determined) between individual 
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proteins were analyzed by STRING database version 11.0 (http://string-db.org) with minimum 
required interaction scores set at medium confi dence (0.400).
Results
 The expression and transcriptional activation of FH-TRα1 and FH-TRβ1 in SH-SY5Y 
cells were evaluated before using the cells in TR purifi cation. Both TR isoforms were detected 
with equal intensity on immunoblots of nuclear extracts (NEs) from FH-TRα1 and FH-TRβ1 
expressing cells, showing similar expression levels of the TR isoforms in the cells (Figure 
1A). FH-TRα1 and -TRβ1 cells also showed T3-dependent transactivation of the reporter 
gene in luciferase assays (Figure 1B), confi rming that the stably expressed TRs have normal 
transcriptional activity, and the FH-tag did not interfere with receptor activity. 
Figure 1. (A) Immunoblots show an equal amount of FH-TRα1 and FH-TRβ1 in nuclear extracts and 
purifi cation products from SH-SY5Y cells of two tandem-affi  nity TR purifi cations (TR, thyroid hormone 
receptor; EV, empty vector control). (B) The T3-induced transcriptional activity of FH-TRα1, FH-TRβ1, and 
MCS (EV) confi rms a normal function of stably expressing TRs in SH-SY5Y cells (data are presented as 
mean ± SEM of three independent experiments performed in triplicate).
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 To identify the nuclear coregulatory proteins that interact with TRs in SH-SY5Y cells, 
we performed two independent tandem-affi  nity TR purifi cation using NEs of the FH-TRα1, 
FH-TRβ1, and MCS cells after 4 hours stimulation with 0 or 100 nM T3. TRs and associated 
proteins were sequentially co-immunoprecipitated using anti-FLAG and anti-HA resins. To 
estimate the recovery of the FH-TRs, proportional amounts of NEs and eluates from both 
FLAG- and HA-purifi cation steps were analyzed by immunoblotting with HA antibodies. The 
amount of FH-TRα1 and -TRβ1 in the fi nal (HA) eluates after tandem-affi  nity purifi cation was 
slightly less than in the NE input but equal between conditions (Figure 1A), ensuring similar 
amounts of complexes in fi nal eluates. These eluates were then subjected to LC-MS/MS 
analysis to identify distinct nuclear proteins associated with FH-TRs. 
Figure 2. Venn diagram showing the number of distinct nuclear proteins that co-purifi ed with FH-TRs. 
Most of the proteins are associated with both TR isoforms, indicating that TR action in SH-SY5Y cells is 
mainly regulated by common coregulatory proteins. However, eleven proteins were found to be exclusively 
associated with only one TR isoform (nine proteins for TRα1 and two proteins for TRβ1), suggesting an 
isoform-specifi c coregulatory protein recruitment.
 One hundred and one diff erent proteins were present in the two replicates of at 
least one TR (FH-TRα1 or -TRβ1) and T3 (0 or 100 nM) condition, but absent in MCS control 
eluates (Figure 2, Supplementary Table S1). Our strategy was validated by the identifi cation 
of known TR-interacting proteins, such as RXRβ, the NCoR1/SMRT/HDAC3 corepressor 
complex, SRC coactivators, the Mediator complex, and the RNA polymerase II complex with 
a high percent coverage. Approximately 90% of the proteins overlapped between FH-TRα1 
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and FH-TRβ1, indicating that both TR isoforms mainly interact with the same coregulatory 
proteins to regulate gene transcription. However, nine proteins (8.9%) were only associated 
with FH-TRα1 (such as ASH2L, KDM6A (as known as UTX), and RBBP5) and two (2.0%) 
only with FH-TRβ1 (PDE4D and TIAM2) (Figure 2), suggesting that TRs could also be partly 
regulated by an isoform-specific subset of coregulatory proteins. 
 All identified proteins were then categorized by heat map analysis into two clusters 
(Figure 3). Cluster 1 consists of proteins that are predominantly identified in the absence of 
T3 (vehicle enriched group), and cluster 2 consists of proteins that are mainly identified in the 
presence of T3 (T3-enriched group). The molecular functions of proteins in these two clusters 
were explored by gene ontology (GO) enrichment analysis. The results showed that the 
proteins in the cluster 1 or vehicle enriched group (total N = 21) were significantly associated 
with transcriptional gene repression GO terms, such as transcription corepressor activity (N 
= 7, p-value <0.001) and histone deacetylase activity (N = 3, p-value <0.05) (Figure 4A). The 
proteins in the cluster 2 or T3-enriched group (total N = 80) were significantly associated 
with transcriptional gene activation GO terms, for instance, RNA polymerase II transcriptional 
cofactor activity (N = 22, p-value <0.01), transcriptional coactivator activity (N = 24, p-value 
<0.01), and histone acetyltransferase activity (N = 11, p-value <0.01) (Figure 4B). 
 Each cluster was subsequently analyzed for known interactions based on 
experimental data using the STRING online database (Figure 5). The analysis showed that 
the NCoR/SMRT complex was enriched in the absence of T3 for both isoforms. Apart from the 
direct TR-binding proteins NCoR1 and NCoR2/SMRT, the profiles included other members 
of the complex, such as HDAC3, transducin beta like 1 X-linked (TBL1X), transducing beta 
like 1 X-linked receptor 1 (TBL1XR1), and G-protein pathway suppressor 2 (GPS2). Many 
other proteins in this cluster have never been described to be associated with TRs, including 
the Forkhead box (FOX) transcription factor K1 and K2 (FOXK1 and FOXK2) proteins that 
are known to be part of Wnt/β-catenin signaling complex (Supplementary Table S2), ankyrin 
repeat domain-containing protein 11 (ANKRD11), and activity-dependent neuroprotector 
homeobox protein (ADNP).
 The majority (77%) of the identified proteins co-purified with TRs in the presence of 
T3 (Figure 5B). The nuclear receptor coactivator (NCoA, also known as SRC) isoforms 1, 2, 
and 3, the Mediator complex, and RNA polymerase II complex that are known to associate 
with liganded TRs were all present in the T3-enriched cluster (Figure 5B, Supplementary Table 
S2). We also identified proteins belonging to chromatin remodeling complexes, including the 
nucleosome remodeling deacetylase (NuRD), the Spt-Ada-Gcn5-Acetyltransferase (SAGA), 
and the MLL/SET methyltransferase complexes (Figure 5B, Supplementary Table S2), all of 
which have not previously been reported to interact with TRs. The T3-enriched also contained 
other proteins which are unknown to interact with TRs and could not be categorized into any 
known complex, such as the transcription factors Prospero homeobox protein 1 (PROX1) and 
transcription factor 4 and 12 (TCF4 and TCF12). 
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Figure 3. Heat map showing the profile of distinct nuclear proteins co-purified with FH-TRα1 and FH-
TRβ1 after stimulating with 0 or 100 nM T3. The color intensity correlates with the Z-score of exclusive 
unique peptides identified by LC-MS/MS (white, low or undetectable level; blue, high level). According 
to hierarchical clustering (demonstrated by dendrogram on the left), the proteins are divided into two 
main clusters. The cluster 1 consists of proteins that are predominantly identified in the absence of T3 
(vehicle enriched group), and the cluster 2 consists of proteins that are mainly identified in the presence 
of T3 (T3-enriched group). (Proteins are clustered by average linkage clustering and Pearson distance 
measurement methods using Heatmapper online software.)
0 nM T3 100 nM T3
Cluster 1
Cluster 2
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Figure 4. Gene Ontology term (molecular function) enrichment analysis. (A) The proteins found in the 
absence of T3 (cluster 1) are significantly related to transcriptional corepressor activity and histone 
deacetylase activity whereas (B) the proteins found in the presence of T3 (cluster 2) are related to 
transcriptional coactivator activity, histone acetyltransferase activity, and RNA polymerase II activity. Data 
are presented as –log (p value) of modified Fisher’s exact test (EASE score) with Benjamini post-test 
from DAVID functional annotation chart [DAVID Bioinformatics Resources 6.8, NIAID/NIH]. (N = number 
of proteins associated to GO term)
Figure 5 (right page). Protein-protein interaction (PPI) network demonstrating known interactions 
(pink line) between identified proteins in the (A) absence and (B) presence of T3. Known TR-interacting 
proteins, such as the NCoR1, NCoR2 (SMRT), HDAC3, TBL1X, and TBL1XR1, in the absence of T3, 
and the SRC 1-3 coactivators, the Mediator complex, and RNA polymerase II complex, in the presence 
of T3, were identified, validating our strategy and suggesting a role for these proteins in neuronal TR 
activity. Strikingly, many other identified proteins are members of protein complexes that are involved in 
chromatin remodeling but have never been described as TR coregulators, for instance, ADNP, ANKRD11, 
FOXK1, and FOXK2, all of which were co-purified with TRs in the absence of T3, and the nucleosome 
remodeling deacetylase (NuRD), the Spt-Ada-Gcn5-Acetyltransferase (SAGA) complexes, and the MLL/
SET methyltransferase complex, all of which were co-purified with TRs in the presence of T3. (Data are 
analyzed by STRING version 11.0)
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Discussion
 In this study, we identified known and potentially novel binding partners for TRs in a 
human neuronal cell model. The majority of identified proteins associated with both TRα1 and 
TRβ1, suggesting that these two TR isoforms interact with common coregulatory proteins to 
regulate gene transcription. However, a subset of distinct nuclear proteins seems to interact 
with TRs in an isoform-specific manner. 
 We successfully identified a large number of TR associated proteins in this study. 
The yield of our study is higher than previous reports (17,18). Although the tandem-affinity TR 
purification technique we used was adopted from Fozzatti et al. (17), we performed direct LC-
MS/MS analysis of the eluates rather than separated proteins by SDS-PAGE gel and subjected 
only proteins that are visualized on gel to LC-MS/MS analysis, which may lead to a higher 
yield. Therefore, we suggest that the methods we used is an optimal and effective technique 
for the interactome analysis of TRs. We also replicated the purifications for each condition and 
found some previously reported TR specific proteins in our controls. We, therefore, suggest to 
replicate the purifications as well, in order to increase the reliability of the results. 
 The nuclear proteins associated with TRs were categorized by heat map and 
hierarchical clustering into two groups. A vehicle enriched group is a group of proteins 
identified in the absence of T3, and a T3-enriched group is a group of proteins identified in 
the presence of T3. Gene ontology enrichment analyses confirmed this separation since the 
proteins from the two groups were significantly enriched with transcriptional gene repression 
and activation terms, respectively. 
 In the vehicle enriched group, we identified two well-known TR corepressors, NCoR1 
and SMRT (NCoR2), showing the effectiveness of our approach. We also identified other 
members of the NCoR/SMRT complex that do not directly interact with TRs, namely HDAC3, 
TBL1X, TBL1XR1, and GPS2 (24-27), which shows that our method preserves protein 
complexes and can find distant binding partners for TRs. HDAC3 is responsible for remodeling 
of the chromatin by deacetylating histone tails, which promotes transcriptional repression of 
the TRs (24,27). TBL1X and its homolog TBL1XR1 stabilize the NCoR/SMRT complexes on 
the chromatin and promote efficient histone deacetylation by HDAC3 (26). GPS2 associates 
with the NCoR/SMRT complex to regulate gene repression of estrogen receptor (ER) α (28) 
and peroxisome proliferator-activated receptor (PPAR) γ (29). Although Guo et al. showed 
that the transcriptional activity of TRα1 is not affected in embryonic fibroblast cells derived 
from GPS2 knock-out mice (29), this does not necessarily rule out a role for GPS2 in neuronal 
T3-regulated gene expression. 
 Another protein that was identified in the absence of T3 is MLL5. This protein has been 
grouped into the lysine N-methyltransferase (KMTs) family because of its structural homology; 
however, it lacks intrinsic histone methyltransferase (HMT) activity (30). An orthologue protein, 
SETD5, was also found in the absence of T3 but with a lower peptide count than MLL5. 
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Osipovich et al. showed that SETD5 associates with NCoR repressor complexes (NCoR1, 
TBL1X, and HDAC3) and regulates histone deacetylation in HEK 293T cells (31). Evidence 
in yeast shows that Set3 (orthologue of human MLL5) interacts with Snt1 and Sif2 (i.e. Hif2) 
proteins (orthologues of human SMRT and TBL1X, respectively) to regulate gene transcription 
(32,33). Recently, MLL5 was found to interact with SMRT and also TBL1X and TBL1XR1 in 
nuclear extracts of HeLa cells (34)(www.nursa.org/10.1621/datasets.01002), indicating the 
role of this protein in corepressor complex. Therefore, the identification of MLL5 and SETD5 
in our profiles suggests that they may play a role in transcriptional gene repression by TRs in 
neuronal cells as well. 
 Two closely related Forkhead box (FOX) transcription factors, FOXK1 and FOXK2, 
were also identified in the absence of T3 and have previously been shown to regulate gene 
repression. FOXK1/2, in combination with Sin3A-HDAC transcriptional repression complexes 
(Sin3A, SIN3 transcription regulator family member A), inhibit expression of cell autophagy 
genes in muscle cells and fibroblast (35). FOXK1 also interacts with Ten-eleven translocation 1 
(TET1), a tumor suppressor protein, in breast cancer cell line and repress vascular endothelial 
growth factor VEGF gene expression (36). Wang et al. reported that FOXK1 and 2 positively 
regulate Wnt/β-catenin pathway by promoting the nuclear localization of phosphorylated 
Dishevelled (DVL) protein which helps to stabilize β-catenin/T-cell factor (TCF) transcriptional 
complex at the promoter region of Wnt target genes (37). Although the interaction between 
TRs and FOXK1/2 is unknown, both physical and functional interactions between TRs and 
Wnt/β-catenin signaling have been established (38-40).
 In the T3-enriched group, we found many know TR-coactivator proteins, including 
SRC 1, 2, and 3, the RNA polymerase II complex, and the Mediator complex, together with 
both TR isoforms. In addition, several proteins belonging to the NuRD complex were co-
purified with both TR isoforms in the presence of T3. Although originally identified as a gene 
repressing complex, subsequent studies have shown that the NuRD complex is involved in 
both transcriptional repression (41-43) and activation (44) by forming direct interactions with 
many nuclear receptors (45-47). The identification of the NuRD complex in the presence of 
T3 was similar to our previous TRα1 interactomes (Chapter 6a), suggesting that this complex 
may take part in T3-induced transcriptional activation. However, we and others (17) identified 
CHD4, one of the core components of the NuRD complex, also with TRs in the absence of T3. 
Ostapcuk et al. showed that apart from the NuRD complex, CHD4 can also form a complex 
with ADNP and HP1β and γ (heterochromatin protein 1 β and γ), called ChAHP, to represses 
gene transcription, which seems to be essential for neuronal cells differentiation (48). Since 
we and others (17) identified both CHD4 and ADNP with TRs in the absence of T3, TRs may 
interact with the ChAHP complex to facilitate T3-dependent gene repression as well.
 The SAGA complex is one of the known coactivator complex which consists of a 
core structural module, a histone deubiquitinase module (DUB), a histone acetyltransferase 
module (HAT), and an activator-biding module (49,50). In this study, we co-purified many 
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nuclear proteins that belong to the SAGA complex with the TRs in the presence of T3, including 
members of core structural module (TAF5L, TAF6L, TAF10, SUPT7L, and SUPT20H), HAT 
module (KAT2A, TADA3, and CCDC101), and activator-binding module (TRRAP). A recent 
study showed that SAGA is recruited to upstream activating sequences (UASs) of most RNA 
polymerase II-transcribed genes (51,52), indicating that SAGA may act as a cofactor to modify 
chromatin structure and recruit the preinitiation complex (PIC) for transcriptional activation. To 
our knowledge, this is the first study showing an interaction between the SAGA complex and 
TRs. 
 Although the majority of identified proteins were associated with both TR isoforms, 
we identified a subset of nuclear proteins interacts with TRs in an isoform-specific manner, 
which is in line with previous reports (17,18). The confidence of these hits being isoform-
specific is strengthened by the fact that they were explicitly identified with certain TR isoform 
in two independent purifications. Interestingly, we identified that lysine-specific demethylase 
6A (KDM6A or UTX), set1/Ash2 histone methyltransferase complex subunit ASH2 (ASH2L), 
and retinoblastoma-binding protein 5 (RBBP5) are specific for TRα1. KDM6A removes 
repressive histone marks (H3K27me), and ASH2L and RBBP5, in combination with MLL1-
4 (KMT2A-D) and WDR5 proteins, subsequently add active histone marks (H3K4me) to 
establish transcriptionally permissive chromatin for many key developmental genes such as 
HOX genes (53-56). The importance of these proteins in neurodevelopment was postulated 
because mutations in genes encoding KDM6A and MLL4 lead to a similar phenotype, including 
growth retardation, intellectual disability, and characteristic facial features (long palpebral 
fissures and ectropion of the lateral 1/3 of lower eyelids), as known as Kabuki syndrome 
(55,57,58). However, further studies are needed to explore the specificity for TRα1 and the 
role in transcriptional regulation of these proteins. 
 In summary, we identified known and potential novel binding partners of TRs 
in SH-SY5Y cells. In addition, a subset of distinct nuclear proteins seems to interact with 
TRs in an isoform-specific manner. These findings enable us to gain more understanding 
of the transcriptional gene regulation by TRs in the brain. However, additional experiments 
are needed to confirm the interaction between these proteins and TRs and to elucidate a 
functional relevance of these proteins in TR actions. 
Acknowledgement
 This work is supported by Zon-MWTOP Grant 91212044 and an Erasmus MC Medical 
Research Advisory Committee (MRACE) grant (RPP, MEM), and Chiang Mai University (KW).
 Author Disclosure Statement
 The authors have nothing to disclose.
Embargoed: Unpubl ished Chapter
169
Coregulatory protein recrui tment by TRs in neuronal  cel ls
6
References
1. Prezioso G, Giannini C, Chiarelli F. Effect of Thyroid Hormones on Neurons and 
Neurodevelopment. Horm Res Paediatr. 2018;90(2):73-81.
2. Rovet JF. Congenital hypothyroidism: an analysis of persisting deficits and associated factors. 
Child Neuropsychol. 2002;8(3):150-162.
3. Salazar P, Cisternas P, Martinez M, Inestrosa NC. Hypothyroidism and Cognitive Disorders 
during Development and Adulthood: Implications in the Central Nervous System. Mol Neurobiol. 
2019;56(4):2952-2963.
4. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla 
EE, Svensson J, Kester MH, Kuiper GG, Balkassmi S, Uitterlinden AG, Koehrle J, Rodien P, 
Halestrap AP, Visser TJ. Association between mutations in a thyroid hormone transporter and 
severe X-linked psychomotor retardation. Lancet. 2004;364(9443):1435-1437.
5. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining 
thyroid and neurological abnormalities is associated with mutations in a monocarboxylate 
transporter gene. Am J Hum Genet. 2004;74(1):168-175.
6. Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam O, Keogh JM, 
Henning E, Reinemund J, Gevers E, Sarri M, Downes K, Offiah A, Albanese A, Halsall D, 
Schwabe JW, Bain M, Lindley K, Muntoni F, Vargha-Khadem F, Dattani M, Farooqi IS, Gurnell 
M, Chatterjee K. A mutation in the thyroid hormone receptor alpha gene. N Engl J Med. 
2012;366(3):243-249.
7. van Mullem A, van Heerebeek R, Chrysis D, Visser E, Medici M, Andrikoula M, Tsatsoulis A, 
Peeters R, Visser TJ. Clinical phenotype and mutant TRalpha1. N Engl J Med. 2012;366(15):1451-
1453.
8. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 
2010;31(2):139-170.
9. Mellstrom B, Naranjo JR, Santos A, Gonzalez AM, Bernal J. Independent expression of the 
alpha and beta c-erbA genes in developing rat brain. Mol Endocrinol. 1991;5(9):1339-1350.
10. Schwartz HL, Strait KA, Ling NC, Oppenheimer JH. Quantitation of rat tissue thyroid hormone 
binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. J 
Biol Chem. 1992;267(17):11794-11799.
11. Bradley DJ, Towle HC, Young WS, 3rd. Spatial and temporal expression of alpha- and beta-
thyroid hormone receptor mRNAs, including the beta 2-subtype, in the developing mammalian 
nervous system. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
1992;12(6):2288-2302.
12. Wallis K, Dudazy S, van Hogerlinden M, Nordstrom K, Mittag J, Vennstrom B. The thyroid 
hormone receptor alpha1 protein is expressed in embryonic postmitotic neurons and persists in 
most adult neurons. Mol Endocrinol. 2010;24(10):1904-1916.
13. Ercan-Fang S, Schwartz HL, Oppenheimer JH. Isoform-specific 3,5,3’-triiodothyronine receptor 
binding capacity and messenger ribonucleic acid content in rat adenohypophysis: effect of 
thyroidal state and comparison with extrapituitary tissues. Endocrinology. 1996;137(8):3228-
3233.
14. Flamant F, Gauthier K. Thyroid hormone receptors: the challenge of elucidating isotype-specific 
functions and cell-specific response. Biochim Biophys Acta. 2013;1830(7):3900-3907.
15. Harvey CB, Williams GR. Mechanism of thyroid hormone action. Thyroid. 2002;12(6):441-446.
16. Astapova I. Role of co-regulators in metabolic and transcriptional actions of thyroid hormone. J 
Mol Endocrinol. 2016;56(3):73-97.
17. Fozzatti L, Lu C, Kim DW, Cheng SY. Differential recruitment of nuclear coregulators directs the 
isoform-dependent action of mutant thyroid hormone receptors. Mol Endocrinol. 2011;25(6):908-
921.
18. Hahm JB, Schroeder AC, Privalsky ML. The two major isoforms of thyroid hormone receptor, 
Embargoed: Unpubl ished Chapter
170
Chapter  6b
6
TRalpha1 and TRbeta1, preferentially partner with distinct panels of auxiliary proteins. Mol Cell 
Endocrinol. 2014;383(1-2):80-95.
19. Paul BD, Buchholz DR, Fu L, Shi YB. Tissue- and gene-specific recruitment of steroid 
receptor coactivator-3 by thyroid hormone receptor during development. J Biol Chem. 
2005;280(29):27165-27172.
20. Bebermeier JH, Brooks JD, DePrimo SE, Werner R, Deppe U, Demeter J, Hiort O, Holterhus 
PM. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. J 
Mol Med (Berl). 2006;84(11):919-931.
21. van Gucht AL, Meima ME, Zwaveling-Soonawala N, Visser WE, Fliers E, Wennink JM, 
Henny C, Visser TJ, Peeters RP, van Trotsenburg AS. Resistance to Thyroid Hormone Alpha 
in an 18-Month-Old Girl: Clinical, Therapeutic, and Molecular Characteristics. Thyroid. 
2016;26(3):338-346.
22. Wejaphikul K, Groeneweg S, Dejkhamron P, Unachak K, Visser WE, Chatterjee K, Visser TJ, 
Meima ME, Peeters RP. Role of Leucine 341 in Thyroid Hormone Receptor Beta Revealed by a 
Novel Mutation Causing Thyroid Hormone Resistance. Thyroid. 2018;28(12):1723-1726.
23. Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, Wishart DS. Heatmapper: web-
enabled heat mapping for all. Nucleic Acids Res. 2016;44(W1):W147-153.
24. Li J, Wang J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J. Both corepressor proteins SMRT and 
N-CoR exist in large protein complexes containing HDAC3. EMBO J. 2000;19(16):4342-4350.
25. Zhang J, Kalkum M, Chait BT, Roeder RG. The N-CoR-HDAC3 nuclear receptor corepressor 
complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 2002;9(3):611-
623.
26. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J. Purification and functional 
characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. 
2003;22(6):1336-1346.
27. Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors 
for histone deacetylase 3. Mol Cell Biol. 2001;21(18):6091-6101.
28. Cheng X, Kao HY. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor 
important for estrogen receptor alpha-mediated transcriptional regulation. J Biol Chem. 
2009;284(52):36395-36404.
29. Guo C, Li Y, Gow CH, Wong M, Zha J, Yan C, Liu H, Wang Y, Burris TP, Zhang J. The 
optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome 
proliferator-activated receptor gamma requires G protein pathway suppressor 2. J Biol Chem. 
2015;290(6):3666-3679.
30. Zhang X, Novera W, Zhang Y, Deng LW. MLL5 (KMT2E): structure, function, and clinical 
relevance. Cell Mol Life Sci. 2017;74(13):2333-2344.
31. Osipovich AB, Gangula R, Vianna PG, Magnuson MA. Setd5 is essential for mammalian 
development and the co-transcriptional regulation of histone acetylation. Development. 
2016;143(24):4595-4607.
32. Rentas S, Saberianfar R, Grewal C, Kanippayoor R, Mishra M, McCollum D, Karagiannis 
J. The SET domain protein, Set3p, promotes the reliable execution of cytokinesis in 
Schizosaccharomyces pombe. PLoS One. 2012;7(2):e31224.
33. Pijnappel WW, Schaft D, Roguev A, Shevchenko A, Tekotte H, Wilm M, Rigaut G, Seraphin B, 
Aasland R, Stewart AF. The S. cerevisiae SET3 complex includes two histone deacetylases, 
Hos2 and Hst1, and is a meiotic-specific repressor of the sporulation gene program. Genes Dev. 
2001;15(22):2991-3004.
34. Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M, Miroslaw L, Poser I, Lawo S, Grabner H, 
Kozak K, Wagner J, Surendranath V, Richter C, Bowen W, Jackson AL, Habermann B, Hyman 
AA, Buchholz F. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat 
Cell Biol. 2007;9(12):1401-1412.
35. Bowman CJ, Ayer DE, Dynlacht BD. Foxk proteins repress the initiation of starvation-induced 
atrophy and autophagy programs. Nat Cell Biol. 2014;16(12):1202-1214.
Embargoed: Unpubl ished Chapter
171
Coregulatory protein recrui tment by TRs in neuronal  cel ls
6
36. Sun T, Wang H, Li Q, Qian Z, Shen C. Forkhead box protein k1 recruits TET1 to act as a tumor 
suppressor and is associated with MRI detection. Jpn J Clin Oncol. 2016;46(3):209-221.
37. Wang W, Li X, Lee M, Jun S, Aziz KE, Feng L, Tran MK, Li N, McCrea PD, Park JI, Chen J. 
FOXKs promote Wnt/beta-catenin signaling by translocating DVL into the nucleus. Dev Cell. 
2015;32(6):707-718.
38. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. Regulation of beta-catenin by a novel 
nongenomic action of thyroid hormone beta receptor. Mol Cell Biol. 2008;28(14):4598-4608.
39. Ely KA, Bischoff LA, Weiss VL. Wnt Signaling in Thyroid Homeostasis and Carcinogenesis. 
Genes (Basel). 2018;9(4).
40. Skah S, Uchuya-Castillo J, Sirakov M, Plateroti M. The thyroid hormone nuclear receptors and 
the Wnt/beta-catenin pathway: An intriguing liaison. Dev Biol. 2017;422(2):71-82.
41. Xue Y, Wong J, Moreno GT, Young MK, Cote J, Wang W. NURD, a novel complex with both ATP-
dependent chromatin-remodeling and histone deacetylase activities. Mol Cell. 1998;2(6):851-
861.
42. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an 
ATP-dependent nucleosome remodelling complex. Nature. 1998;395(6705):917-921.
43. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen 
Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling 
activities. Cell. 1998;95(2):279-289.
44. Bornelov S, Reynolds N, Xenophontos M, Gharbi S, Johnstone E, Floyd R, Ralser M, Signolet J, 
Loos R, Dietmann S, Bertone P, Hendrich B. The Nucleosome Remodeling and Deacetylation 
Complex Modulates Chromatin Structure at Sites of Active Transcription to Fine-Tune Gene 
Expression. Mol Cell. 2018;71(1):56-72 e54.
45. Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SA. Metastasis-associated protein 2 
is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent 
growth of human breast cancer cells. Mol Endocrinol. 2006;20(9):2020-2035.
46. Johnson DR, Lovett JM, Hirsch M, Xia F, Chen JD. NuRD complex component Mi-2beta binds 
to and represses RORgamma-mediated transcriptional activation. Biochem Biophys Res 
Commun. 2004;318(3):714-718.
47. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, 
Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 
corepressor. Nat Cell Biol. 2001;3(1):30-37.
48. Ostapcuk V, Mohn F, Carl SH, Basters A, Hess D, Iesmantavicius V, Lampersberger L, Flemr 
M, Pandey A, Thoma NH, Betschinger J, Buhler M. Activity-dependent neuroprotective protein 
recruits HP1 and CHD4 to control lineage-specifying genes. Nature. 2018;557(7707):739-743.
49. Samara NL, Wolberger C. A new chapter in the transcription SAGA. Curr Opin Struct Biol. 
2011;21(6):767-774.
50. Helmlinger D, Tora L. Sharing the SAGA. Trends Biochem Sci. 2017;42(11):850-861.
51. Baptista T, Grunberg S, Minoungou N, Koster MJE, Timmers HTM, Hahn S, Devys D, Tora L. 
SAGA Is a General Cofactor for RNA Polymerase II Transcription. Mol Cell. 2017;68(1):130-143 
e135.
52. Taatjes DJ. The Continuing SAGA of TFIID and RNA Polymerase II Transcription. Mol Cell. 
2017;68(1):1-2.
53. Sengoku T, Yokoyama S. Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. 
Genes Dev. 2011;25(21):2266-2277.
54. Shpargel KB, Starmer J, Wang C, Ge K, Magnuson T. UTX-guided neural crest function underlies 
craniofacial features of Kabuki syndrome. Proc Natl Acad Sci U S A. 2017;114(43):E9046-E9055.
55. Steward MM, Lee JS, O’Donovan A, Wyatt M, Bernstein BE, Shilatifard A. Molecular regulation 
of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol. 
2006;13(9):852-854.
56. Froimchuk E, Jang Y, Ge K. Histone H3 lysine 4 methyltransferase KMT2D. Gene. 2017;627:337-
Embargoed: Unpubl ished Chapter
172
Chapter  6b
6
342.
57. Van Laarhoven PM, Neitzel LR, Quintana AM, Geiger EA, Zackai EH, Clouthier DE, Artinger 
KB, Ming JE, Shaikh TH. Kabuki syndrome genes KMT2D and KDM6A: functional analyses 
demonstrate critical roles in craniofacial, heart and brain development. Human molecular 
genetics. 2015;24(15):4443-4453.
58. Miyake N, Koshimizu E, Okamoto N, Mizuno S, Ogata T, Nagai T, Kosho T, Ohashi H, Kato M, 
Sasaki G, Mabe H, Watanabe Y, Yoshino M, Matsuishi T, Takanashi J, Shotelersuk V, Tekin 
M, Ochi N, Kubota M, Ito N, Ihara K, Hara T, Tonoki H, Ohta T, Saito K, Matsuo M, Urano M, 
Enokizono T, Sato A, Tanaka H, Ogawa A, Fujita T, Hiraki Y, Kitanaka S, Matsubara Y, Makita T, 
Taguri M, Nakashima M, Tsurusaki Y, Saitsu H, Yoshiura K, Matsumoto N, Niikawa N. MLL2 and 
KDM6A mutations in patients with Kabuki syndrome. Am J Med Genet A. 2013;161A(9):2234-
2243.
Embargoed: Unpubl ished Chapter
173
Coregulatory protein recrui tment by TRs in neuronal  cel ls
6
Su
pp
le
m
en
ta
ry
 Ta
bl
e 
S1
. L
is
t 
of
 p
ro
te
in
s 
id
en
ti
fie
d 
by
 L
C-
M
S/
M
S.
Pr
ot
ei
n
0 
nM
 T
3
10
0 
nM
 T
3
TR
α1
TR
β1
TR
α1
TR
β1
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
AD
N
P
9
11
.7
10
0.
0
7
10
.7
10
0.
0
3
4.
3
10
0.
0
12
18
.4
10
0.
0
1
1.
1
12
.3
0
0
0
0
0
0
0
0
0
AN
KR
D
11
3
2.
8
10
0.
0
17
11
.4
10
0.
0
1
0.
4
99
.7
7
4.
3
10
0.
0
1
0.
3
8.
6
0
0
0
0
0
0
0
0
0
AS
H
2L
0
0
0
0
0
0
0
0
0
0
0
0
2
3.
8
99
.9
3
6.
4
10
0.
0
0
0
0
0
0
0
C
C
D
C
10
1 
0
0
0
0
0
0
0
0
0
0
0
0
2
8.
9
10
0.
0
2
8.
2
10
0.
0
3
13
.3
10
0.
0
3
10
.6
10
0.
0
C
C
N
C
0
0
0
0
0
0
0
0
0
0
0
0
3
9.
9
10
0.
0
3
8.
5
10
0.
0
4
14
.5
10
0.
0
5
20
.1
10
0.
0
C
D
K1
9
0
0
0
0
0
0
0
0
0
0
0
0
4
16
.7
10
0.
0
8
31
.5
10
0.
0
8
26
.7
10
0.
0
10
36
.5
10
0.
0
C
D
K8
0
0
0
0
0
0
0
0
0
0
0
0
8
19
.4
10
0.
0
8
23
.5
10
0.
0
8
22
.4
10
0.
0
8
25
.2
10
0.
0
C
H
D
4
4
2.
8
10
0.
0
6
5.
7
10
0.
0
5
4.
9
10
0.
0
6
4.
4
10
0.
0
3
3.
5
10
0.
0
12
11
.5
10
0.
0
4
4.
1
10
0.
0
1
1.
15
 
98
.7
C
PV
L
2
4.
2
10
0.
0
6
13
.9
10
0.
0
2
3.
8
10
0.
0
7
16
.8
10
0.
0
0
0
0
0
0
0
0
0
0
0
0
0
EP
40
0 
0
0
0
0
0
0
0
0
0
0
0
0
8
4.
0
10
0.
0
0
0
0
1
1.
0
16
.8
1
0.
5
39
.8
EX
O
SC
10
1
1.
1
27
.1
2
3.
3
10
0.
0
0
0
0
0
0
0
0
0
0
2
3.
3
99
.9
0
0
0
0
0
0
FO
XK
1 
9
20
.9
10
0.
0
10
22
.0
10
0.
0
2
3.
7
10
0.
0
8
18
.0
10
0.
0
2
4.
1
99
.8
0
0
0
0
0
0
0
0
0
FO
XK
2
4
7.
0
10
0.
0
6
14
.8
10
0.
0
0
0
0
4
14
.1
10
0.
0
0
0
0
0
0
0
0
0
0
0
0
0
G
AT
AD
2A
0
0
0
0
0
0
0
0
0
0
0
0
1
3.
8
99
.4
3
7.
6
10
0.
0
0
0
0
0
0
0
G
O
N
4L
0
0
0
0
0
0
0
0
0
0
0
0
20
13
.8
10
0.
0
18
11
.9
10
0.
0
5
3.
4
10
0.
0
3
2.
2
10
0.
0
G
PS
2
9
41
.9
10
0.
0
8
42
.5
10
0.
0
3
15
.9
10
0.
0
6
24
.5
10
0.
0
1
2.
5
87
.4
0
0
0
0
0
0
0
0
0
H
D
AC
2
0
0
0
1
3.
3
87
.6
0
0
0
1
9.
0
92
.7
0
1
1.
6
87
.4
3
11
.1
10
0.
0
0
0
0
2
5.
5
99
.9
H
D
AC
3 
17
48
.4
10
0.
0
21
66
.4
10
0.
0
15
42
.8
10
0.
0
15
44
.6
10
0.
0
7
25
.9
10
0.
0
7
27
.6
10
0.
0
0
0
0
0
0
0
H
M
BO
X1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
4.
5
10
0.
0
3
10
.2
10
0.
0
2
8.
6
10
0.
0
H
O
O
K2
0
0
0
0
0
0
0
0
0
0
0
0
1
1.
0
38
.7
2
3.
3
93
.1
0
0
0
1
1.
0
39
.3
IN
SM
2
13
38
.9
10
0.
0
13
40
.6
10
0.
0
7
19
.8
10
0.
0
18
57
.2
10
0.
0
0
0
0
0
0
0
0
0
0
0
0
0
Embargoed: Unpubl ished Chapter
174
Chapter  6b
6
Pr
ot
ei
n
0 
nM
 T
3
10
0 
nM
 T
3
TR
α1
TR
β1
TR
α1
TR
β1
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
KA
T2
A
0
0
0
0
0
0
0
0
0
0
0
0
3
4.
7
10
0.
0
1
1.
3
75
.7
1
2.
3
97
.7
2
3.
1
99
.9
KD
M
1A
 
3
4.
5
10
0.
0
10
17
.0
10
0.
0
0
0
0
5
8.
6
10
0.
0
0
0
0
0
0
0
0
0
0
0
0
0
KD
M
6A
0
0
0
0
0
0
0
0
0
0
0
0
3
3.
9 
10
0.
0
3
4.
1 
10
0.
0
0
0
0
0
0
0
KM
T2
E
3
2.
9
10
0.
0
9
6.
9
10
0.
0
0
0
0
1
1.
3 
40
.7
 
0
0
0
0
0
0
0
0
0
0
0
0
M
BD
3
0
0
0
0
0
0
0
0
0
0
0
0
2
8.
9 
99
.8
 
5
19
.9
 
10
0.
0 
1
5.
5 
67
.1
 
0
0
0
M
ED
10
0
0
0
0
0
0
0
0
0
0
0
0
7
60
.0
 
10
0.
0 
6
57
.8
 
10
0.
0 
7
59
.3
 
10
0.
0 
6
57
.8
 
10
0.
0 
M
ED
11
0
0
0
0
0
0
0
0
0
0
0
0
4
55
.6
 
10
0.
0 
4
55
.6
 
10
0.
0 
3
49
.6
 
10
0.
0 
4
55
.6
 
10
0.
0 
M
ED
12
0
0
0
0
0
0
0
0
0
0
0
0
53
33
.6
 
10
0.
0 
58
32
.7
 
10
0.
0 
52
32
.2
 
10
0.
0 
61
39
.2
 
10
0.
0 
M
ED
13
0
0
0
0
0
0
0
0
0
0
0
0
49
30
.6
 
10
0.
0 
52
31
.7
 
10
0.
0 
51
32
.0
 
10
0.
0 
46
29
.5
 
10
0.
0 
M
ED
13
L
0
0
0
0
0
0
0
0
0
0
0
0
25
20
.5
 
10
0.
0 
39
31
.4
 
10
0.
0 
35
27
.9
 
10
0.
0 
40
31
.9
 
10
0.
0 
M
ED
14
0
0
0
0
0
0
0
0
0
0
0
0
34
31
.7
 
10
0.
0 
43
37
.6
 
10
0.
0 
42
36
.1
 
10
0.
0 
41
37
.9
 
10
0.
0 
M
ED
15
0
0
0
0
0
0
0
0
0
0
0
0
12
23
.0
 
10
0.
0 
13
23
.9
 
10
0.
0 
12
23
.0
 
10
0.
0 
12
21
.1
 
10
0.
0 
M
ED
17
0
0
0
0
0
0
0
0
0
0
0
0
24
43
.8
 
10
0.
0 
28
50
.8
 
10
0.
0 
28
51
.2
 
10
0.
0 
27
45
.3
 
10
0.
0 
M
ED
18
0
0
0
0
0
0
0
0
0
0
0
0
3
15
.4
 
10
0.
0 
3
15
.4
 
10
0.
0 
3
15
.4
 
10
0.
0 
3
15
.4
 
10
0.
0 
M
ED
19
0
0
0
0
0
0
0
0
0
0
0
0
4
32
.4
 
10
0.
0 
3
21
.7
 
10
0.
0 
6
42
.2
 
10
0.
0 
3
21
.7
 
10
0.
0 
M
ED
20
0
0
0
0
0
0
0
0
0
0
0
0
6
31
.1
 
10
0.
0 
5
26
.9
 
10
0.
0 
5
29
.2
 
10
0.
0 
5
29
.2
 
10
0.
0 
M
ED
21
0
0
0
0
0
0
0
0
0
0
0
0
3
39
.6
 
10
0.
0 
4
53
.5
 
10
0.
0 
4
53
.5
 
10
0.
0 
4
53
.5
 
10
0.
0 
M
ED
22
0
0
0
0
0
0
0
0
0
0
0
0
3
12
.0
 
10
0.
0 
3
14
.0
 
10
0.
0 
3
18
.5
 
10
0.
0 
5
23
.0
 
10
0.
0 
M
ED
23
0
0
0
0
0
0
0
0
0
0
0
0
11
10
.8
 
10
0.
0 
20
17
.6
 
10
0.
0 
24
24
.7
 
10
0.
0 
20
17
.4
 
10
0.
0 
M
ED
24
0
0
0
0
0
0
0
0
0
0
0
0
17
23
.2
 
10
0.
0 
23
28
.9
 
10
0.
0 
23
29
.5
 
10
0.
0 
21
26
.8
 
10
0.
0 
M
ED
25
0
0
0
0
0
0
0
0
0
0
0
0
6
19
.0
 
10
0.
0 
5
17
.4
 
10
0.
0 
5
13
.4
 
10
0.
0 
6
20
.2
 
10
0.
0 
M
ED
26
0
0
0
0
0
0
0
0
0
0
0
0
13
29
.7
 
10
0.
0 
13
36
.5
 
10
0.
0 
8
19
.7
 
10
0.
0 
11
25
.2
 
10
0.
0 
Embargoed: Unpubl ished Chapter
175
Coregulatory protein recrui tment by TRs in neuronal  cel ls
6
Pr
ot
ei
n
0 
nM
 T
3
10
0 
nM
 T
3
TR
α1
TR
β1
TR
α1
TR
β1
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
M
ED
27
 
0
0
0
0
0
0
0
0
0
0
0
0
9
28
.6
 
10
0.
0 
11
39
.5
 
10
0.
0 
10
27
.7
 
10
0.
0 
10
30
.5
 
10
0.
0 
M
ED
28
 
0
0
0
0
0
0
0
0
0
0
0
0
7
47
.8
 
10
0.
0 
6
41
.0
 
10
0.
0 
8
46
.1
 
10
0.
0 
8
48
.9
 
10
0.
0 
M
ED
29
 
0
0
0
0
0
0
0
0
0
0
0
0
2
13
.0
 
10
0.
0 
3
19
.0
 
10
0.
0 
2
13
.0
 
10
0.
0 
4
34
.0
 
10
0.
0 
M
ED
30
0
0
0
0
0
0
0
0
0
0
0
0
1
5.
1 
96
.2
 
1
5.
1 
96
.2
 
1
5.
1 
96
.4
 
2
11
.8
 
10
0.
0 
M
ED
31
0
0
0
0
0
0
0
0
0
0
0
0
2
24
.4
 
10
0.
0 
3
38
.9
 
10
0.
0 
3
31
.3
 
10
0.
0 
4
40
.5
 
10
0.
0 
M
ED
4
0
0
0
0
0
0
0
0
0
0
0
0
10
43
.0
 
10
0.
0 
9
39
.6
 
10
0.
0 
10
43
.3
 
10
0.
0 
9
39
.6
 
10
0.
0 
M
ED
6 
0
0
0
0
0
0
0
0
0
0
0
0
8
30
.1
 
10
0.
0 
10
37
.8
 
10
0.
0 
11
40
.7
 
10
0.
0 
13
45
.1
 
10
0.
0 
M
ED
7
0
0
0
0
0
0
0
0
0
0
0
0
2
15
.0
 
10
0.
0 
2
15
.0
 
10
0.
0 
3
24
.5
 
10
0.
0 
3
24
.5
 
10
0.
0 
M
ED
8 
0
0
0
0
0
0
0
0
0
0
0
0
6
29
.9
 
10
0.
0 
4
20
.9
 
10
0.
0 
6
28
.4
 
10
0.
0 
6
32
.5
 
10
0.
0 
M
ED
9 
0
0
0
0
0
0
0
0
0
0
0
0
2
17
.8
 
10
0.
0 
2
12
.3
 
99
.9
 
1
12
.3
 
96
.4
 
5
40
.4
 
10
0.
0 
M
TA
1
0
0
0
0
0
0
0
0
0
0
0
0
6
15
.1
 
10
0.
0 
15
29
.4
 
10
0.
0 
5
14
.4
 
10
0.
0 
3
10
.9
 
10
0.
0 
M
TA
2 
0
0
0
0
0
0
0
0
0
0
0
0
3
8.
1 
10
0.
0 
9
21
.7
 
10
0.
0 
5
11
.8
 
10
0.
0 
1
2.
4 
69
.3
 
N
CO
A
1
0
0
0
0
0
0
0
0
0
0
0
0
36
34
.4
 
10
0.
0 
25
26
.2
 
10
0.
0 
29
32
.8
 
10
0.
0 
29
31
.9
 
10
0.
0 
N
CO
A
2 
0
0
0
0
0
0
0
0
0
0
0
0
12
12
.5
 
10
0.
0 
3
2.
7 
10
0.
0 
6
5.
5 
10
0.
0 
4
4.
8 
10
0.
0 
N
CO
A
3
0
0
0
0
0
0
0
0
0
0
0
0
12
12
.6
 
10
0.
0 
0
0
0
5
5.
4 
10
0.
0 
4
4.
5 
10
0.
0 
N
CO
R1
10
5
52
.8
10
0.
0
96
50
.5
10
0.
0
81
43
.6
 
10
0.
0 
86
45
.3
 
10
0.
0 
54
32
.6
 
10
0.
0 
29
17
.3
 
10
0.
0 
2
1.
4 
10
0.
0 
1
0.
7 
95
.6
 
N
CO
R2
35
22
.2
10
0.
0
26
17
.3
10
0.
0
2
3.
0 
98
.0
 
10
7.
1 
10
0.
0 
1
2.
9 
71
.1
 
0
0
0
0
0
0
0
0
0
N
SD
1
5
2.
5
10
0.
0
1
0.
5
53
.8
0
0
0
0
0
0
3
1.
8 
10
0.
0 
0
0
0
0
0
0
0
0
0
N
T5
C1
A
2
7.
3
98
.6
0
0
0
2
9.
2 
10
0.
0 
1
4.
6 
96
.8
 
0
0
0
0
0
0
0
0
0
0
0
0
PA
TZ
1
0
0
0
1
1.
9
96
.8
0
0
0
0
0
0
1
1.
9 
96
.2
 
2
2.
9 
99
.9
 
0
0
0
0
0
0
PD
E4
D
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
3.
2 
96
.4
 
2
5.
9 
10
0.
0 
PN
M
A
2
2
14
.0
10
0.
0
3
16
.5
10
0.
0
0
0
0
0
0
0
6
22
.3
 
10
0.
0 
6
23
.4
 
10
0.
0 
8
27
.5
 
10
0.
0 
6
23
.4
 
10
0.
0 
Embargoed: Unpubl ished Chapter
176
Chapter  6b
6
Pr
ot
ei
n
0 
nM
 T
3
10
0 
nM
 T
3
TR
α1
TR
β1
TR
α1
TR
β1
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
PO
LR
2A
0
0
0
0
0
0
0
0
0
0
0
0
34
18
.8
 
10
0.
0 
37
21
.8
 
10
0.
0 
25
17
.3
 
10
0.
0 
28
18
.7
 
10
0.
0 
PO
LR
2B
1
1.
6
76
.6
0
0
0
2
2.
4 
99
.5
 
4
4.
9 
10
0.
0 
25
25
.3
 
10
0.
0 
28
25
.0
 
10
0.
0 
21
19
.9
 
10
0.
0 
21
17
.9
 
10
0.
0 
PO
LR
2C
2
12
.0
10
0.
0
0
0
0
0
0
0
2
13
.5
 
10
0.
0 
10
52
.7
 
10
0.
0 
13
69
.5
 
10
0.
0 
9
46
.9
 
10
0.
0 
10
56
.7
 
10
0.
0 
PO
LR
2D
0
0
0
0
0
0
0
0
0
0
0
0
3
28
.2
 
10
0.
0 
3
34
.5
 
10
0.
0 
1
11
.3
 
98
.7
 
4
40
.8
 
10
0.
0 
PO
LR
2E
0
0
0
0
0
0
0
0
0
0
0
0
3
17
.1
 
10
0.
0 
4
21
.4
 
10
0.
0 
3
17
.1
 
10
0.
0 
2
9.
1 
97
.3
 
PO
LR
2G
0
0
0
0
0
0
0
0
0
0
0
0
1
12
.8
 
78
.0
 
3
23
.8
 
10
0.
0 
1
12
.8
 
96
.4
 
2
17
.4
 
99
.9
 
PO
LR
2H
0
0
0
0
0
0
0
0
0
0
0
0
3
34
.7
 
10
0.
0 
3
34
.7
 
10
0.
0 
3
34
.7
 
10
0.
0 
2
16
.7
 
99
.5
 
PO
LR
2I
 
0
0
0
0
0
0
0
0
0
0
0
0
5
56
.8
 
10
0.
0 
5
56
.8
 
10
0.
0 
3
40
.8
 
10
0.
0 
4
46
.4
 
10
0.
0 
PO
LR
2K
0
0
0
0
0
0
0
0
0
0
0
0
2
13
.8
 
94
.3
 
2
13
.8
 
93
.7
 
1
12
.1
 
89
.8
 
1
12
.1
 
39
.3
 
PR
O
X1
0
0
0
5
8.
3
10
0.
0
0
0
0
2
3.
8 
99
.9
 
18
34
.6
 
10
0.
0 
28
48
.6
 
10
0.
0 
14
28
.4
 
10
0.
0 
13
22
.4
 
10
0.
0 
RB
BP
4
0
0
0
1
3.
8
96
.8
0
0
0
1
3.
8 
81
.4
 
5
29
.9
 
10
0.
0 
10
61
.2
 
10
0.
0 
2
14
.1
 
10
0.
0 
2
12
.0
 
10
0.
0 
RB
BP
5
0
0
0
0
0
0
0
0
0
0
0
0
3
7.
6 
10
0.
0 
2
5.
8 
10
0.
0 
0
0
0
0
0
0
RB
BP
7 
0
0
0
0
0
0
0
0
0
0
0
0
2
12
.2
 
85
.8
 
4
30
.4
 
10
0.
0 
0
0
0
1
5.
7 
99
.8
 
RE
CQ
L5
0
0
0
0
0
0
0
0
0
0
0
0
12
14
.0
 
10
0.
0 
18
24
.8
 
10
0.
0 
8
11
.6
 
10
0.
0 
10
16
.0
 
10
0.
0 
RP
A
P2
 
0
0
0
0
0
0
0
0
0
0
0
0
3
8.
0 
10
0.
0 
4
6.
7 
10
0.
0 
0
0
0
0
0
0
RP
L5
 
1
3.
4
93
.6
0
0
0
0
0
0
0
0
0
3
18
.5
 
10
0.
0 
0
0
0
1
11
.8
 
96
.4
 
2
16
.5
 
10
0.
0 
RX
RB
14
41
.3
10
0.
0
8
33
.8
10
0.
0
2
6.
6 
10
0.
0 
5
22
.7
 
10
0.
0 
18
52
.7
 
10
0.
0 
14
49
.9
 
10
0.
0 
9
38
.3
 
10
0.
0 
7
28
.9
 
10
0.
0 
SE
TD
5 
2
2.
8
10
0.
0
7
9.
3
10
0.
0
0
0
0
1
1.
8 
49
.7
 
0
0
0
0
0
0
0
0
0
0
0
0
SU
PT
20
H
0
0
0
0
0
0
0
0
0
0
0
0
5
10
.8
 
10
0.
0 
5
10
.4
 
10
0.
0 
5
8.
6 
10
0.
0 
7
17
.3
 
10
0.
0 
SU
PT
7L
 
0
0
0
0
0
0
0
0
0
0
0
0
5
14
.3
 
10
0.
0 
4
11
.8
 
10
0.
0 
4
12
.3
 
10
0.
0 
5
14
.3
 
10
0.
0 
TA
DA
1 
0
0
0
0
0
0
0
0
0
0
0
0
2
8.
4 
10
0.
0 
2
8.
7 
90
.2
 
1
3.
9 
73
.4
 
4
17
.3
 
10
0.
0 
TA
DA
3
0
0
0
0
0
0
0
0
0
0
0
0
4
11
.1
 
10
0.
0 
2
7.
6 
10
0.
0 
4
14
.6
 
10
0.
0 
2
7.
6 
10
0.
0 
Embargoed: Unpubl ished Chapter
177
Coregulatory protein recrui tment by TRs in neuronal  cel ls
6
Pr
ot
ei
n
0 
nM
 T
3
10
0 
nM
 T
3
TR
α1
TR
β1
TR
α1
TR
β1
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
1s
t
2n
d
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
UPC
% Cov
% Prob
TA
F1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
11
.5
 
96
.2
 
1
11
.5
 
65
.8
 
1
11
.5
 
85
.5
 
2
17
.9
 
10
0.
0 
TA
F5
L
0
0
0
0
0
0
0
0
0
0
0
0
7
13
.6
 
10
0.
0 
3
6.
1 
10
0.
0 
4
8.
0 
10
0.
0 
6
12
.1
 
10
0.
0 
TA
F6
L 
0
0
0
0
0
0
0
0
0
0
0
0
4
10
.5
 
10
0.
0 
3
7.
2 
10
0.
0 
3
7.
2 
10
0.
0 
1
2.
4 
98
.3
 
TB
L1
X 
10
39
.3
10
0.
0
13
54
.2
10
0.
0
5
32
.1
 
10
0.
0 
12
56
.5
 
10
0.
0 
0
0
0
1
19
.9
 
10
0.
0 
0
0
0
0
0
0
TB
L1
XR
1
27
74
.7
10
0.
0
25
80
.2
99
.7
22
65
.8
 
10
0.
0 
24
80
.2
 
10
0.
0 
16
59
.5
 
10
0.
0 
17
60
.7
 
10
0.
0 
3
14
.6
 
10
0.
0 
4
16
.9
 
10
0.
0 
TC
F1
2
0
0
0
1
4.
11
95
.4
0
0
0
2
5.
0 
99
.9
 
0
0
0
1
2.
8 
96
.2
 
2
6.
5 
10
0.
0 
1
2.
8 
96
.3
 
TC
F4
0
0
0
0
0
0
0
0
0
1
2.
4 
96
.8
 
1
3.
8 
99
.8
 
1
2.
4 
96
.2
 
1
3.
8 
99
.8
 
1
2.
4 
96
.3
 
TF
A
P2
A
 
0
0
0
1
4.
6
96
.8
1
4.
6 
97
.9
 
2
6.
6 
10
0.
0 
0
0
0
1
4.
6 
96
.2
 
2
6.
6 
10
0.
0 
1
4.
6 
96
.3
 
TH
RA
 
25
60
.6
10
0.
0
25
61
.2
10
0.
0
2
11
.2
 
10
0.
0 
1
8.
37
 
99
.7
 
27
59
.2
 
10
0.
0 
20
54
.7
 
10
0.
0 
1
6.
7 
99
.7
 
1
8.
4 
99
.9
 
TH
RB
1
6.
9
10
0.
0
1
6.
9
10
0.
0
26
59
.9
 
10
0.
0 
32
66
.6
 
10
0.
0 
2
10
.8
 
10
0.
0 
2
8.
5 
10
0.
0 
29
63
.6
 
10
0.
0 
28
65
.9
 
10
0.
0 
TI
A
M
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
1.
2 
92
.1
 
1
0.
8 
28
.6
 
TR
RA
P
0
0
0
0
0
0
0
0
0
0
0
0
17
5.
5 
10
0.
0 
16
6.
3 
10
0.
0 
20
7.
2 
10
0.
0 
17
6.
8 
10
0.
0 
W
IZ
 
0
0
0
0
0
0
0
0
0
1
1.
2 
29
.1
 
2
2.
2 
99
.6
 
1
1.
0 
9.
5 
0
0
0
1
1.
2 
99
.0
 
ZK
SC
A
N
1
0
0
0
0
0
0
2
3.
7 
99
.5
 
3
7.
1
10
0.
0 
2
5.
3 
10
0.
0 
2
4.
6 
98
.9
 
2
3.
7 
99
.9
 
2
5.
0 
10
0.
0 
ZN
F5
12
2
5.
5
99
.8
1
2.
3
32
.3
0
0
0
0
0
0
2
4.
9 
10
0.
0 
0
0
0
0
0
0
0
0
0
ZN
F6
29
1
1.
5
97
.5
0
0
0
0
0
0
0
0
0
4
6.
0 
10
0.
0 
2
3.
0 
97
.3
 
2
2.
7
10
0.
0 
1
1.
5 
89
.5
 
U
PC
, e
xc
lu
si
ve
 u
ni
qu
e 
pe
pt
id
e 
co
un
t; 
%
C
ov
, p
er
ce
nt
 c
ov
er
ag
e;
 %
P
ro
b,
 p
er
ce
nt
 p
ro
ba
bi
lit
yEmbargoed: Unpubl ished Chapter
178
Chapter  6b
6
Supplementary Table S2. Identified TR-interacting proteins are associated in large protein complexes. 
Protein complex Identified proteins Associated condition
NCoR/SMRT corepressor NCoR1; SMRT (NCoR2); HDAC3; 
TBL1X; TBL1XR1; GPS2
Unliganded TRα and β
Wnt/β-catenin signalling FOXK1; FOXK2 Unliganded TRα and β
RNA polymerase II POLR2A, B, C, D, E, G, H, I, K; 
RECQL5; RPAP2
Liganded TRα and β
Mediators CCNC; CKD8, 19; MED 4, 6-15, 17-31, 
13L
Liganded TRα and β
MLL/SET methyltransferase ASH2L; KDM6A; RBBP5 Liganded TRα only
NuRD (Nucleosome 
Remodeling Deacetylase) 
GATAD2A*; MBD3; MTA1, 2; CHD4**; 
RBBP4, 7  
Liganded TRα and β
SAGA (Spt-Ada-Gcn5-
Acetyltransferase)
CCDC101 (SGF29); KAT2A (GCN5); 
SUPT20H; SUPT7L; TADA3; TAF5L, 
6L, 10; TRRAP
Liganded TRα and β
*TRα1 only; **predominant with unliganded TRs
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Overview
 Genomic actions of thyroid hormone (TH) are regulated by the binding of TH to 
thyroid hormone receptors (TRs). Mutations of the genes encoding TRα and TRβ lead to 
resistance to thyroid hormone (RTH) α and β, respectively. In the first part of this thesis, 
we describe two novel mutations identified in an RTHα and RTHβ patient. In silico and in 
vitro studies confirmed the pathogenic impact of the amino acid substitutions on receptor 
function. In addition, these studies allowed us to gain more insight into the role of particular 
amino acid residues in TR functions. In the second part, we focus on the genotype-phenotype 
correlation in RTHα (1,2). Based on our observations, the severity of the clinical phenotype 
of these patients is not solely explained by the degree of impairment in T3 binding affinity. 
Therefore, we conducted studies to evaluate the diverse functional impairment of mutant TRs 
to correlate the in vitro functional impairment to the severity of the phenotype of reported 
patients. The last part of this thesis focuses on nuclear coregulatory proteins that are involved 
in TR functions. We asked whether the nuclear coregulatory protein recruitment by TRs have 
tissue- and isoform-specific patterns. In this chapter, we discuss the relevance of our studies 
to the current knowledge gaps and further research strategies to confirm our findings and 
broaden the understanding of the complexity of TR actions.
Role of specific amino acid residue on TR function: lessons from 
mutated TRs
 Pathogenic mutations in TRs that cause RTH are located in the ligand binding domain 
(LBD) and adjacent hinge region of the receptors and lead to a reduced affinity for TH. The LBD 
shares a high sequence homology between isoforms and among species (3). However, not 
all amino acids in the LBD are equally important for T3 binding and T3-induced transcriptional 
activity. For instance, a study of Hayashi et al. on sixteen TRβ1 mutations located in the LBD 
(six patient-derived and ten artificial mutations) showed that six artificial mutations did not 
significantly affect T3 binding affinity (4), suggesting that only certain residues in the LBD play 
a role in T3 binding and are sensitive to amino acid changes. Subsequent crystal structures of 
TRα1 and TRβ1 showed that amino acid residues located at the surface of the ligand-binding 
pocket interact with T3 and mainly determine T3 binding affinity (3,5). This was confirmed by 
mutations of TRα1 and TRβ1 identified in RTH patients that reduce T3 binding affinity of the 
receptor (6-8).
 In addition to the affinity for T3, studies of mutated TRs also emphasized the role 
of particular amino acid residues in interaction between TRs and cofactor proteins. For 
example, Arg243, Arg383, and Pro453 of TRβ1 seem to be important for the interaction with 
corepressor proteins because mutations at these residues (R243Q and R243W (9), R383H 
(10), and P453S (11)) impair interaction with the corepressor NCoR1. In addition, Thr277 and 
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Leu454 of TRβ1 are likely involved in the interaction with coactivator proteins, since mutations 
of these residues (T277A (12) and L454V (13)) affect interaction with the coactivator SRC1. 
Therefore, functional studies of the mutant TRs do not only confirm the pathogenicity of a 
mutation in the diagnosis of RTH in patients, but also allow us to gain more understanding 
about the role of specific amino acid residues in TR function. 
Role of Leu341 in T3 binding affinity of TRβ
 In chapter 2, we describe the role of Leu341 in TRβ1 function, prompted by the 
identification of a novel L341V mutation in RTHβ patients. Another mutation at this residue 
(L341P) has been reported as a cause of RTHβ (14,15). However, the functional importance 
of this amino acid residue has never been established. Our in-depth inspection of wild-type 
(WT) TRβ crystal structure showed that Leu341 lines the ligand-binding pocket of TRβ1 
and form a direct hydrophobic interaction with the outer ring of the T3 molecule, which is 
in agreement with previous reports (16-18). This residue also interacts with the surrounded 
residues such as Phe272 and Leu346 to stabilize the microarchitecture of the ligand-binding 
pocket. The leucine to valine substitution (L341V) in the in silico model showed that the 
consequential shortening of the aliphatic amino acid side-chain alters the shape of the ligand-
binding pocket and abolishes the direct hydrophobic interaction of the side-chain with T3. 
The functional impairment of TRβ1-L341V predicted by the in silico model was confirmed 
by the in vitro studies. The mutant has reduced T3 binding affinity, impaired T3-induced 
transcriptional activation, and a dominant-negative effect on WT receptor function. The 
importance of Leu341 was further confirmed by three artificial mutations, L341A, L341I and 
L341F, which were created based on the in silico prediction. The side-chains of these three 
amino acids (alanine, isoleucine, and phenylalanine) have similar hydrophobic properties but 
different in size and orientation, resulting in a variable distance to the T3 molecule. We also 
demonstrated a correlation between the degree of receptor impairment and the side-chain 
size and orientation of these artificial mutants. Based on this study, we suggested that the 
direct interaction between Leu341 and T3 and the microarchitecture formed by interactions 
between Leu341 and its surrounding residues are required for optimal T3 binding affinity and 
T3-induced transcriptional activation of TRβ1. 
Role of TRα1-Met256 and TRβ1-Met310 in T3 versus T4 recognition of TRs 
 The concept that T4 is a prohormone which has to be converted to the biologically 
active form T3 to activate TRs in target tissues has been established for several decades 
based on the seminal studies showing that T3 has a greater biological potency than T4 (19-
22). However, molecular and structural mechanisms underlying this concept have never 
been thoroughly examined. In chapter 3, we highlight the role of residues Met256 of TRα1 
and Met310 of TRβ1 in determining the differential biological potency of T3 versus T4, by 
characterizing a novel mutation (TRα1-M256T) identified in an RTHα patient and a mutation 
at the corresponding position (TRβ1-M310T) identified in RTHβ patients (23-25). The crystal 
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structure previously showed that the ligand-binding pocket of WT TRβ1 can accommodate 
both T3 and T4, but that it is more tightly packed in the case of T3 binding than T4 binding (26). 
Helix 12 of T4-bound TRβ1 is more mobile than that of T3-bound TRβ1. Therefore, T4 is less 
stably retained in the LBD, resulting in a higher ligand dissociation rate and a lower binding 
affi  nity of T4-bound TRβ1. By focusing on Met256 of TRα1, we demonstrated that this residue 
forms a direct (hydrophobic) interaction with 5’ carbon of the outer ring of T3 and interacts with 
surrounding residues to create a niche that allows the accommodation of T3. The bulky 5’ iodine 
of T4 abolishes these direct interactions between the ligand and Met256 and, consequently, 
aff ects the stability of T4 in this niche. Therefore, we predicted based on our in silico models 
that Met256 in TRα1 plays a pivotal role in discriminating between T3 and T4. This prediction 
was confi rmed by the studies on threonine and alanine substitutions. We demonstrated that 
TRα1-M256T and the artifi cial mutant TRα1-M256A have a more pronounced distortion of 
the hydrophobic niche accommodating the outer ring of T3 than that of T4, which suggests a 
greater impact on the affi  nity for T3 of these two mutations. The in vitro studies confi rmed that 
threonine and alanine substitutions at Met256 selectively reduced the affi  nity for T3 and had a 
greater impact on T3- versus T4-dependent transcriptional activation. The naturally occurring 
mutation at the corresponding residue in the TRβ1 (M310T) also showed the same result. In 
contrast, amino acid substitutions at other residues of TRα1 (D211G (27), A263S, and R384H 
(28)) equally aff ect the transactivation potency of both T3 and T4. These fi ndings confi rm that 
Met256 in TRα1 and Met310 in TRβ1 are important for T3 versus T4 discrimination and shed 
light on the underlying molecular and structural basis for the role of T4 as a prohormone and 
T3 as a biologically active hormone in a widely accepted concept of TH physiology.
Novel TR muta�on
In silico 
model predic�on
In vitro assays
TH binding assay
(TH binding aﬃnity)
EMSA
(Receptor dimeriza�on on TRE)
Two-hybrid assay
(TR-cofactor interac�on)
Transcrip�onal ac�vity assay
(Transcrip�onal ac�vity)
Figure 1. A pipeline of assays for confi rming functi onal impairment of mutant TRs. The assay details 
are described in chapters 2-4 of this thesis. (EMSA, electrophoreti c mobility shi�  assay; TRE, thyroid 
hormone response elements) 
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 These studies in chapters 2 and 3 are based on the identification of novel mutations 
in RTHα and β patients. Our studies showed that the combination of in silico model prediction 
and the creation of artificial mutations is a highly relevant approach to further explore the role 
of mutated amino acid residues of TRs in RTH patients and expand the knowledge about 
underlying structural and molecular basis for interactions of TR with its ligands and protein co-
partners. In addition to the in silico prediction, we have applied a pipeline of assays, including 
in vitro TH binding assay, electrophoretic mobility shift assay (EMSA), TR-cofactor (two-
hybrid) interaction assay, and transcriptional activity assay, in order to rapidly and extensively 
confirm functional impairment of mutant TRs (Figure 1). 
Diverse functional impairment of TRα1 mutants and phenotype 
variability in RTHα
 RTHα caused by mutations of the THRA gene was first identified in 2012 (1,2). 
To date, 25 mutations (in a total of 40 patients) have been reported. These mutations can 
be categorized into two groups based on the type of mutation. The first group consists of 
nonsense and frameshift mutations that generate premature stop codons. These mutations 
lead to truncated receptors that exhibit negligible T3 binding and a lack T3-induced gene 
expression (1,2,28-32). The second group consists of missense mutations that result in amino 
acid substitutions (7,27,28,33-39). These missense mutants can bind T3 but with a lower 
affinity than WT receptors.
 The common phenotype of RTHα patients includes growth retardation, delayed bone 
maturation, macrocephaly, constipation, delayed cognitive and motor development, anemia, 
and a high (F)T3/(F)T4 ratio (7). An increase in the number of RTHα patients identified and 
their clinical characterization allows us to investigate the variability in the phenotype of 
RTHα patients. In general, patients with truncating mutations have more severe phenotype 
than patients with missense mutations that can still bind T3 (7). However, there are specific 
differences in the phenotype of patients in each group. For instance, the neurological 
phenotype of patients with truncating mutations varies from mild cognitive and motor 
impairment (F397fsx406 (2) and E403X (1)) to severe mental retardation and in some cases 
inability to walk and no developed speech (C380fsx387 (28), A382fsx388 (33), R384fsx388, 
and C392X (29)) (Table 1). Likewise, some patients with missense mutations displayed clear 
motor and cognitive impairment, whereas in a large family with patients carrying an A263S 
mutation, the affected members only showed mild symptoms and even partially overlapped 
with unaffected members for some characteristics (Table 2). So far, the underlying molecular 
mechanism to explain these observations has not yet been clearly established.
 In chapter 4, we evaluated the differences in the degree of functional impairment of 
seven TRα1 missense mutants, four of which were derived from RTHα patients (D211G (27), 
187
General  Discussion
7
M256T (37), A263S, and R384H (28)) and the other three were derived from RTHβ patients 
(P398H, T223A, and L287V). These mutations covered the three CpG-rich regions of the LBD 
of TRα1 that are homologous to the mutation-prone hotspots of the TRβ1, namely R384H and 
P398H in cluster 1, M256T, A263S and L287V in cluster 2, and D211G and T223A in cluster 3 
(Figure 2). Studies in patient-derived TRβ1 mutants showed that some mutants have severe 
transcriptional impairment despite only mild T3 binding defect. This finding would be explained 
by either impaired dimerization (40-42) or defective TR-cofactor interaction (9-13). In addition, 
a subset of TRβ1 mutants showed a defective transcriptional activation only on specific TRE 
configurations (12). Since TRα1 and TRβ1 are highly homologous, we asked whether impaired 
dimerization, defective TR-cofactor interaction, and configuration of TREs (DR4, IR0, and 
ER6) could contribute to the functional impairment of TRα1 mutants. Our results showed that 
in these seven TRα1 missense mutants it is predominantly the reduced T3 binding affinity 
that determines the severity of impaired transcriptional activation and defective interactions 
with the cofactors (NCoR1 and SRC1). There is no substantial evidence that suggests an 
additional TRE-specific transcriptional impairment of these mutants. 
1 410
DBD LBDHA/B
180 228 256 299 375 406
D211G
T223A
M256T
A263S
L287V
R384H
P398H
Cluster III Cluster II Cluster I
Figure 2. The diagram shows the location of selected mutations in the three CpG-rich regions of the 
LBD of TRα1 (adapted from Rebai M et al. 2012(43)) [A/B, A/B domain; DBD, DNA-binding domain; H, 
Hinge region; LBD, ligand binding domain]
 The degree of reduced T3 binding affinity and impaired transcriptional activation 
of the mutants seems to be correlated with the phenotype of the patients. For instance, as 
previously mentioned, patients carrying D211G and R384H mutations have a more severely 
impaired motor development than patients carrying the A263S mutation. This is in agreement 
with the more prominent transcriptional impairment that we showed for the D211G and R384H 
mutants than for the A263S mutant. This finding is in line with the report of Moran et al. 
that showed that the degree of transcriptional impairment of two TRα1 missense mutations, 
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A263V and L274P, correlates with the severity of the clinical phenotype of the patients (36). 
However, there is an exception. The M256T mutation exhibited the most severe transcriptional 
impairment, but the available clinical information showed that patient carrying this mutation 
does not have severe cognitive impairment and delayed motor development (Table 2). There 
is no clear explanation yet for this paradox. Since our studies did not take the dominant-
negative effect of the mutant on WT receptor function into account, it might be that this is one 
of the factors that further complicates the phenotype of the patients.
 In addition to the variation between different mutations, the severity of clinical 
phenotype is also diverse between patients who carry the same mutation (28). This 
phenomenon has also been reported in RTHβ patients who belong to the same family and 
carry a similar mutation (44-48). The mechanisms underlying this finding is unknown. This may 
very well be explained by other factors beyond TRs such as genetic variability or epigenetic 
modification that might modulate the phenotype of RTH patients. 
 As previously mentioned, the diversity in phenotype severity was also observed in 
RTHα patients carrying truncating mutations. In chapter 5, we analyzed gene transcription 
regulated by two TRα1 truncating mutations, C380fsx387 and F397fsx406, both of which lack 
T3-induced gene expression (1,2) but result in a different degree in cognitive impairment of 
the patient (Table 1). The patient who carries the TRα1-C380fsx387 mutation was severely 
handicapped and unable to communicate at 12 years of age, suggesting severe cognitive 
impairment (28). In contrast, the index patient who carries the TRα1-F397fsx406 mutation 
had borderline cognitive impairment (IQ score 90 at 11 years old) (2). The transcriptome 
analysis was performed in a human neuronal cell line (SH-SY5Y) overexpressing Flag- and 
Hemagglutinin double-epitope tagged TRα1 (FHTRα1) to focus on neurological phenotype. 
The results showed that overexpressing FHTRα1-C380fsx387 and -F397fsx406 mutants 
altered the transcriptomes when compared to cells overexpressing FHTRα1 WT and abolished 
T3-induced gene expression. In addition, the transcriptomes of these two mutants were very 
different from each other, suggesting a differential effect of these two mutations on gene 
transcription. The genes that were differentially expressed in the two mutant cells were related 
to nervous system development and neuronal pathfinding. For instance, we identified many 
genes (SEMA3A, SEMA3C, SLIT1, EFNB2, UNC5A, and UNC5D) that encode proteins that 
act as extracellular guidance cues for axonal/dendritic growth (49,50). We also identified many 
genes that are related to cell adhesion molecules (e.g., NRCAM, CNTNs, PCDHs, ITGs, and 
ASTNs) and neural growth factor receptors (NGFR, NTRK3, and GFRA2), which are essential 
for neural growth and migration (51-56). Additionally, the expression of ASCL1 and NEUROG2, 
which encode two master proteins for neuronal differentiation, Achaete-scute homolog 1 and 
Neurogenin 2, respectively, was different between the two mutant cells. Evidence in murine 
models showed that Neurog2 assigns neuron progenitor cells to differentiate into excitatory 
(glutamatergic) neurons, whereas Ascl1 assigns progenitor cells to differentiate into inhibitory 
(GABAergic) neurons (57-61). Progenitor cells that highly express Ascl1 also keep proliferating 
rather than differentiate into a mature neuron. Since the expression of NEUROG2 and ASCL1 
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was respectively lower and higher in SH-SY5Y/FHTRα1-C380fsx387 cells compared to both 
SH-SY5Y/FHTRα1-F397fsx406 and SH-SY5Y/FHTRα1 WT cells, this may keep more cells in 
a proliferating phase or drive them into becoming inhibitory neurons, thereby contribute to the 
more severe neurological phenotype in the C380fsx387 patient.
 The studies in chapters 4 and 5 showed a relationship between functional impairment 
of the mutant TRs and the neurological phenotype of the patients. However, the limitation of 
our studies is that the neurological phenotype of patients was not systematically evaluated, 
which leads to difficulty in phenotype comparison. For instance, cognitive and motor function 
was assessed at a different age and by different tests/scores or described only as a qualitative 
observation in some publications. The test was also performed and interpreted by different 
investigators without standardization. In addition, the effect of treatments/interventions which 
had been given to some patients before the RTH diagnosis and might improve the cognitive 
and motor function were not taken into account. Therefore, our results need to be interpreted 
cautiously, and further studies with standardized assessment methods are required in order 
to solve this issue and confirm our findings.
Recruitment of nuclear coregulatory protein by TRs
 TRs regulate gene transcription by interacting with nuclear coregulatory proteins that 
modify local chromatin structure and accessibility of the promotor region of target genes. 
In the absence of T3, TRs repress gene transcription by binding to the main corepressor 
proteins, NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoid 
and thyroid hormone receptors), that form complexes with other nuclear proteins to promote 
histone deacetylation and nucleosome compaction. Binding of TH to TRs creates a closed-
conformation of TR-LBD, leading to the dissociation of the corepressor complex and the 
association of coactivator proteins. Steroid hormone receptor coactivator 1, 2, and 3 (SRC-1, 
-2, and -3) directly bind to TRs and recruit other proteins such as histone acetyltransferase 
(HAT), resulting in histone acetylation, chromatin accessibility, and gene transcription.
 Apart from the classical TR cofactors, other nuclear proteins have been identified as 
corepressors or coactivators. There is evidence indicates that TRs recruit cofactor proteins in 
a tissue- and isoform-dependent manner, which may further explain the diverse transcriptional 
regulation of TRs in different tissues (62-65). Understanding the complexity in TR-cofactor 
interactions will gain more insight into the impact of TR mutations in RTH syndromes in 
addition to the effect on T3 binding. Therefore, in chapters 6a and 6b, we used an unbiased 
approach to identify TR-interactomes by using a tandem-affinity protein purification method.
 In chapter 6a, we compared the unliganded and liganded TRα1-interactomes in 
a human liver cell model (HepG2) and a human neuronal cell model (SH-SY5Y). The main 
objective was to evaluate the tissue-dependency of TR-cofactor interactions. FHTRα1 WT 
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was stably expressed in these two cell types by lentiviral transduction. To identify nuclear 
proteins that interact with TRα1 in the absence and presence of T3, we purified FHTRα1 and 
its associated proteins from the nuclear extracts of HepG2 and SH-SY5Y (after stimulating with 
0 or 100 nM T3) using a tandem-affinity purification. The TRα1-interactomes were identified 
by LC-MS/MS and confirmed by co-immunoprecipitation. By this approach, we were able to 
identify several proteins and protein complexes that are associated with TRα1. The number 
of hits is larger than in previous TR-interactome studies (63,65). The composition of TRα1-
interactomes is strongly dependent on ligand-binding state and largely overlapped between 
HepG2 and SH-SY5Y cells, suggesting that TRα1 uses common nuclear coregulatory proteins 
to regulate gene transcription in these two cell types. However, some proteins are likely to 
interact with TRα1 in a cell-type specific manner, including nuclear receptor interacting protein 
1 (NRIP), as known as RIP140, in HepG2 cells and transcription factor 4 (TCF4) in SH-SY5Y 
cells. Given that NRIP and TCF4 are exclusively expressed in HepG2 and SH-SY5Y cells, 
respectively, the cell-type specific TR-cofactor recruitment found in our study may be mainly 
explained by the differential availability of these particular cofactors and may not necessarily 
prove a tissue-specific interaction. 
 In addition to the cell-type specificity, we also identified a novel putative binding 
partner, transcription factor Prospero homeobox 1 (Prox1), in both HepG2 and SH-SY5Y 
cells. The interaction of this transcription factor with TR was increased in the presence of T3. 
Prox1 is known to be involved in cell fate specification and metabolism. Prox1 can interact 
with many nuclear receptors, including chicken ovalbumin upstream promoter transcription 
factor II (COUP-TFII) in lymphatic endothelial cells (66), and hepatic nuclear factor 4 alpha 
(HNF4α), liver receptor homologue-1 (LRH-1), and Retinoid Orphan Receptor (ROR) α and γ 
in the liver (67-69). The interaction between TR and Prox1 had not previously been described, 
although Broekema et al. recently showed the interaction between TRs and a binding motif of 
Prox1 by using the Microarray Assay for Realtime Coregulator-Nuclear Receptor Interaction 
(MARCoNI) technology (70). Our finding further confirms that Prox1 may work as TR 
coregulatory protein to regulate gene transcription. In addition, we identified several proteins 
belonging to multisubunit chromatin remodelling complexes that help to rearrange local 
chromatin architecture and regulate gene transcription. The most notable one was the nuclear 
remodelling and deacetylase (NuRD) complex that was identified in both HepG2 and SH-
SY5Y cells. The NuRD complex was initially identified as a transcriptional repression complex 
(71-73). However, it was later shown that this complex can also be involved in transcriptional 
gene activation (74), which is in line with our finding that components of the NuRD complex 
identified in our study were slightly enriched in the presence of T3. 
 In chapter 6b, we studied the isoform-specific recruitment of coregulatory proteins 
for TRs in SH-SY5Y cells in order to understand the complexity of TR actions in the brain. 
Since previous studies in other cell models showed that TRs recruit a subset of coregulatory 
proteins in an isoform-specific manner (63,65), we asked whether the isoform-specific 
coregulatory protein recruitment exists in SH-SY5Y cells as well. Therefore, we compared 
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the interactomes for the two major TR isoforms (TRα1 and TRβ1) using the same tandem-
affinity purification method and LC-MS/MS analysis as in chapter 6a. The result showed that 
the majority of identified proteins were associated with both TRα1 and TRβ1, suggesting 
that both TR isoforms associate with common nuclear coregulatory proteins to regulate gene 
transcription. However, a subset of nuclear proteins interacted with TRs in an isoform-specific 
manner. The interesting hits are lysine-specific demethylase 6A (KDM6A, as known as UTX), 
set1/Ash2 histone methyltransferase complex subunit ASH2 (ASH2L), and retinoblastoma-
binding protein 5 (RBBP5), all of which were identified exclusively with TRα1 in the presence of 
T3. These proteins are likely to work together to establish transcriptional permissive chromatin 
for many key developmental genes such as HOX genes (75-78). 
 In agreement with the study in chapter 6a, we identified many components of 
multisubunit chromatin remodelling complexes that regulate gene transcription together with 
both TR isoforms in SH-SY5Y cells, such as the NuRD complex and the Spt-Ada-Gcn5-
Acetyltransferase (SAGA) complex, both of which seems to interact with TR more prominently 
in the presence of T3. Identifying the NuRD complex again in this study confirms that this 
protein complex is a common co-partner that plays a crucial role in TR actions, regardless of 
TR isoform and tissue context. The proteins in the SAGA complex were also co-purified with 
TRs exclusively in the presence of T3, suggesting the role of this complex in transcriptional 
activation. To our knowledge, this is the first study suggesting a relationship between SAGA 
complex and TRs. Other novel binding co-partners of TRs, Foxhead box transcription factor 
K1 and K2 (FOXK1 and FOXK2), were identified in the absence of T3. The FOXK1 and 
FOXK2 are the proteins that positively regulate the Wnt/β-catenin signaling pathway (79). 
These studies indicate crosstalk between TH-TR and the Wnt/β-catenin pathway at multiple 
levels, such as an effect of TH on the Wnt and β-catenin protein expression, a physical 
interaction between TRs and β-catenin in specific tissues, and synergistic effect of TH-TRs 
and Wnt/β-catenin signaling on cell proliferation and differentiation (80). However, the role of 
FOXK1 and FOXK2 in this crosstalk has not yet been established. Our finding suggests that 
these proteins may also take part in the interaction between TRs and Wnt/β-catenin signaling. 
 In summary, our results in chapters 6a and 6b showed that TRs interact with not 
only classic nuclear coregulatory proteins, such as NCoR/SMRT and SRC complexes, but 
also several potential novel binding partners. TRs also interact with a number of transcription 
factors and chromatin remodeling complexes, which highlights the role of TRs in local 
chromatin accessibility. Although the majority of identified proteins are able to interact with 
both TR isoforms and regardless of cellular context, we also found that a small subset of 
nuclear proteins seems to interact with TRs in tissue- and isoform-specific manner. These 
findings expand the knowledge about the interaction between TRs and cofactor proteins in 
transcriptional gene regulation and may lead to a more understanding of the impact of TR 
mutations in RTH syndrome. 
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Concluding remarks and future perspective
 TRs are key controllers for transcriptional regulation (genomic actions) by TH. 
Research on molecular functions of TRs provides more understanding about the physiology 
of TR actions which are more complicated than merely binding of TH to TRs. 
 The knowledge of TR actions has been broadened by the identification of mutations 
in RTH patients. All identified mutants help to confirm a crucial role of that particular residue/
domain in TR functions, which includes interactions with TH in the ligand-binding pocket and 
interactions with regulatory proteins, such as RXR, corepressors, and coactivators. In this 
thesis, we provide more information about the importance of particular amino acid residues 
in TR functions prompted by identifying two RTH patients who carry novel mutations. The 
combination of in silico model prediction and in vitro studies of mutated TRs allows us to 
understand not only the effect of the mutation but also the role of the residue of interest in 
TR function. We, therefore, suggest using this approach to further explore the role of mutated 
amino acid residues of TRs in RTH patients. According to this, we have applied a pipeline of 
assays for a novel TR mutation by combining all of the techniques we have used, including 
in silico protein modeling and several in vitro functional assays. Since we are now capable 
of performing TR transcriptome and interactome analyses, we could also incorporate these 
techniques in order to explore all aspects of transcriptional regulation by TRs and effect of TR 
mutations in RTH syndromes. 
 One of the interesting issues is the factor that determine the functional impairment 
of the mutated TRs and the severity of phenotype of RTHα patients. Our study with the 
TRα missense mutants showed that the reduced affinity for T3 is the main factor that 
determines the severity of impaired transcriptional activity of mutants and seems to define 
patients’ phenotypes. However, the transcriptome analysis of two TRα1 truncating mutations 
(C380fsx387 and F397fsx406), both of which exhibit negligible T3 binding, showed that there is 
a difference in baseline RNA expression between mutants. This finding suggests that additional 
factors, apart from the affinity for T3, could also influence the severity of patients’ phenotype 
in RTH, which is confirmed by the diversity of the cognitive phenotype in these patients. We 
are aware that our studies have some limitations. For instance, the in vitro overexpression 
system we used may not perfectly represent the in vivo situation. The system also not allow 
us to study the effect of the mutant on WT receptor function (i.e., dominant-negative effect) 
since it was difficult to mimic heterozygosity. For this, other cell models, such as patient-
derived primary cells or CRISPR-Cas9 genome editing, need to be developed. There is also 
a difficulty in phenotype comparison of RTHα patients since the phenotype description is 
often incomplete, and clinical assessment methods sometimes vary among publications. This 
may affect the reliability of the relationship between genotype and phenotype we reported. A 
patient registry for RTH syndrome, which provides a guideline and standardized methods for 
clinical assessment should overcome this limitation and will lead to a more comprehensive 
understanding of the genotype-phenotype correlation in RTH syndromes.
193
General  Discussion
7
 Interaction between TR and cofactors is important for transcriptional gene regulation 
by TH. Our studies showed that TRs interact with not only classical nuclear coregulatory 
proteins but also several potential novel binding partners to regulate gene transcriptions. A small 
subset of proteins interacts with TRs in tissue- and isoform-specific manner. These findings 
provide more insight into the complexity of TR actions and may expand the understanding 
about the impact of mutated TRs on phenotype of RTH patients, especially in patients who 
carry mutated TRs that have a greater impaired transcriptional activation than the degree 
of T3 binding defect. However, further studies are still needed to confirm the interaction 
between WT TRs and novel binding protein copartners and the functional importance of these 
interactions in both the physiological actions of TRs and RTH syndromes.
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SUMMARY
 Thyroid hormone (TH) is indispensable for normal growth, development, and 
metabolic homeostasis. The principal action of TH is transcriptional gene regulation (genomic 
actions), which is mediated by binding of TH to thyroid hormone receptors (TRs). Two major 
forms of TH are produced from the thyroid gland under tight regulation of the hypothalamic-
pituitary-thyroid (HPT) axis, namely 3,3’,5,5’-tetraiodothyronine or thyroxine (T4), and 
3,3’,5-triiodothyronine (T3). T3 is the bioactive hormone, whereas T4 is a prohormone, since 
T3 binds to TRs with a higher affinity than T4. However, the mechanism underlying this 
difference in affinity has received marginal attention.
 There are three functional isoforms of TRs that are capable of binding T3 and 
controlling gene transcription, namely TRα1, TRβ1, and TRβ2. TRα1 is encoded by the 
THRA gene on chromosome 17, and TRβ1 and TRβ2 are encoded by the THRB gene on 
chromosome 3. TRs mainly heterodimerize with the retinoid X receptor (RXR) and bind to 
thyroid hormone response elements (TREs) to regulate gene transcription. In the absence of 
T3, the TRs recruit corepressor proteins to repress transcription of positively regulated genes. 
In the presence of T3, TRs then release the corepressors and recruit coactivators to induce 
gene transcriptional activation. Mutations of the TRs cause resistance to thyroid hormone 
(RTH) that results in two distinct disorders; RTHα and RTHβ, dependent on THRA and THRB 
mutations, respectively. 
 This thesis focuses on the complexity of the genomic actions of TH. Chapter 1 
provides a general introduction of TH actions, especially the function of TRs and genetic 
abnormalities that cause RTH. The general aims and outline of this thesis are also presented 
in this chapter. Chapter 2 describes the role of Leu341 in TRβ function, prompted by the 
identification of a novel mutation, TRβ1-L341V, as a cause of RTHβ. By using an in silico 
prediction model and a pipeline of in vitro studies (T3 binding assays, electromobility shift 
assays, transcriptional activity assays, and protein-protein interaction [two-hybrid] assays). 
Our study shows that the direct interaction between Leu341 and T3 and the microarchitecture 
formed by interactions between Leu341 and its surrounding residues are required for optimal 
T3 binding affinity and T3-induced transcriptional activity of TRβ1. Chapter 3 unravels the 
molecular and structural mechanism underlying the differences in biological activity of T3 
and T4, prompted by the identification of a novel TRα1-M256T mutation and the previously 
reported TRβ1-M310T mutations in RTHα and RTHβ patients, respectively. We found that 
these mutations have a greater impact on the affinity of T3 than of T4 for the receptors. This 
finding suggests that Met256 in TRα1 and the equivalent Met310 in TRβ1 are important for 
T3 versus T4 discrimination and may partially explain the underlying molecular and structural 
basis for the role of T4 as a prohormone and T3 as a biologically active hormone in a widely 
accepted concept of TH physiology.
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 To date, 25 mutations (in a total of 40 patients) have been identified as a cause of 
RTHα. The increase in the number of patients allowed us to study the variability in patients’ 
phenotype. So far, the underlying molecular mechanisms to explain this variation have not 
yet been clearly established. In chapter 4, we investigate the factors that contribute to the 
differential impaired transcriptional activity of seven TRα missense mutations, four of which 
are derived from RTHα patients. The results show that reduced T3 binding affinity is the 
predominant factor that determines the severity of impaired transcriptional activation and 
defective interactions with the cofactor NCoR1 and SRC1. In addition, the degree of reduced 
T3 binding affinity and impaired transcriptional activation of the mutants seems to be related 
to the phenotype of the patients. In chapter 5, we study the difference of the neurological 
phenotype found in two RTHα patients carrying TRα1-C380fsx387 and TRα1-F397fsx406 
truncating mutations that both entirely abolish T3 binding affinity. The transcriptomes of these 
two mutants in a human neuronal cell line show that the TRα1-C380fsx387 mutant alters 
baseline gene expression to a larger and different extent than the TRα1-F397fsx406 mutant, 
which is in agreement with the more severe cognitive impairment of the patient carrying the 
TRα1-C380fsx387 mutation. This finding suggests that the effect of the mutants on gene 
expression is not only due to the reduced T3 binding, but that other defects in receptor function 
may contribute to the differences in the phenotype of patients. 
 As mentioned previously, nuclear coregulatory proteins are important in transcriptional 
gene regulation by TRs. Understanding the complexity of TR-cofactor interactions will gain 
more insight into mechanisms of disease in RTH. In chapter 6, we used an unbiased approach 
using a tandem-affinity TR purification technique to identify the interactomes of TRs. Chapter 
6a focuses on the cell-type specific coregulatory protein recruitment of TRα1 by performing the 
experiments in human liver and neuronal cell lines. In general, TRα1 uses common nuclear 
coregulatory proteins to regulate gene transcription in these two cell types. However, some 
proteins are likely to interact with TRα1 in a cell-type specific manner. Chapter 6b focuses 
on the isoform-dependent (TRα1 versus TRβ1) coregulatory protein recruitment by TRs in 
a human neuronal cell line in order to understand the complexity of TR actions in the brain. 
We show that the majority of identified proteins were associated with both TRα1 and TRβ1, 
suggesting that both TR isoforms associate with common nuclear coregulatory proteins to 
regulate gene transcription. However, a subset of nuclear proteins interacts with TRs in an 
isoform-specific manner. These findings expand the knowledge about the interaction between 
TRs and coregulatory proteins in transcriptional gene regulation and may provide more 
understanding about the impact of TR mutations in RTH syndromes.
 Finally, in chapter 7, we discuss the findings presented in this thesis in light of the 
currently available literature. The possible implications of these studies and future perspective 
are also suggested.
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SAMENVATTING
 Schildklierhormoon (TH) is onmisbaar voor normale groei, ontwikkeling en metabole 
homeostase. De belangrijkste actie van TH is transcriptionele genregulatie (genomische acties) 
dat wordt gemedieerd door binding van TH aan schildklierhormoonreceptoren (TRs). Twee 
belangrijke vormen van TH worden geproduceerd door de schildklier onder strikte regulering 
door de hypothalamus-hypofyse-schildklier (HPT) as, namelijk 3,3',5,5' tetraiodothyronine of 
thyroxine (T4), en 3,3',5- triiodothyronine (T3). T3 is het biologisch actieve hormoon, terwijl 
T4 een prohormoon is, aangezien T3 met een hogere affiniteit aan de TR bindt dan T4. Het 
mechanisme dat aan dit verschil in affiniteit ten grondslag ligt heeft echter slecht beperkte 
aandacht gekregen.
 Er zijn drie functionele TR isovormen die in staat zijn om T3 te binden en 
gentranscriptie te reguleren, namelijk TRα1, TRβ1 en TRβ2. TRα1 wordt gecodeerd door 
het THRA-gen op chromosoom 17 en TRβ1 en TRβ2 worden gecodeerd door het THRB-gen 
op chromosoom 3. TRs heterodimeriseren voornamelijk met retinoïde X-receptoren (RXR) 
en reguleren gentranscriptie via binding aan schildklierhormoon respons elementen (TRE's). 
Bij afwezigheid van T3 binden de TRs aan corepressor-eiwitten waardoor de transcriptie 
van positief gereguleerde genen wordt onderdrukt. In de aanwezigheid van T3 worden de 
corepressoren uitgewisseld voor co-activatoren, wat vervolgens gentranscriptie te induceert. 
Mutaties in de TRs zijn de oorzaak van twee verschillende vormen van resistentie tegen 
schildklierhormoon (RTH), namelijk  RTHα en β door mutaties in respectievelijk THRA en 
THRB. 
 Dit proefschrift gaat over de complexiteit van de genomische acties van TH. 
Hoofdstuk 1 geeft een algemene inleiding over TH werking, met name de functie van TRs en 
genetische afwijkingen in TRs die RTH veroorzaken. De algemene doelstellingen en de rode 
draad van dit proefschrift worden ook in dit hoofdstuk gepresenteerd. Hoofdstuk 2 beschrijft 
de rol van Leu341 in de werking van TRβ, naar aanleiding van de identificatie van een nieuwe 
mutatie, TRβ1-L341V gevonden in een RTHβ patiënt. Deze mutatie is getest door gebruik 
te maken van een voorspellend in silico model en een pijplijn van in vitro-onderzoeken (T3-
bindingsassays, elektroforetische mobiliteit shift assay, transcriptionele activiteit assays en 
eiwit-eiwit interacties [twee-hybride] assays). Onze studie toont aan dat de directe interactie 
tussen Leu341 en T3 en de microarchitectuur gevormd door interacties tussen Leu341 
en de omliggende residuen vereist zijn voor een optimale bindingsaffiniteit voor T3 en T3-
geïnduceerde transcriptionele activiteit van TRβ1. Hoofdstuk 3 ontrafelt het moleculaire en 
structurele mechanisme dat ten grondslag ligt aan de verschillen in de biologische activiteit 
van T3 en T4, naar aanleiding van de identificatie van respectievelijk een nieuwe TRα1-M256T 
mutatie en de eerder gemelde TRβ1-M310T-mutatie in RTHα- en RTHβ-patiënten. We vonden 
dat deze mutaties een grotere impact hebben op de affiniteit van de receptoren voor T3 dan 
voor T4. Deze bevinding suggereert dat Met256 in TRα1 en de equivalente Met310 in TRβ1 
belangrijk zijn voor het T3- versus T4-onderscheid en kan deels de onderliggende moleculaire 
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en structurele basis voor de rol van T4 als een prohormoon en T3 als een biologisch actief 
hormoon verklaren, binnen een algemeen geaccepteerd concept van TH fysiologie.
 Tot op heden zijn 25 mutaties (in totaal 40 patiënten) geïdentificeerd die RTHα 
veroorzaken. Een toename van het aantal patiënten stelt ons in staat de variabiliteit van 
het fenotype van de patiënten te bestuderen. Tot dusverre is het onderliggende moleculaire 
mechanisme om de variatie te verklaren nog niet duidelijk opgehelderd. In hoofdstuk 4 
hebben we de factoren onderzocht die bijdragen aan de differentieel gestoorde transcriptionele 
activiteit van zeven TRα-mutaties, waarvan er vier zijn afgeleid van RTHα-patiënten. De 
resultaten tonen aan dat verminderde T3-bindingsaffiniteit de belangrijkste factor is die de 
mate van de verminderde transcriptionele activiteit en interacties met de cofactoren NCoR1 
en SRC1 bepaalt. Bovendien lijkt de mate van verminderde bindingsaffiniteit voor T3 en 
verminderde transcriptionele activiteit van de mutanten gerelateerd te zijn aan het fenotype 
van de patiënten. In hoofdstuk 5 bestuderen we het verschil in het neurologisch fenotype 
gevonden in twee RTHα-patiënten, één met een TRα1-C380fsx387 mutatie en één met 
een TRα1-F397fsx406 truncerende mutatie, die beide de binding van T3 volledig opheffen. 
De transcriptomen van deze twee mutanten in een menselijke neuronale cellijn laten zien 
dat de TRα1-C380fsx387 mutant de baseline genexpressie in een grotere mate verandert 
dan de TRα1-F397fsx406 mutant, wat in overeenstemming is met de ernstigere cognitieve 
stoornissen van de patiënt met de TRα1-C380fsx387 mutatie. Deze bevinding suggereert 
dat het effect van de mutanten op genexpressie niet enkel wordt veroorzaakt door een 
verminderde T3-binding, maar dat andere defecten in receptor functie kunnen bijdragen aan 
de verschillen in het fenotype van patiënten.
 Zoals eerder vermeld, zijn nucleaire coregulatoire eiwitten belangrijk voor de 
transcriptionele regulatie door TRs. Het begrijpen van de complexiteit van de TR-cofactor 
interacties kan verder inzicht geven in de impact van TR-mutaties bij RTH-syndromen, naast 
het effect op T3-binding. In hoofdstuk 6 hebben we een hypothese vrije benadering gebruikt 
door middels een tandem-affiniteitszuiveringstechniek de interactomen van TRs te identificeren. 
Hoofdstuk 6a is gericht op de celtype specifieke associatie van coregulatoire eiwitten met TRα1 
door de identificatie van de interactomen in zowel een menselijke lever als neuronale cellijn. 
Over het algemeen gebruikt TRα1 dezelfde nucleaire coregulatoire eiwitten om gentranscriptie 
in deze twee celtypen te reguleren. Het is echter waarschijnlijk dat sommige eiwitten interacties 
aangaan met TRα1 op een celtype specifieke manier. Hoofdstuk 6b is gericht op de isovorm-
afhankelijke (TRα1 versus TRβ1) coregulatoire eiwit interacties in een menselijke neuronale 
cellijn, om de complexiteit van TR-werking in de hersenen te begrijpen. We laten zien dat de 
meerderheid van de geïdentificeerde eiwitten geassocieerd was met zowel TRα1 als TRβ1, wat 
suggereert dat beide TR-isovormen associëren met dezelfde nucleaire coregulatoire eiwitten 
om gentranscriptie te reguleren. Een aantal nucleaire eiwitten bindt echter aan TRs op een 
isovormspecifieke manier. Deze bevindingen vergroten de kennis over de interactie tussen 
TRs en coregulatoire eiwitten tijdens transcriptionele genregulatie en kunnen meer inzicht 
verschaffen in het effect van TR-mutaties bij RTH-syndromen, naast het effect op T3-binding.
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 Tot slot bespreken we in hoofdstuk 7 de bevindingen uit dit proefschrift in het kader 
van de momenteel beschikbare literatuur. De mogelijke implicaties van deze studies en het 
toekomstperspectief worden ook besproken.
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